id	sid	tid	token	lemma	pos
ajst-25053	1	1	academic	academic	ADJ
ajst-25053	1	2	journal	journal	NOUN
ajst-25053	1	3	of	of	ADP
ajst-25053	1	4	science	science	NOUN
ajst-25053	1	5	and	and	CCONJ
ajst-25053	1	6	technology	technology	NOUN
ajst-25053	1	7	issn	issn	NOUN
ajst-25053	1	8	:	:	PUNCT
ajst-25053	1	9	2771	2771	NUM
ajst-25053	1	10	-	-	SYM
ajst-25053	1	11	3032	3032	NUM
ajst-25053	1	12	|	|	NOUN
ajst-25053	1	13	vol	vol	NOUN
ajst-25053	1	14	.	.	PROPN
ajst-25053	2	1	12	12	NUM
ajst-25053	2	2	,	,	PUNCT
ajst-25053	2	3	no	no	INTJ
ajst-25053	2	4	.	.	NOUN
ajst-25053	2	5	1	1	NUM
ajst-25053	2	6	,	,	PUNCT
ajst-25053	2	7	2024	2024	NUM
ajst-25053	2	8	356	356	NUM
ajst-25053	2	9	the	the	DET
ajst-25053	2	10	key	key	ADJ
ajst-25053	2	11	technique	technique	NOUN
ajst-25053	2	12	in	in	ADP
ajst-25053	2	13	the	the	DET
ajst-25053	2	14	mrna	mrna	PROPN
ajst-25053	2	15	vaccine	vaccine	NOUN
ajst-25053	2	16	therapy	therapy	NOUN
ajst-25053	2	17	siyu	siyu	PROPN
ajst-25053	2	18	liu	liu	PROPN
ajst-25053	2	19	*	*	PROPN
ajst-25053	2	20	guangzhou	guangzhou	PROPN
ajst-25053	2	21	dublin	dublin	PROPN
ajst-25053	2	22	international	international	PROPN
ajst-25053	2	23	college	college	PROPN
ajst-25053	2	24	of	of	ADP
ajst-25053	2	25	life	life	NOUN
ajst-25053	2	26	sciences	science	NOUN
ajst-25053	2	27	and	and	CCONJ
ajst-25053	2	28	technology	technology	NOUN
ajst-25053	2	29	at	at	ADP
ajst-25053	2	30	south	south	PROPN
ajst-25053	2	31	china	china	PROPN
ajst-25053	2	32	agricultural	agricultural	PROPN
ajst-25053	2	33	university	university	PROPN
ajst-25053	2	34	,	,	PUNCT
ajst-25053	2	35	south	south	PROPN
ajst-25053	2	36	china	china	PROPN
ajst-25053	2	37	agricultural	agricultural	PROPN
ajst-25053	2	38	university	university	PROPN
ajst-25053	2	39	,	,	PUNCT
ajst-25053	2	40	guangzhou	guangzhou	PROPN
ajst-25053	2	41	,	,	PUNCT
ajst-25053	2	42	guangdong	guangdong	PROPN
ajst-25053	2	43	,	,	PUNCT
ajst-25053	2	44	510642	510642	NUM
ajst-25053	2	45	,	,	PUNCT
ajst-25053	2	46	china	china	PROPN
ajst-25053	2	47	*	*	PUNCT
ajst-25053	2	48	corresponding	correspond	VERB
ajst-25053	2	49	author	author	NOUN
ajst-25053	2	50	email	email	NOUN
ajst-25053	2	51	:	:	PUNCT
ajst-25053	2	52	lsycsgssl@163.com	lsycsgssl@163.com	PROPN
ajst-25053	2	53	abstract	abstract	NOUN
ajst-25053	2	54	:	:	PUNCT
ajst-25053	2	55	mrna	mrna	PROPN
ajst-25053	2	56	-	-	PUNCT
ajst-25053	2	57	based	base	VERB
ajst-25053	2	58	gene	gene	NOUN
ajst-25053	2	59	therapy	therapy	NOUN
ajst-25053	2	60	drugs	drug	NOUN
ajst-25053	2	61	and	and	CCONJ
ajst-25053	2	62	preventive	preventive	ADJ
ajst-25053	2	63	vaccines	vaccine	NOUN
ajst-25053	2	64	have	have	AUX
ajst-25053	2	65	become	become	VERB
ajst-25053	2	66	a	a	DET
ajst-25053	2	67	hot	hot	ADJ
ajst-25053	2	68	topic	topic	NOUN
ajst-25053	2	69	of	of	ADP
ajst-25053	2	70	development	development	NOUN
ajst-25053	2	71	.	.	PUNCT
ajst-25053	3	1	the	the	DET
ajst-25053	3	2	technical	technical	ADJ
ajst-25053	3	3	principle	principle	NOUN
ajst-25053	3	4	is	be	AUX
ajst-25053	3	5	that	that	SCONJ
ajst-25053	3	6	mrna	mrna	PROPN
ajst-25053	3	7	delivered	deliver	VERB
ajst-25053	3	8	to	to	ADP
ajst-25053	3	9	the	the	DET
ajst-25053	3	10	body	body	NOUN
ajst-25053	3	11	cells	cell	NOUN
ajst-25053	3	12	can	can	AUX
ajst-25053	3	13	be	be	AUX
ajst-25053	3	14	expressed	express	VERB
ajst-25053	3	15	through	through	ADP
ajst-25053	3	16	the	the	DET
ajst-25053	3	17	translation	translation	NOUN
ajst-25053	3	18	mechanism	mechanism	NOUN
ajst-25053	3	19	of	of	ADP
ajst-25053	3	20	host	host	NOUN
ajst-25053	3	21	cells	cell	NOUN
ajst-25053	3	22	to	to	PART
ajst-25053	3	23	produce	produce	VERB
ajst-25053	3	24	therapeutic	therapeutic	ADJ
ajst-25053	3	25	proteins	protein	NOUN
ajst-25053	3	26	or	or	CCONJ
ajst-25053	3	27	immunogenic	immunogenic	ADJ
ajst-25053	3	28	proteins	protein	NOUN
ajst-25053	3	29	,	,	PUNCT
ajst-25053	3	30	which	which	PRON
ajst-25053	3	31	have	have	VERB
ajst-25053	3	32	therapeutic	therapeutic	ADJ
ajst-25053	3	33	effects	effect	NOUN
ajst-25053	3	34	on	on	ADP
ajst-25053	3	35	the	the	DET
ajst-25053	3	36	body	body	NOUN
ajst-25053	3	37	or	or	CCONJ
ajst-25053	3	38	stimulate	stimulate	VERB
ajst-25053	3	39	the	the	DET
ajst-25053	3	40	body	body	NOUN
ajst-25053	3	41	to	to	PART
ajst-25053	3	42	produce	produce	VERB
ajst-25053	3	43	immune	immune	ADJ
ajst-25053	3	44	effects	effect	NOUN
ajst-25053	3	45	.	.	PUNCT
ajst-25053	4	1	mrna	mrna	PROPN
ajst-25053	4	2	vaccines	vaccine	NOUN
ajst-25053	4	3	have	have	VERB
ajst-25053	4	4	many	many	ADJ
ajst-25053	4	5	advantages	advantage	NOUN
ajst-25053	4	6	over	over	ADP
ajst-25053	4	7	traditional	traditional	ADJ
ajst-25053	4	8	vaccines	vaccine	NOUN
ajst-25053	4	9	,	,	PUNCT
ajst-25053	4	10	such	such	ADJ
ajst-25053	4	11	as	as	ADP
ajst-25053	4	12	their	their	PRON
ajst-25053	4	13	safety	safety	NOUN
ajst-25053	4	14	,	,	PUNCT
ajst-25053	4	15	flexibility	flexibility	NOUN
ajst-25053	4	16	,	,	PUNCT
ajst-25053	4	17	rapid	rapid	ADJ
ajst-25053	4	18	production	production	NOUN
ajst-25053	4	19	and	and	CCONJ
ajst-25053	4	20	low	low	ADJ
ajst-25053	4	21	cost	cost	NOUN
ajst-25053	4	22	.	.	PUNCT
ajst-25053	5	1	mrna	mrna	PROPN
ajst-25053	5	2	vaccines	vaccine	NOUN
ajst-25053	5	3	are	be	AUX
ajst-25053	5	4	therefore	therefore	ADV
ajst-25053	5	5	proposed	propose	VERB
ajst-25053	5	6	as	as	ADP
ajst-25053	5	7	a	a	DET
ajst-25053	5	8	new	new	ADJ
ajst-25053	5	9	frontier	frontier	NOUN
ajst-25053	5	10	in	in	ADP
ajst-25053	5	11	vaccination	vaccination	NOUN
ajst-25053	5	12	.	.	PUNCT
ajst-25053	6	1	in	in	ADP
ajst-25053	6	2	this	this	DET
ajst-25053	6	3	review	review	NOUN
ajst-25053	6	4	,	,	PUNCT
ajst-25053	6	5	the	the	DET
ajst-25053	6	6	main	main	ADJ
ajst-25053	6	7	key	key	ADJ
ajst-25053	6	8	technologies	technology	NOUN
ajst-25053	6	9	based	base	VERB
ajst-25053	6	10	on	on	ADP
ajst-25053	6	11	mrna	mrna	PROPN
ajst-25053	6	12	drug	drug	PROPN
ajst-25053	6	13	design	design	NOUN
ajst-25053	6	14	,	,	PUNCT
ajst-25053	6	15	such	such	ADJ
ajst-25053	6	16	as	as	ADP
ajst-25053	6	17	in	in	ADP
ajst-25053	6	18	vitro	vitro	X
ajst-25053	6	19	transcription	transcription	NOUN
ajst-25053	6	20	(	(	PUNCT
ajst-25053	6	21	ivt	ivt	NOUN
ajst-25053	6	22	)	)	PUNCT
ajst-25053	6	23	,	,	PUNCT
ajst-25053	6	24	nucleotide	nucleotide	NOUN
ajst-25053	6	25	and	and	CCONJ
ajst-25053	6	26	cap	cap	NOUN
ajst-25053	6	27	and	and	CCONJ
ajst-25053	6	28	tail	tail	NOUN
ajst-25053	6	29	structure	structure	NOUN
ajst-25053	6	30	modification	modification	NOUN
ajst-25053	6	31	,	,	PUNCT
ajst-25053	6	32	were	be	AUX
ajst-25053	6	33	reviewed	review	VERB
ajst-25053	6	34	,	,	PUNCT
ajst-25053	6	35	followed	follow	VERB
ajst-25053	6	36	by	by	ADP
ajst-25053	6	37	a	a	DET
ajst-25053	6	38	brief	brief	ADJ
ajst-25053	6	39	introduction	introduction	NOUN
ajst-25053	6	40	to	to	ADP
ajst-25053	6	41	mrna	mrna	PROPN
ajst-25053	6	42	purification	purification	NOUN
ajst-25053	6	43	methods	method	NOUN
ajst-25053	6	44	and	and	CCONJ
ajst-25053	6	45	delivery	delivery	NOUN
ajst-25053	6	46	systems	system	NOUN
ajst-25053	6	47	.	.	PUNCT
ajst-25053	7	1	several	several	ADJ
ajst-25053	7	2	novel	novel	ADJ
ajst-25053	7	3	mrna	mrna	NOUN
ajst-25053	7	4	drugs	drug	NOUN
ajst-25053	7	5	are	be	AUX
ajst-25053	7	6	also	also	ADV
ajst-25053	7	7	briefly	briefly	ADV
ajst-25053	7	8	described	describe	VERB
ajst-25053	7	9	.	.	PUNCT
ajst-25053	8	1	finally	finally	ADV
ajst-25053	8	2	,	,	PUNCT
ajst-25053	8	3	the	the	DET
ajst-25053	8	4	latest	late	ADJ
ajst-25053	8	5	research	research	NOUN
ajst-25053	8	6	directions	direction	NOUN
ajst-25053	8	7	and	and	CCONJ
ajst-25053	8	8	possible	possible	ADJ
ajst-25053	8	9	challenges	challenge	NOUN
ajst-25053	8	10	of	of	ADP
ajst-25053	8	11	mrna	mrna	PROPN
ajst-25053	8	12	are	be	AUX
ajst-25053	8	13	mentioned	mention	VERB
ajst-25053	8	14	,	,	PUNCT
ajst-25053	8	15	aiming	aim	VERB
ajst-25053	8	16	to	to	PART
ajst-25053	8	17	provide	provide	VERB
ajst-25053	8	18	support	support	NOUN
ajst-25053	8	19	for	for	ADP
ajst-25053	8	20	the	the	DET
ajst-25053	8	21	development	development	NOUN
ajst-25053	8	22	of	of	ADP
ajst-25053	8	23	mrna	mrna	PROPN
ajst-25053	8	24	gene	gene	NOUN
ajst-25053	8	25	therapy	therapy	NOUN
ajst-25053	8	26	drugs	drug	NOUN
ajst-25053	8	27	and	and	CCONJ
ajst-25053	8	28	vaccines	vaccine	NOUN
ajst-25053	8	29	.	.	PUNCT
ajst-25053	9	1	keywords	keyword	NOUN
ajst-25053	9	2	:	:	PUNCT
ajst-25053	9	3	mrna	mrna	PROPN
ajst-25053	9	4	vaccine	vaccine	NOUN
ajst-25053	9	5	;	;	PUNCT
ajst-25053	9	6	lipid	lipid	NOUN
ajst-25053	9	7	nanoparticles	nanoparticle	NOUN
ajst-25053	9	8	(	(	PUNCT
ajst-25053	9	9	lnp	lnp	PROPN
ajst-25053	9	10	)	)	PUNCT
ajst-25053	9	11	;	;	PUNCT
ajst-25053	9	12	cancer	cancer	NOUN
ajst-25053	9	13	treatment	treatment	NOUN
ajst-25053	9	14	;	;	PUNCT
ajst-25053	9	15	infectious	infectious	ADJ
ajst-25053	9	16	diseases	disease	NOUN
ajst-25053	9	17	;	;	PUNCT
ajst-25053	9	18	delivery	delivery	NOUN
ajst-25053	9	19	;	;	PUNCT
ajst-25053	9	20	in	in	ADP
ajst-25053	9	21	vitro	vitro	X
ajst-25053	9	22	transcription	transcription	NOUN
ajst-25053	9	23	;	;	PUNCT
ajst-25053	9	24	mrna	mrna	PROPN
ajst-25053	9	25	modification	modification	NOUN
ajst-25053	9	26	.	.	PUNCT
ajst-25053	10	1	1	1	X
ajst-25053	10	2	.	.	X
ajst-25053	10	3	introduction	introduction	NOUN
ajst-25053	10	4	in	in	ADP
ajst-25053	10	5	1961	1961	NUM
ajst-25053	10	6	,	,	PUNCT
ajst-25053	10	7	brenner	brenner	PROPN
ajst-25053	10	8	et	et	PROPN
ajst-25053	10	9	al	al	PROPN
ajst-25053	10	10	.	.	PROPN
ajst-25053	10	11	proposed	propose	VERB
ajst-25053	10	12	the	the	DET
ajst-25053	10	13	carrier	carrier	NOUN
ajst-25053	10	14	of	of	ADP
ajst-25053	10	15	genetic	genetic	ADJ
ajst-25053	10	16	information	information	NOUN
ajst-25053	10	17	between	between	ADP
ajst-25053	10	18	dna	dna	NOUN
ajst-25053	10	19	and	and	CCONJ
ajst-25053	10	20	protein	protein	NOUN
ajst-25053	10	21	-mrna[1	-mrna[1	PROPN
ajst-25053	10	22	]	]	PUNCT
ajst-25053	10	23	.	.	PUNCT
ajst-25053	11	1	due	due	ADP
ajst-25053	11	2	to	to	ADP
ajst-25053	11	3	its	its	PRON
ajst-25053	11	4	instability	instability	NOUN
ajst-25053	11	5	,	,	PUNCT
ajst-25053	11	6	the	the	DET
ajst-25053	11	7	idea	idea	NOUN
ajst-25053	11	8	of	of	ADP
ajst-25053	11	9	applying	apply	VERB
ajst-25053	11	10	to	to	ADP
ajst-25053	11	11	disease	disease	NOUN
ajst-25053	11	12	treatment	treatment	NOUN
ajst-25053	11	13	has	have	AUX
ajst-25053	11	14	not	not	PART
ajst-25053	11	15	been	be	AUX
ajst-25053	11	16	verified	verify	VERB
ajst-25053	11	17	.	.	PUNCT
ajst-25053	12	1	it	it	PRON
ajst-25053	12	2	was	be	AUX
ajst-25053	12	3	not	not	PART
ajst-25053	12	4	until	until	ADP
ajst-25053	12	5	1990	1990	NUM
ajst-25053	12	6	,	,	PUNCT
ajst-25053	12	7	when	when	SCONJ
ajst-25053	12	8	wolff	wolff	X
ajst-25053	12	9	et	et	PROPN
ajst-25053	12	10	al	al	PROPN
ajst-25053	12	11	.	.	PROPN
ajst-25053	12	12	expressed	express	VERB
ajst-25053	12	13	mrna	mrna	PROPN
ajst-25053	12	14	transcribed	transcribe	VERB
ajst-25053	12	15	in	in	ADP
ajst-25053	12	16	vitro	vitro	X
ajst-25053	12	17	in	in	ADP
ajst-25053	12	18	mouse	mouse	NOUN
ajst-25053	12	19	skeletal	skeletal	ADJ
ajst-25053	12	20	muscle	muscle	NOUN
ajst-25053	12	21	for	for	ADP
ajst-25053	12	22	the	the	DET
ajst-25053	12	23	first	first	ADJ
ajst-25053	12	24	time	time	NOUN
ajst-25053	12	25	,	,	PUNCT
ajst-25053	12	26	that	that	SCONJ
ajst-25053	12	27	the	the	DET
ajst-25053	12	28	feasibility	feasibility	NOUN
ajst-25053	12	29	of	of	ADP
ajst-25053	12	30	mrna	mrna	PROPN
ajst-25053	12	31	drugs	drug	NOUN
ajst-25053	12	32	became	become	VERB
ajst-25053	12	33	apparent[2	apparent[2	PROPN
ajst-25053	12	34	]	]	PUNCT
ajst-25053	12	35	.	.	PUNCT
ajst-25053	13	1	in	in	ADP
ajst-25053	13	2	recent	recent	ADJ
ajst-25053	13	3	years	year	NOUN
ajst-25053	13	4	,	,	PUNCT
ajst-25053	13	5	the	the	DET
ajst-25053	13	6	research	research	NOUN
ajst-25053	13	7	on	on	ADP
ajst-25053	13	8	mrna	mrna	PROPN
ajst-25053	13	9	vaccine	vaccine	NOUN
ajst-25053	13	10	has	have	AUX
ajst-25053	13	11	been	be	AUX
ajst-25053	13	12	carried	carry	VERB
ajst-25053	13	13	out	out	ADP
ajst-25053	13	14	,	,	PUNCT
ajst-25053	13	15	but	but	CCONJ
ajst-25053	13	16	it	it	PRON
ajst-25053	13	17	has	have	AUX
ajst-25053	13	18	not	not	PART
ajst-25053	13	19	been	be	AUX
ajst-25053	13	20	applied	apply	VERB
ajst-25053	13	21	to	to	ADP
ajst-25053	13	22	human	human	ADJ
ajst-25053	13	23	body	body	NOUN
ajst-25053	13	24	.	.	PUNCT
ajst-25053	14	1	the	the	DET
ajst-25053	14	2	success	success	NOUN
ajst-25053	14	3	of	of	ADP
ajst-25053	14	4	sars	sar	NOUN
ajst-25053	14	5	-	-	PUNCT
ajst-25053	14	6	cov-2	cov-2	NOUN
ajst-25053	14	7	vaccine	vaccine	NOUN
ajst-25053	14	8	mrna1273	mrna1273	PROPN
ajst-25053	14	9	and	and	CCONJ
ajst-25053	14	10	bnt162b2	bnt162b2	NOUN
ajst-25053	14	11	has	have	AUX
ajst-25053	14	12	made	make	VERB
ajst-25053	14	13	people	people	NOUN
ajst-25053	14	14	realize	realize	VERB
ajst-25053	14	15	the	the	DET
ajst-25053	14	16	advantages	advantage	NOUN
ajst-25053	14	17	of	of	ADP
ajst-25053	14	18	mrna	mrna	PROPN
ajst-25053	14	19	drug	drug	NOUN
ajst-25053	14	20	therapy	therapy	NOUN
ajst-25053	14	21	and	and	CCONJ
ajst-25053	14	22	the	the	DET
ajst-25053	14	23	broad	broad	ADJ
ajst-25053	14	24	development	development	NOUN
ajst-25053	14	25	prospect	prospect	NOUN
ajst-25053	14	26	in	in	ADP
ajst-25053	14	27	the	the	DET
ajst-25053	14	28	future	future	NOUN
ajst-25053	14	29	.	.	PUNCT
ajst-25053	15	1	mrna	mrna	PROPN
ajst-25053	15	2	vaccines	vaccine	NOUN
ajst-25053	15	3	have	have	VERB
ajst-25053	15	4	huge	huge	ADJ
ajst-25053	15	5	advantages	advantage	NOUN
ajst-25053	15	6	.	.	PUNCT
ajst-25053	16	1	most	most	ADJ
ajst-25053	16	2	mrna	mrna	PROPN
ajst-25053	16	3	vaccines	vaccine	NOUN
ajst-25053	16	4	are	be	AUX
ajst-25053	16	5	produced	produce	VERB
ajst-25053	16	6	and	and	CCONJ
ajst-25053	16	7	purified	purify	VERB
ajst-25053	16	8	in	in	ADP
ajst-25053	16	9	a	a	DET
ajst-25053	16	10	similar	similar	ADJ
ajst-25053	16	11	way	way	NOUN
ajst-25053	16	12	,	,	PUNCT
ajst-25053	16	13	and	and	CCONJ
ajst-25053	16	14	when	when	SCONJ
ajst-25053	16	15	different	different	ADJ
ajst-25053	16	16	proteins	protein	NOUN
ajst-25053	16	17	are	be	AUX
ajst-25053	16	18	needed	need	VERB
ajst-25053	16	19	,	,	PUNCT
ajst-25053	16	20	the	the	DET
ajst-25053	16	21	mrna	mrna	PROPN
ajst-25053	16	22	sequence	sequence	NOUN
ajst-25053	16	23	is	be	AUX
ajst-25053	16	24	theoretically	theoretically	ADV
ajst-25053	16	25	only	only	ADV
ajst-25053	16	26	changed	change	VERB
ajst-25053	16	27	,	,	PUNCT
ajst-25053	16	28	which	which	PRON
ajst-25053	16	29	is	be	AUX
ajst-25053	16	30	important	important	ADJ
ajst-25053	16	31	in	in	ADP
ajst-25053	16	32	terms	term	NOUN
ajst-25053	16	33	of	of	ADP
ajst-25053	16	34	time	time	NOUN
ajst-25053	16	35	and	and	CCONJ
ajst-25053	16	36	economic	economic	ADJ
ajst-25053	16	37	cost	cost	NOUN
ajst-25053	16	38	savings	saving	NOUN
ajst-25053	16	39	,	,	PUNCT
ajst-25053	16	40	especially	especially	ADV
ajst-25053	16	41	in	in	ADP
ajst-25053	16	42	response	response	NOUN
ajst-25053	16	43	to	to	ADP
ajst-25053	16	44	some	some	DET
ajst-25053	16	45	global	global	ADJ
ajst-25053	16	46	health	health	NOUN
ajst-25053	16	47	emergencies	emergency	NOUN
ajst-25053	16	48	such	such	ADJ
ajst-25053	16	49	as	as	ADP
ajst-25053	16	50	covid-19	covid-19	PROPN
ajst-25053	16	51	.	.	PUNCT
ajst-25053	17	1	in	in	ADP
ajst-25053	17	2	addition	addition	NOUN
ajst-25053	17	3	,	,	PUNCT
ajst-25053	17	4	it	it	PRON
ajst-25053	17	5	is	be	AUX
ajst-25053	17	6	also	also	ADV
ajst-25053	17	7	useful	useful	ADJ
ajst-25053	17	8	for	for	ADP
ajst-25053	17	9	viruses	virus	NOUN
ajst-25053	17	10	that	that	PRON
ajst-25053	17	11	can	can	AUX
ajst-25053	17	12	mutate	mutate	VERB
ajst-25053	17	13	,	,	PUNCT
ajst-25053	17	14	as	as	SCONJ
ajst-25053	17	15	rna	rna	NOUN
ajst-25053	17	16	viruses	virus	NOUN
ajst-25053	17	17	like	like	ADP
ajst-25053	17	18	covid-19	covid-19	PROPN
ajst-25053	17	19	are	be	AUX
ajst-25053	17	20	prone	prone	ADJ
ajst-25053	17	21	to	to	ADP
ajst-25053	17	22	mutating	mutate	VERB
ajst-25053	17	23	,	,	PUNCT
ajst-25053	17	24	rendering	render	VERB
ajst-25053	17	25	existing	exist	VERB
ajst-25053	17	26	vaccines	vaccine	NOUN
ajst-25053	17	27	ineffective	ineffective	ADJ
ajst-25053	17	28	.	.	PUNCT
ajst-25053	18	1	but	but	CCONJ
ajst-25053	18	2	the	the	DET
ajst-25053	18	3	similarity	similarity	NOUN
ajst-25053	18	4	in	in	ADP
ajst-25053	18	5	the	the	DET
ajst-25053	18	6	manufacturing	manufacturing	NOUN
ajst-25053	18	7	process	process	NOUN
ajst-25053	18	8	has	have	AUX
ajst-25053	18	9	allowed	allow	VERB
ajst-25053	18	10	pharmaceutical	pharmaceutical	ADJ
ajst-25053	18	11	companies	company	NOUN
ajst-25053	18	12	to	to	PART
ajst-25053	18	13	quickly	quickly	ADV
ajst-25053	18	14	develop	develop	VERB
ajst-25053	18	15	similar	similar	ADJ
ajst-25053	18	16	mrna	mrna	NOUN
ajst-25053	18	17	vaccines	vaccine	NOUN
ajst-25053	18	18	.	.	PUNCT
ajst-25053	19	1	in	in	ADP
ajst-25053	19	2	addition	addition	NOUN
ajst-25053	19	3	,	,	PUNCT
ajst-25053	19	4	in	in	ADP
ajst-25053	19	5	vitro	vitro	X
ajst-25053	19	6	transcription	transcription	NOUN
ajst-25053	19	7	also	also	ADV
ajst-25053	19	8	makes	make	VERB
ajst-25053	19	9	it	it	PRON
ajst-25053	19	10	easier	easy	ADJ
ajst-25053	19	11	to	to	PART
ajst-25053	19	12	produce	produce	VERB
ajst-25053	19	13	mrna	mrna	NOUN
ajst-25053	19	14	vaccines	vaccine	NOUN
ajst-25053	19	15	.	.	PUNCT
ajst-25053	20	1	at	at	ADP
ajst-25053	20	2	the	the	DET
ajst-25053	20	3	same	same	ADJ
ajst-25053	20	4	time	time	NOUN
ajst-25053	20	5	,	,	PUNCT
ajst-25053	20	6	mrna	mrna	PROPN
ajst-25053	20	7	vaccines	vaccine	NOUN
ajst-25053	20	8	are	be	AUX
ajst-25053	20	9	safer	safe	ADJ
ajst-25053	20	10	than	than	ADP
ajst-25053	20	11	dna	dna	NOUN
ajst-25053	20	12	-	-	PUNCT
ajst-25053	20	13	based	base	VERB
ajst-25053	20	14	nucleotide	nucleotide	ADJ
ajst-25053	20	15	vaccines	vaccine	NOUN
ajst-25053	20	16	.	.	PUNCT
ajst-25053	21	1	except	except	SCONJ
ajst-25053	21	2	for	for	ADP
ajst-25053	21	3	the	the	DET
ajst-25053	21	4	rare	rare	ADJ
ajst-25053	21	5	recombination	recombination	NOUN
ajst-25053	21	6	of	of	ADP
ajst-25053	21	7	single	single	ADJ
ajst-25053	21	8	-	-	PUNCT
ajst-25053	21	9	stranded	strand	VERB
ajst-25053	21	10	rna	rna	NOUN
ajst-25053	21	11	molecules	molecule	NOUN
ajst-25053	21	12	,	,	PUNCT
ajst-25053	21	13	mrna	mrna	PROPN
ajst-25053	21	14	vaccines	vaccine	NOUN
ajst-25053	21	15	do	do	AUX
ajst-25053	21	16	not	not	PART
ajst-25053	21	17	integrate	integrate	VERB
ajst-25053	21	18	into	into	ADP
ajst-25053	21	19	the	the	DET
ajst-25053	21	20	host	host	NOUN
ajst-25053	21	21	genome	genome	NOUN
ajst-25053	21	22	,	,	PUNCT
ajst-25053	21	23	and	and	CCONJ
ajst-25053	21	24	mrna	mrna	PROPN
ajst-25053	21	25	is	be	AUX
ajst-25053	21	26	expressed	express	VERB
ajst-25053	21	27	in	in	ADP
ajst-25053	21	28	the	the	DET
ajst-25053	21	29	cytoplasm	cytoplasm	NOUN
ajst-25053	21	30	,	,	PUNCT
ajst-25053	21	31	thus	thus	ADV
ajst-25053	21	32	avoiding	avoid	VERB
ajst-25053	21	33	possible	possible	ADJ
ajst-25053	21	34	genetic	genetic	ADJ
ajst-25053	21	35	contamination	contamination	NOUN
ajst-25053	21	36	.	.	PUNCT
ajst-25053	22	1	in	in	ADP
ajst-25053	22	2	addition	addition	NOUN
ajst-25053	22	3	,	,	PUNCT
ajst-25053	22	4	mrna	mrna	PROPN
ajst-25053	22	5	vaccines	vaccine	NOUN
ajst-25053	22	6	have	have	VERB
ajst-25053	22	7	autogenous	autogenous	ADJ
ajst-25053	22	8	properties	property	NOUN
ajst-25053	22	9	that	that	PRON
ajst-25053	22	10	induce	induce	VERB
ajst-25053	22	11	the	the	DET
ajst-25053	22	12	body	body	NOUN
ajst-25053	22	13	to	to	PART
ajst-25053	22	14	produce	produce	VERB
ajst-25053	22	15	cytokines	cytokine	NOUN
ajst-25053	22	16	that	that	PRON
ajst-25053	22	17	activate	activate	VERB
ajst-25053	22	18	a	a	DET
ajst-25053	22	19	strong	strong	ADJ
ajst-25053	22	20	and	and	CCONJ
ajst-25053	22	21	long	long	ADV
ajst-25053	22	22	-	-	PUNCT
ajst-25053	22	23	lasting	last	VERB
ajst-25053	22	24	immune	immune	ADJ
ajst-25053	22	25	response	response	NOUN
ajst-25053	22	26	compared	compare	VERB
ajst-25053	22	27	to	to	ADP
ajst-25053	22	28	protein	protein	NOUN
ajst-25053	22	29	-	-	PUNCT
ajst-25053	22	30	based	base	VERB
ajst-25053	22	31	vaccines	vaccine	NOUN
ajst-25053	22	32	,	,	PUNCT
ajst-25053	22	33	which	which	PRON
ajst-25053	22	34	require	require	VERB
ajst-25053	22	35	additional	additional	ADJ
ajst-25053	22	36	adjuvants	adjuvant	NOUN
ajst-25053	22	37	to	to	PART
ajst-25053	22	38	achieve	achieve	VERB
ajst-25053	22	39	the	the	DET
ajst-25053	22	40	same	same	ADJ
ajst-25053	22	41	effect	effect	NOUN
ajst-25053	22	42	.	.	PUNCT
ajst-25053	23	1	in	in	ADP
ajst-25053	23	2	the	the	DET
ajst-25053	23	3	long	long	ADJ
ajst-25053	23	4	run	run	NOUN
ajst-25053	23	5	,	,	PUNCT
ajst-25053	23	6	in	in	ADP
ajst-25053	23	7	addition	addition	NOUN
ajst-25053	23	8	to	to	ADP
ajst-25053	23	9	covid-19	covid-19	PROPN
ajst-25053	23	10	vaccine	vaccine	NOUN
ajst-25053	23	11	,	,	PUNCT
ajst-25053	23	12	mrna	mrna	PROPN
ajst-25053	23	13	technology	technology	PROPN
ajst-25053	23	14	has	have	AUX
ajst-25053	23	15	gradually	gradually	ADV
ajst-25053	23	16	matured	mature	VERB
ajst-25053	23	17	in	in	ADP
ajst-25053	23	18	the	the	DET
ajst-25053	23	19	fields	field	NOUN
ajst-25053	23	20	of	of	ADP
ajst-25053	23	21	tumor	tumor	NOUN
ajst-25053	23	22	vaccine	vaccine	NOUN
ajst-25053	23	23	,	,	PUNCT
ajst-25053	23	24	gene	gene	NOUN
ajst-25053	23	25	editing	editing	NOUN
ajst-25053	23	26	,	,	PUNCT
ajst-25053	23	27	car	car	NOUN
ajst-25053	23	28	t	t	NOUN
ajst-25053	23	29	cell	cell	NOUN
ajst-25053	23	30	therapy	therapy	NOUN
ajst-25053	23	31	,	,	PUNCT
ajst-25053	23	32	protein	protein	NOUN
ajst-25053	23	33	replacement	replacement	NOUN
ajst-25053	23	34	therapy	therapy	NOUN
ajst-25053	23	35	and	and	CCONJ
ajst-25053	23	36	other	other	ADJ
ajst-25053	23	37	infectious	infectious	ADJ
ajst-25053	23	38	disease	disease	NOUN
ajst-25053	23	39	preventive	preventive	ADJ
ajst-25053	23	40	vaccines	vaccine	NOUN
ajst-25053	23	41	,	,	PUNCT
ajst-25053	23	42	and	and	CCONJ
ajst-25053	23	43	products	product	NOUN
ajst-25053	23	44	have	have	AUX
ajst-25053	23	45	emerged	emerge	VERB
ajst-25053	23	46	one	one	NUM
ajst-25053	23	47	after	after	ADP
ajst-25053	23	48	another	another	PRON
ajst-25053	23	49	.	.	PUNCT
ajst-25053	24	1	mrna	mrna	PROPN
ajst-25053	24	2	has	have	AUX
ajst-25053	24	3	become	become	VERB
ajst-25053	24	4	a	a	DET
ajst-25053	24	5	hot	hot	ADJ
ajst-25053	24	6	research	research	NOUN
ajst-25053	24	7	and	and	CCONJ
ajst-25053	24	8	development	development	NOUN
ajst-25053	24	9	spot	spot	NOUN
ajst-25053	24	10	in	in	ADP
ajst-25053	24	11	the	the	DET
ajst-25053	24	12	field	field	NOUN
ajst-25053	24	13	of	of	ADP
ajst-25053	24	14	biomedicine	biomedicine	NOUN
ajst-25053	24	15	in	in	ADP
ajst-25053	24	16	recent	recent	ADJ
ajst-25053	24	17	years	year	NOUN
ajst-25053	24	18	.	.	PUNCT
ajst-25053	25	1	2	2	X
ajst-25053	25	2	.	.	X
ajst-25053	25	3	mrna	mrna	PROPN
ajst-25053	25	4	modification	modification	NOUN
ajst-25053	25	5	and	and	CCONJ
ajst-25053	25	6	synthesis	synthesis	VERB
ajst-25053	25	7	exogenous	exogenous	ADJ
ajst-25053	25	8	mrna	mrna	NOUN
ajst-25053	25	9	,	,	PUNCT
ajst-25053	25	10	like	like	ADP
ajst-25053	25	11	endogenous	endogenous	ADJ
ajst-25053	25	12	mrna	mrna	NOUN
ajst-25053	25	13	,	,	PUNCT
ajst-25053	25	14	needs	need	VERB
ajst-25053	25	15	to	to	PART
ajst-25053	25	16	be	be	AUX
ajst-25053	25	17	sequenced	sequence	VERB
ajst-25053	25	18	and	and	CCONJ
ajst-25053	25	19	modified	modify	VERB
ajst-25053	25	20	in	in	ADP
ajst-25053	25	21	order	order	NOUN
ajst-25053	25	22	to	to	PART
ajst-25053	25	23	function	function	VERB
ajst-25053	25	24	in	in	ADP
ajst-25053	25	25	the	the	DET
ajst-25053	25	26	human	human	ADJ
ajst-25053	25	27	body	body	NOUN
ajst-25053	25	28	.	.	PUNCT
ajst-25053	26	1	for	for	ADP
ajst-25053	26	2	example	example	NOUN
ajst-25053	26	3	,	,	PUNCT
ajst-25053	26	4	cap	cap	NOUN
ajst-25053	26	5	structure	structure	NOUN
ajst-25053	26	6	and	and	CCONJ
ajst-25053	26	7	tail	tail	NOUN
ajst-25053	26	8	structure	structure	NOUN
ajst-25053	26	9	are	be	AUX
ajst-25053	26	10	critical	critical	ADJ
ajst-25053	26	11	for	for	ADP
ajst-25053	26	12	the	the	DET
ajst-25053	26	13	stability	stability	NOUN
ajst-25053	26	14	of	of	ADP
ajst-25053	26	15	mrna	mrna	PROPN
ajst-25053	26	16	in	in	ADP
ajst-25053	26	17	the	the	DET
ajst-25053	26	18	human	human	ADJ
ajst-25053	26	19	body	body	NOUN
ajst-25053	26	20	,	,	PUNCT
ajst-25053	26	21	while	while	SCONJ
ajst-25053	26	22	the	the	DET
ajst-25053	26	23	design	design	NOUN
ajst-25053	26	24	of	of	ADP
ajst-25053	26	25	the	the	DET
ajst-25053	26	26	open	open	ADJ
ajst-25053	26	27	reading	reading	NOUN
ajst-25053	26	28	frame	frame	NOUN
ajst-25053	26	29	(	(	PUNCT
ajst-25053	26	30	orf	orf	PROPN
ajst-25053	26	31	)	)	PUNCT
ajst-25053	26	32	and	and	CCONJ
ajst-25053	26	33	utr	utr	X
ajst-25053	26	34	affects	affect	VERB
ajst-25053	26	35	the	the	DET
ajst-25053	26	36	efficiency	efficiency	NOUN
ajst-25053	26	37	of	of	ADP
ajst-25053	26	38	mrna	mrna	PROPN
ajst-25053	26	39	translation	translation	NOUN
ajst-25053	26	40	.	.	PUNCT
ajst-25053	27	1	there	there	PRON
ajst-25053	27	2	are	be	VERB
ajst-25053	27	3	reports	report	NOUN
ajst-25053	27	4	that	that	SCONJ
ajst-25053	27	5	mrna	mrna	PROPN
ajst-25053	27	6	can	can	AUX
ajst-25053	27	7	cause	cause	VERB
ajst-25053	27	8	the	the	DET
ajst-25053	27	9	body	body	NOUN
ajst-25053	27	10	to	to	PART
ajst-25053	27	11	produce	produce	VERB
ajst-25053	27	12	type	type	NOUN
ajst-25053	27	13	i	i	PRON
ajst-25053	27	14	interferon	interferon	NOUN
ajst-25053	27	15	and	and	CCONJ
ajst-25053	27	16	cytokines	cytokine	NOUN
ajst-25053	27	17	,	,	PUNCT
ajst-25053	27	18	which	which	PRON
ajst-25053	27	19	can	can	AUX
ajst-25053	27	20	induce	induce	VERB
ajst-25053	27	21	immune	immune	ADJ
ajst-25053	27	22	rejection	rejection	NOUN
ajst-25053	27	23	and	and	CCONJ
ajst-25053	27	24	reduce	reduce	VERB
ajst-25053	27	25	the	the	DET
ajst-25053	27	26	effectiveness	effectiveness	NOUN
ajst-25053	27	27	of	of	ADP
ajst-25053	27	28	drugs	drug	NOUN
ajst-25053	27	29	.	.	PUNCT
ajst-25053	28	1	in	in	ADP
ajst-25053	28	2	addition	addition	NOUN
ajst-25053	28	3	,	,	PUNCT
ajst-25053	28	4	the	the	DET
ajst-25053	28	5	self	self	NOUN
ajst-25053	28	6	-	-	PUNCT
ajst-25053	28	7	adjuvant	adjuvant	ADJ
ajst-25053	28	8	effect	effect	NOUN
ajst-25053	28	9	makes	make	VERB
ajst-25053	28	10	mrna	mrna	PROPN
ajst-25053	28	11	have	have	VERB
ajst-25053	28	12	strong	strong	ADJ
ajst-25053	28	13	immunogenicity	immunogenicity	NOUN
ajst-25053	28	14	,	,	PUNCT
ajst-25053	28	15	which	which	PRON
ajst-25053	28	16	will	will	AUX
ajst-25053	28	17	strengthen	strengthen	VERB
ajst-25053	28	18	the	the	DET
ajst-25053	28	19	immune	immune	ADJ
ajst-25053	28	20	response	response	NOUN
ajst-25053	28	21	that	that	PRON
ajst-25053	28	22	stimulates	stimulate	VERB
ajst-25053	28	23	the	the	DET
ajst-25053	28	24	body	body	NOUN
ajst-25053	28	25	to	to	PART
ajst-25053	28	26	produce	produce	VERB
ajst-25053	28	27	similar	similar	ADJ
ajst-25053	28	28	to	to	ADP
ajst-25053	28	29	the	the	DET
ajst-25053	28	30	rejection	rejection	NOUN
ajst-25053	28	31	of	of	ADP
ajst-25053	28	32	rna	rna	NOUN
ajst-25053	28	33	viruses	virus	NOUN
ajst-25053	28	34	.	.	PUNCT
ajst-25053	29	1	therefore	therefore	ADV
ajst-25053	29	2	,	,	PUNCT
ajst-25053	29	3	it	it	PRON
ajst-25053	29	4	is	be	AUX
ajst-25053	29	5	necessary	necessary	ADJ
ajst-25053	29	6	to	to	PART
ajst-25053	29	7	find	find	VERB
ajst-25053	29	8	feasible	feasible	ADJ
ajst-25053	29	9	measures	measure	NOUN
ajst-25053	29	10	to	to	PART
ajst-25053	29	11	reduce	reduce	VERB
ajst-25053	29	12	the	the	DET
ajst-25053	29	13	immunogenicity	immunogenicity	NOUN
ajst-25053	29	14	of	of	ADP
ajst-25053	29	15	gene	gene	NOUN
ajst-25053	29	16	therapy	therapy	NOUN
ajst-25053	29	17	products	product	NOUN
ajst-25053	29	18	.	.	PUNCT
ajst-25053	30	1	2.1	2.1	NUM
ajst-25053	30	2	.	.	X
ajst-25053	30	3	dna	dna	PROPN
ajst-25053	30	4	design	design	VERB
ajst-25053	30	5	the	the	DET
ajst-25053	30	6	target	target	NOUN
ajst-25053	30	7	dna	dna	NOUN
ajst-25053	30	8	for	for	ADP
ajst-25053	30	9	transcription	transcription	NOUN
ajst-25053	30	10	is	be	AUX
ajst-25053	30	11	often	often	ADV
ajst-25053	30	12	prepared	prepare	VERB
ajst-25053	30	13	by	by	ADP
ajst-25053	30	14	plasmids	plasmid	NOUN
ajst-25053	30	15	.	.	PUNCT
ajst-25053	31	1	plasmid	plasmid	VERB
ajst-25053	31	2	dna	dna	PROPN
ajst-25053	31	3	should	should	AUX
ajst-25053	31	4	be	be	AUX
ajst-25053	31	5	designed	design	VERB
ajst-25053	31	6	to	to	PART
ajst-25053	31	7	include	include	VERB
ajst-25053	31	8	replication	replication	NOUN
ajst-25053	31	9	start	start	NOUN
ajst-25053	31	10	sites	site	NOUN
ajst-25053	31	11	,	,	PUNCT
ajst-25053	31	12	promoters	promoter	NOUN
ajst-25053	31	13	,	,	PUNCT
ajst-25053	31	14	5	5	NUM
ajst-25053	31	15	'	'	PUNCT
ajst-25053	31	16	utr	utr	PROPN
ajst-25053	31	17	,	,	PUNCT
ajst-25053	31	18	orf	orf	PROPN
ajst-25053	31	19	,	,	PUNCT
ajst-25053	31	20	3	3	NUM
ajst-25053	31	21	'	'	PART
ajst-25053	31	22	utr	utr	PROPN
ajst-25053	31	23	,	,	PUNCT
ajst-25053	31	24	polyclonal	polyclonal	ADJ
ajst-25053	31	25	sites	site	NOUN
ajst-25053	31	26	,	,	PUNCT
ajst-25053	31	27	resistance	resistance	NOUN
ajst-25053	31	28	genes	gene	NOUN
ajst-25053	31	29	,	,	PUNCT
ajst-25053	31	30	and	and	CCONJ
ajst-25053	31	31	in	in	ADP
ajst-25053	31	32	most	most	ADJ
ajst-25053	31	33	cases	case	NOUN
ajst-25053	31	34	poly	poly	ADJ
ajst-25053	31	35	(	(	PUNCT
ajst-25053	31	36	a	a	X
ajst-25053	31	37	)	)	PUNCT
ajst-25053	31	38	tail	tail	NOUN
ajst-25053	31	39	coding	code	VERB
ajst-25053	31	40	sequences	sequence	NOUN
ajst-25053	31	41	.	.	PUNCT
ajst-25053	32	1	before	before	ADP
ajst-25053	32	2	synthesizing	synthesize	VERB
ajst-25053	32	3	the	the	DET
ajst-25053	32	4	target	target	NOUN
ajst-25053	32	5	gene	gene	NOUN
ajst-25053	32	6	sequence	sequence	NOUN
ajst-25053	32	7	,	,	PUNCT
ajst-25053	32	8	selecting	select	VERB
ajst-25053	32	9	appropriate	appropriate	ADJ
ajst-25053	32	10	5	5	NUM
ajst-25053	32	11	'	'	NOUN
ajst-25053	32	12	,	,	PUNCT
ajst-25053	32	13	3	3	NUM
ajst-25053	32	14	'	'	PUNCT
ajst-25053	32	15	utr	utr	AUX
ajst-25053	32	16	coding	code	VERB
ajst-25053	32	17	sequences	sequence	NOUN
ajst-25053	32	18	and	and	CCONJ
ajst-25053	32	19	poly	poly	ADJ
ajst-25053	32	20	(	(	PUNCT
ajst-25053	32	21	a	a	X
ajst-25053	32	22	)	)	PUNCT
ajst-25053	32	23	tail	tail	NOUN
ajst-25053	32	24	coding	code	VERB
ajst-25053	32	25	sequences	sequence	NOUN
ajst-25053	32	26	to	to	PART
ajst-25053	32	27	design	design	VERB
ajst-25053	32	28	at	at	ADP
ajst-25053	32	29	both	both	DET
ajst-25053	32	30	ends	end	NOUN
ajst-25053	32	31	of	of	ADP
ajst-25053	32	32	the	the	DET
ajst-25053	32	33	target	target	NOUN
ajst-25053	32	34	gene	gene	NOUN
ajst-25053	32	35	will	will	AUX
ajst-25053	32	36	be	be	AUX
ajst-25053	32	37	conducive	conducive	ADJ
ajst-25053	32	38	to	to	ADP
ajst-25053	32	39	mrna	mrna	VERB
ajst-25053	32	40	stability	stability	NOUN
ajst-25053	32	41	and	and	CCONJ
ajst-25053	32	42	expression	expression	NOUN
ajst-25053	32	43	.	.	PUNCT
ajst-25053	33	1	in	in	ADP
ajst-25053	33	2	addition	addition	NOUN
ajst-25053	33	3	,	,	PUNCT
ajst-25053	33	4	when	when	SCONJ
ajst-25053	33	5	designing	design	VERB
ajst-25053	33	6	dna	dna	PROPN
ajst-25053	33	7	sequences	sequence	NOUN
ajst-25053	33	8	,	,	PUNCT
ajst-25053	33	9	it	it	PRON
ajst-25053	33	10	is	be	AUX
ajst-25053	33	11	often	often	ADV
ajst-25053	33	12	necessary	necessary	ADJ
ajst-25053	33	13	to	to	PART
ajst-25053	33	14	analyze	analyze	VERB
ajst-25053	33	15	and	and	CCONJ
ajst-25053	33	16	optimize	optimize	VERB
ajst-25053	33	17	orf	orf	PROPN
ajst-25053	33	18	coders	coder	NOUN
ajst-25053	33	19	to	to	PART
ajst-25053	33	20	obtain	obtain	VERB
ajst-25053	33	21	the	the	DET
ajst-25053	33	22	optimal	optimal	ADJ
ajst-25053	33	23	coding	code	VERB
ajst-25053	33	24	efficiency	efficiency	NOUN
ajst-25053	33	25	.	.	PUNCT
ajst-25053	34	1	2.1.1	2.1.1	X
ajst-25053	34	2	.	.	PUNCT
ajst-25053	34	3	utr	utr	PROPN
ajst-25053	34	4	design	design	NOUN
ajst-25053	34	5	utr	utr	PROPN
ajst-25053	34	6	affects	affect	VERB
ajst-25053	34	7	mrna	mrna	PROPN
ajst-25053	34	8	decay	decay	NOUN
ajst-25053	34	9	and	and	CCONJ
ajst-25053	34	10	translation	translation	NOUN
ajst-25053	34	11	efficiency	efficiency	NOUN
ajst-25053	34	12	.	.	PUNCT
ajst-25053	35	1	the	the	DET
ajst-25053	35	2	5	5	NUM
ajst-25053	35	3	'	'	NUM
ajst-25053	35	4	utr	utr	NOUN
ajst-25053	35	5	sequence	sequence	NOUN
ajst-25053	35	6	plays	play	VERB
ajst-25053	35	7	a	a	DET
ajst-25053	35	8	key	key	ADJ
ajst-25053	35	9	role	role	NOUN
ajst-25053	35	10	in	in	ADP
ajst-25053	35	11	protein	protein	NOUN
ajst-25053	35	12	expression	expression	NOUN
ajst-25053	35	13	,	,	PUNCT
ajst-25053	35	14	and	and	CCONJ
ajst-25053	35	15	the	the	DET
ajst-25053	35	16	possible	possible	ADJ
ajst-25053	35	17	mechanism	mechanism	NOUN
ajst-25053	35	18	is	be	AUX
ajst-25053	35	19	that	that	SCONJ
ajst-25053	35	20	it	it	PRON
ajst-25053	35	21	affects	affect	VERB
ajst-25053	35	22	the	the	DET
ajst-25053	35	23	recognition	recognition	NOUN
ajst-25053	35	24	and	and	CCONJ
ajst-25053	35	25	binding	binding	NOUN
ajst-25053	35	26	of	of	ADP
ajst-25053	35	27	ribosome	ribosome	PROPN
ajst-25053	35	28	and	and	CCONJ
ajst-25053	35	29	mrna	mrna	NOUN
ajst-25053	35	30	at	at	ADP
ajst-25053	35	31	the	the	DET
ajst-25053	35	32	translation	translation	NOUN
ajst-25053	35	33	initiation	initiation	NOUN
ajst-25053	35	34	357	357	NUM
ajst-25053	35	35	stage	stage	NOUN
ajst-25053	35	36	,	,	PUNCT
ajst-25053	35	37	thus	thus	ADV
ajst-25053	35	38	affecting	affect	VERB
ajst-25053	35	39	the	the	DET
ajst-25053	35	40	translation	translation	NOUN
ajst-25053	35	41	efficiency	efficiency	NOUN
ajst-25053	35	42	of	of	ADP
ajst-25053	35	43	mrna	mrna	PROPN
ajst-25053	35	44	,	,	PUNCT
ajst-25053	35	45	including	include	VERB
ajst-25053	35	46	ribosome	ribosome	NOUN
ajst-25053	35	47	recruitment	recruitment	NOUN
ajst-25053	35	48	,	,	PUNCT
ajst-25053	35	49	scanning	scanning	NOUN
ajst-25053	35	50	and	and	CCONJ
ajst-25053	35	51	the	the	DET
ajst-25053	35	52	selection	selection	NOUN
ajst-25053	35	53	of	of	ADP
ajst-25053	35	54	start	start	NOUN
ajst-25053	35	55	codon	codon	PROPN
ajst-25053	35	56	.	.	PUNCT
ajst-25053	36	1	some	some	DET
ajst-25053	36	2	unique	unique	ADJ
ajst-25053	36	3	sequences	sequence	NOUN
ajst-25053	36	4	can	can	AUX
ajst-25053	36	5	be	be	AUX
ajst-25053	36	6	added	add	VERB
ajst-25053	36	7	to	to	ADP
ajst-25053	36	8	the	the	DET
ajst-25053	36	9	5	5	NUM
ajst-25053	36	10	'	'	PUNCT
ajst-25053	36	11	end	end	NOUN
ajst-25053	36	12	to	to	PART
ajst-25053	36	13	improve	improve	VERB
ajst-25053	36	14	the	the	DET
ajst-25053	36	15	translation	translation	NOUN
ajst-25053	36	16	efficiency	efficiency	NOUN
ajst-25053	36	17	and	and	CCONJ
ajst-25053	36	18	stability	stability	NOUN
ajst-25053	36	19	of	of	ADP
ajst-25053	36	20	mrna	mrna	PROPN
ajst-25053	36	21	.	.	PUNCT
ajst-25053	37	1	compared	compare	VERB
ajst-25053	37	2	with	with	ADP
ajst-25053	37	3	the	the	DET
ajst-25053	37	4	5	5	NUM
ajst-25053	37	5	'	'	PUNCT
ajst-25053	37	6	utr	utr	NOUN
ajst-25053	37	7	,	,	PUNCT
ajst-25053	37	8	the	the	DET
ajst-25053	37	9	3	3	NUM
ajst-25053	37	10	'	'	PUNCT
ajst-25053	37	11	utr	utr	ADJ
ajst-25053	37	12	mainly	mainly	ADV
ajst-25053	37	13	affects	affect	VERB
ajst-25053	37	14	the	the	DET
ajst-25053	37	15	half	half	ADJ
ajst-25053	37	16	-	-	PUNCT
ajst-25053	37	17	life	life	NOUN
ajst-25053	37	18	of	of	ADP
ajst-25053	37	19	mrna	mrna	PROPN
ajst-25053	37	20	,	,	PUNCT
ajst-25053	37	21	and	and	CCONJ
ajst-25053	37	22	it	it	PRON
ajst-25053	37	23	is	be	AUX
ajst-25053	37	24	a	a	DET
ajst-25053	37	25	concentrated	concentrated	ADJ
ajst-25053	37	26	region	region	NOUN
ajst-25053	37	27	of	of	ADP
ajst-25053	37	28	unstable	unstable	ADJ
ajst-25053	37	29	factors	factor	NOUN
ajst-25053	37	30	.	.	PUNCT
ajst-25053	38	1	when	when	SCONJ
ajst-25053	38	2	designing	design	VERB
ajst-25053	38	3	this	this	DET
ajst-25053	38	4	region	region	NOUN
ajst-25053	38	5	,	,	PUNCT
ajst-25053	38	6	increasing	increase	VERB
ajst-25053	38	7	the	the	DET
ajst-25053	38	8	proportion	proportion	NOUN
ajst-25053	38	9	of	of	ADP
ajst-25053	38	10	stable	stable	ADJ
ajst-25053	38	11	sequences	sequence	NOUN
ajst-25053	38	12	,	,	PUNCT
ajst-25053	38	13	such	such	ADJ
ajst-25053	38	14	as	as	ADP
ajst-25053	38	15	au	au	ADJ
ajst-25053	38	16	and	and	CCONJ
ajst-25053	38	17	gu	gu	X
ajst-25053	38	18	rich	rich	ADJ
ajst-25053	38	19	regions	region	NOUN
ajst-25053	38	20	,	,	PUNCT
ajst-25053	38	21	can	can	AUX
ajst-25053	38	22	effectively	effectively	ADV
ajst-25053	38	23	improve	improve	VERB
ajst-25053	38	24	the	the	DET
ajst-25053	38	25	stability	stability	NOUN
ajst-25053	38	26	of	of	ADP
ajst-25053	38	27	mrna	mrna	PROPN
ajst-25053	38	28	.	.	PUNCT
ajst-25053	39	1	studies	study	NOUN
ajst-25053	39	2	have	have	AUX
ajst-25053	39	3	shown	show	VERB
ajst-25053	39	4	that	that	SCONJ
ajst-25053	39	5	the	the	DET
ajst-25053	39	6	tandem	tandem	NOUN
ajst-25053	39	7	application	application	NOUN
ajst-25053	39	8	of	of	ADP
ajst-25053	39	9	3	3	NUM
ajst-25053	39	10	'	'	NUM
ajst-25053	39	11	utr	utr	NOUN
ajst-25053	39	12	containing	contain	VERB
ajst-25053	39	13	stable	stable	ADJ
ajst-25053	39	14	sequences	sequence	NOUN
ajst-25053	39	15	significantly	significantly	ADV
ajst-25053	39	16	improves	improve	VERB
ajst-25053	39	17	mrna	mrna	PROPN
ajst-25053	39	18	stability	stability	NOUN
ajst-25053	39	19	and	and	CCONJ
ajst-25053	39	20	translation	translation	NOUN
ajst-25053	39	21	efficiency	efficiency	NOUN
ajst-25053	39	22	.	.	PUNCT
ajst-25053	40	1	2.1.2	2.1.2	X
ajst-25053	40	2	.	.	X
ajst-25053	40	3	orf	orf	PROPN
ajst-25053	40	4	design	design	VERB
ajst-25053	40	5	the	the	DET
ajst-25053	40	6	codon	codon	NOUN
ajst-25053	40	7	sequence	sequence	NOUN
ajst-25053	40	8	in	in	ADP
ajst-25053	40	9	orf	orf	PROPN
ajst-25053	40	10	affects	affect	VERB
ajst-25053	40	11	the	the	DET
ajst-25053	40	12	mrna	mrna	PROPN
ajst-25053	40	13	translation	translation	NOUN
ajst-25053	40	14	efficiency	efficiency	NOUN
ajst-25053	40	15	.	.	PUNCT
ajst-25053	41	1	efficient	efficient	ADJ
ajst-25053	41	2	translation	translation	NOUN
ajst-25053	41	3	of	of	ADP
ajst-25053	41	4	mrna	mrna	PROPN
ajst-25053	41	5	is	be	AUX
ajst-25053	41	6	not	not	PART
ajst-25053	41	7	always	always	ADV
ajst-25053	41	8	beneficial	beneficial	ADJ
ajst-25053	41	9	,	,	PUNCT
ajst-25053	41	10	and	and	CCONJ
ajst-25053	41	11	some	some	DET
ajst-25053	41	12	proteins	protein	NOUN
ajst-25053	41	13	require	require	VERB
ajst-25053	41	14	relatively	relatively	ADV
ajst-25053	41	15	low	low	ADJ
ajst-25053	41	16	translation	translation	NOUN
ajst-25053	41	17	efficiency	efficiency	NOUN
ajst-25053	41	18	for	for	ADP
ajst-25053	41	19	structural	structural	ADJ
ajst-25053	41	20	stability	stability	NOUN
ajst-25053	41	21	.	.	PUNCT
ajst-25053	42	1	therefore	therefore	ADV
ajst-25053	42	2	,	,	PUNCT
ajst-25053	42	3	the	the	DET
ajst-25053	42	4	translation	translation	NOUN
ajst-25053	42	5	efficiency	efficiency	NOUN
ajst-25053	42	6	of	of	ADP
ajst-25053	42	7	mrna	mrna	PROPN
ajst-25053	42	8	can	can	AUX
ajst-25053	42	9	be	be	AUX
ajst-25053	42	10	adjusted	adjust	VERB
ajst-25053	42	11	by	by	ADP
ajst-25053	42	12	adjusting	adjust	VERB
ajst-25053	42	13	the	the	DET
ajst-25053	42	14	frequency	frequency	NOUN
ajst-25053	42	15	of	of	ADP
ajst-25053	42	16	rare	rare	ADJ
ajst-25053	42	17	codons	codon	NOUN
ajst-25053	42	18	in	in	ADP
ajst-25053	42	19	orf	orf	PROPN
ajst-25053	42	20	.	.	PUNCT
ajst-25053	43	1	codon	codon	ADJ
ajst-25053	43	2	optimization	optimization	NOUN
ajst-25053	43	3	has	have	AUX
ajst-25053	43	4	been	be	AUX
ajst-25053	43	5	proved	prove	VERB
ajst-25053	43	6	to	to	PART
ajst-25053	43	7	remarkably	remarkably	ADV
ajst-25053	43	8	enhance	enhance	VERB
ajst-25053	43	9	protein	protein	NOUN
ajst-25053	43	10	expression	expression	NOUN
ajst-25053	43	11	by	by	ADP
ajst-25053	43	12	adding	add	VERB
ajst-25053	43	13	frequent	frequent	ADJ
ajst-25053	43	14	codons	codon	NOUN
ajst-25053	43	15	and	and	CCONJ
ajst-25053	43	16	codons	codon	NOUN
ajst-25053	43	17	with	with	ADP
ajst-25053	43	18	higher	high	ADJ
ajst-25053	43	19	trna	trna	PROPN
ajst-25053	43	20	abundances	abundance	NOUN
ajst-25053	43	21	.	.	PUNCT
ajst-25053	44	1	in	in	ADP
ajst-25053	44	2	addition	addition	NOUN
ajst-25053	44	3	,	,	PUNCT
ajst-25053	44	4	mrna	mrna	PROPN
ajst-25053	44	5	stability	stability	NOUN
ajst-25053	44	6	and	and	CCONJ
ajst-25053	44	7	protein	protein	NOUN
ajst-25053	44	8	expression	expression	NOUN
ajst-25053	44	9	in	in	ADP
ajst-25053	44	10	vivo	vivo	NOUN
ajst-25053	44	11	can	can	AUX
ajst-25053	44	12	be	be	AUX
ajst-25053	44	13	improved	improve	VERB
ajst-25053	44	14	by	by	ADP
ajst-25053	44	15	enriching	enrich	VERB
ajst-25053	44	16	guanine	guanine	NOUN
ajst-25053	44	17	and	and	CCONJ
ajst-25053	44	18	cytosine	cytosine	NOUN
ajst-25053	44	19	contents	content	NOUN
ajst-25053	44	20	.	.	PUNCT
ajst-25053	45	1	2.2	2.2	NUM
ajst-25053	45	2	.	.	PUNCT
ajst-25053	45	3	mrna	mrna	PROPN
ajst-25053	45	4	in	in	ADP
ajst-25053	45	5	vitro	vitro	X
ajst-25053	45	6	transcription	transcription	NOUN
ajst-25053	45	7	the	the	DET
ajst-25053	45	8	technology	technology	NOUN
ajst-25053	45	9	of	of	ADP
ajst-25053	45	10	mrna	mrna	PROPN
ajst-25053	45	11	transcription	transcription	NOUN
ajst-25053	45	12	in	in	ADP
ajst-25053	45	13	vitro	vitro	ADJ
ajst-25053	45	14	has	have	AUX
ajst-25053	45	15	been	be	AUX
ajst-25053	45	16	relatively	relatively	ADV
ajst-25053	45	17	mature	mature	ADJ
ajst-25053	45	18	.	.	PUNCT
ajst-25053	46	1	phage	phage	NOUN
ajst-25053	46	2	rna	rna	NOUN
ajst-25053	46	3	polymerase	polymerase	NOUN
ajst-25053	46	4	uses	use	VERB
ajst-25053	46	5	constructed	construct	VERB
ajst-25053	46	6	linearized	linearize	VERB
ajst-25053	46	7	dna	dna	NOUN
ajst-25053	46	8	as	as	ADP
ajst-25053	46	9	template	template	NOUN
ajst-25053	46	10	,	,	PUNCT
ajst-25053	46	11	nucleotides	nucleotide	NOUN
ajst-25053	46	12	and	and	CCONJ
ajst-25053	46	13	modified	modify	VERB
ajst-25053	46	14	nucleotides	nucleotide	NOUN
ajst-25053	46	15	as	as	ADP
ajst-25053	46	16	raw	raw	ADJ
ajst-25053	46	17	materials	material	NOUN
ajst-25053	46	18	to	to	PART
ajst-25053	46	19	initiate	initiate	VERB
ajst-25053	46	20	transcription	transcription	NOUN
ajst-25053	46	21	and	and	CCONJ
ajst-25053	46	22	produce	produce	VERB
ajst-25053	46	23	mrna	mrna	NOUN
ajst-25053	46	24	precursors	precursor	NOUN
ajst-25053	46	25	.	.	PUNCT
ajst-25053	47	1	at	at	ADP
ajst-25053	47	2	present	present	ADJ
ajst-25053	47	3	,	,	PUNCT
ajst-25053	47	4	the	the	DET
ajst-25053	47	5	most	most	ADV
ajst-25053	47	6	popular	popular	ADJ
ajst-25053	47	7	phage	phage	NOUN
ajst-25053	47	8	rna	rna	NOUN
ajst-25053	47	9	polymerases	polymerase	NOUN
ajst-25053	47	10	are	be	AUX
ajst-25053	47	11	t3	t3	PROPN
ajst-25053	47	12	,	,	PUNCT
ajst-25053	47	13	t7	t7	PROPN
ajst-25053	47	14	and	and	CCONJ
ajst-25053	47	15	sp6rna	sp6rna	PROPN
ajst-25053	47	16	polymerases	polymerase	NOUN
ajst-25053	47	17	,	,	PUNCT
ajst-25053	47	18	among	among	ADP
ajst-25053	47	19	which	which	PRON
ajst-25053	47	20	t7rna	t7rna	ADJ
ajst-25053	47	21	polymerase	polymerase	NOUN
ajst-25053	47	22	is	be	AUX
ajst-25053	47	23	the	the	DET
ajst-25053	47	24	most	most	ADV
ajst-25053	47	25	commonly	commonly	ADV
ajst-25053	47	26	used	use	VERB
ajst-25053	47	27	.	.	PUNCT
ajst-25053	48	1	2.3	2.3	NUM
ajst-25053	48	2	.	.	PUNCT
ajst-25053	49	1	cap	cap	VERB
ajst-25053	49	2	most	most	ADV
ajst-25053	49	3	mature	mature	ADJ
ajst-25053	49	4	mrnas	mrna	NOUN
ajst-25053	49	5	of	of	ADP
ajst-25053	49	6	eukaryotes	eukaryote	NOUN
ajst-25053	49	7	also	also	ADV
ajst-25053	49	8	have	have	VERB
ajst-25053	49	9	a	a	DET
ajst-25053	49	10	cap	cap	NOUN
ajst-25053	49	11	structure	structure	NOUN
ajst-25053	49	12	ending	end	VERB
ajst-25053	49	13	in	in	ADP
ajst-25053	49	14	7	7	NUM
ajst-25053	49	15	-	-	PUNCT
ajst-25053	49	16	methylguanosine	methylguanosine	NOUN
ajst-25053	49	17	.	.	PUNCT
ajst-25053	50	1	the	the	DET
ajst-25053	50	2	5	5	NUM
ajst-25053	50	3	'	'	NOUN
ajst-25053	50	4	cap	cap	NOUN
ajst-25053	50	5	plays	play	VERB
ajst-25053	50	6	an	an	DET
ajst-25053	50	7	important	important	ADJ
ajst-25053	50	8	role	role	NOUN
ajst-25053	50	9	in	in	ADP
ajst-25053	50	10	improving	improve	VERB
ajst-25053	50	11	mrna	mrna	NOUN
ajst-25053	50	12	function	function	NOUN
ajst-25053	50	13	by	by	ADP
ajst-25053	50	14	eliminating	eliminate	VERB
ajst-25053	50	15	free	free	ADJ
ajst-25053	50	16	phosphate	phosphate	ADJ
ajst-25053	50	17	groups	group	NOUN
ajst-25053	50	18	in	in	ADP
ajst-25053	50	19	the	the	DET
ajst-25053	50	20	mrna	mrna	PROPN
ajst-25053	50	21	sequence	sequence	NOUN
ajst-25053	50	22	,	,	PUNCT
ajst-25053	50	23	thereby	thereby	ADV
ajst-25053	50	24	significantly	significantly	ADV
ajst-25053	50	25	enhancing	enhance	VERB
ajst-25053	50	26	mrna	mrna	PROPN
ajst-25053	50	27	stability	stability	NOUN
ajst-25053	50	28	,	,	PUNCT
ajst-25053	50	29	enabling	enable	VERB
ajst-25053	50	30	ribosomes	ribosome	NOUN
ajst-25053	50	31	to	to	PART
ajst-25053	50	32	recognize	recognize	VERB
ajst-25053	50	33	the	the	DET
ajst-25053	50	34	start	start	NOUN
ajst-25053	50	35	of	of	ADP
ajst-25053	50	36	mrna	mrna	NOUN
ajst-25053	50	37	,	,	PUNCT
ajst-25053	50	38	and	and	CCONJ
ajst-25053	50	39	improving	improve	VERB
ajst-25053	50	40	translation	translation	NOUN
ajst-25053	50	41	efficiency	efficiency	NOUN
ajst-25053	50	42	by	by	ADP
ajst-25053	50	43	binding	bind	VERB
ajst-25053	50	44	to	to	ADP
ajst-25053	50	45	eukaryotic	eukaryotic	ADJ
ajst-25053	50	46	translation	translation	NOUN
ajst-25053	50	47	initiation	initiation	NOUN
ajst-25053	50	48	factor	factor	NOUN
ajst-25053	50	49	4e	4e	PROPN
ajst-25053	50	50	(	(	PUNCT
ajst-25053	50	51	eif4e	eif4e	NOUN
ajst-25053	50	52	)	)	PUNCT
ajst-25053	50	53	.	.	PUNCT
ajst-25053	51	1	the	the	DET
ajst-25053	51	2	structure	structure	NOUN
ajst-25053	51	3	of	of	ADP
ajst-25053	51	4	the	the	DET
ajst-25053	51	5	5	5	NUM
ajst-25053	51	6	'	'	NUM
ajst-25053	51	7	end	end	NOUN
ajst-25053	51	8	hat	hat	NOUN
ajst-25053	51	9	has	have	VERB
ajst-25053	51	10	three	three	NUM
ajst-25053	51	11	types	type	NOUN
ajst-25053	51	12	,	,	PUNCT
ajst-25053	51	13	divided	divide	VERB
ajst-25053	51	14	into	into	ADP
ajst-25053	51	15	type	type	NOUN
ajst-25053	51	16	0	0	NUM
ajst-25053	51	17	,	,	PUNCT
ajst-25053	51	18	type	type	NOUN
ajst-25053	51	19	i	i	PRON
ajst-25053	51	20	and	and	CCONJ
ajst-25053	51	21	type	type	PROPN
ajst-25053	51	22	ii	ii	PROPN
ajst-25053	51	23	.	.	PUNCT
ajst-25053	51	24	type	type	NOUN
ajst-25053	51	25	0	0	NUM
ajst-25053	51	26	hat	hat	NOUN
ajst-25053	51	27	refers	refer	VERB
ajst-25053	51	28	to	to	ADP
ajst-25053	51	29	the	the	DET
ajst-25053	51	30	end	end	NOUN
ajst-25053	51	31	of	of	ADP
ajst-25053	51	32	the	the	DET
ajst-25053	51	33	nucleotide	nucleotide	NOUN
ajst-25053	51	34	ribose	ribose	NOUN
ajst-25053	51	35	without	without	ADP
ajst-25053	51	36	methylation	methylation	NOUN
ajst-25053	51	37	,	,	PUNCT
ajst-25053	51	38	type	type	NOUN
ajst-25053	51	39	i	i	PRON
ajst-25053	51	40	hat	hat	NOUN
ajst-25053	51	41	refers	refer	VERB
ajst-25053	51	42	to	to	ADP
ajst-25053	51	43	the	the	DET
ajst-25053	51	44	end	end	NOUN
ajst-25053	51	45	of	of	ADP
ajst-25053	51	46	the	the	DET
ajst-25053	51	47	nucleotide	nucleotide	NOUN
ajst-25053	51	48	ribose	ribose	NOUN
ajst-25053	51	49	is	be	AUX
ajst-25053	51	50	methylated	methylate	VERB
ajst-25053	51	51	under	under	ADP
ajst-25053	51	52	the	the	DET
ajst-25053	51	53	catalysis	catalysis	NOUN
ajst-25053	51	54	of	of	ADP
ajst-25053	51	55	the	the	DET
ajst-25053	51	56	enzyme	enzyme	NOUN
ajst-25053	51	57	,	,	PUNCT
ajst-25053	51	58	type	type	NOUN
ajst-25053	51	59	ii	ii	PROPN
ajst-25053	51	60	hat	hat	NOUN
ajst-25053	51	61	refers	refer	VERB
ajst-25053	51	62	to	to	ADP
ajst-25053	51	63	the	the	DET
ajst-25053	51	64	end	end	NOUN
ajst-25053	51	65	of	of	ADP
ajst-25053	51	66	the	the	DET
ajst-25053	51	67	nucleotide	nucleotide	NOUN
ajst-25053	51	68	ribose	ribose	NOUN
ajst-25053	51	69	is	be	AUX
ajst-25053	51	70	methylated	methylate	VERB
ajst-25053	51	71	.	.	PUNCT
ajst-25053	52	1	in	in	ADP
ajst-25053	52	2	2014	2014	NUM
ajst-25053	52	3	,	,	PUNCT
ajst-25053	52	4	kumar	kumar	PROPN
ajst-25053	52	5	et	et	PROPN
ajst-25053	52	6	al	al	PROPN
ajst-25053	52	7	.	.	PROPN
ajst-25053	52	8	tested	test	VERB
ajst-25053	52	9	the	the	DET
ajst-25053	52	10	ability	ability	NOUN
ajst-25053	52	11	of	of	ADP
ajst-25053	52	12	pattern	pattern	NOUN
ajst-25053	52	13	recognition	recognition	NOUN
ajst-25053	52	14	receptors	receptor	NOUN
ajst-25053	52	15	to	to	PART
ajst-25053	52	16	recognize	recognize	VERB
ajst-25053	52	17	capped	capped	ADJ
ajst-25053	52	18	mrna	mrna	NOUN
ajst-25053	52	19	in	in	ADP
ajst-25053	52	20	three	three	NUM
ajst-25053	52	21	different	different	ADJ
ajst-25053	52	22	ways	way	NOUN
ajst-25053	52	23	,	,	PUNCT
ajst-25053	52	24	including	include	VERB
ajst-25053	52	25	cap0	cap0	NOUN
ajst-25053	52	26	,	,	PUNCT
ajst-25053	52	27	cap1	cap1	NOUN
ajst-25053	52	28	and	and	CCONJ
ajst-25053	52	29	uncapped	uncapped	PROPN
ajst-25053	52	30	mrna	mrna	PROPN
ajst-25053	52	31	,	,	PUNCT
ajst-25053	52	32	and	and	CCONJ
ajst-25053	52	33	found	find	VERB
ajst-25053	52	34	that	that	PRON
ajst-25053	52	35	cap1	cap1	NOUN
ajst-25053	52	36	capped	cap	VERB
ajst-25053	52	37	mrna	mrna	PROPN
ajst-25053	52	38	could	could	AUX
ajst-25053	52	39	still	still	ADV
ajst-25053	52	40	translate	translate	VERB
ajst-25053	52	41	into	into	ADP
ajst-25053	52	42	protein	protein	NOUN
ajst-25053	52	43	after	after	ADP
ajst-25053	52	44	being	be	AUX
ajst-25053	52	45	recognized	recognize	VERB
ajst-25053	52	46	by	by	ADP
ajst-25053	52	47	pattern	pattern	NOUN
ajst-25053	52	48	recognition	recognition	NOUN
ajst-25053	52	49	receptors	receptor	NOUN
ajst-25053	52	50	.	.	PUNCT
ajst-25053	53	1	however	however	ADV
ajst-25053	53	2	,	,	PUNCT
ajst-25053	53	3	cap0	cap0	PROPN
ajst-25053	53	4	and	and	CCONJ
ajst-25053	53	5	uncapped	uncapped	PROPN
ajst-25053	53	6	mrna	mrna	PROPN
ajst-25053	53	7	can	can	AUX
ajst-25053	53	8	not	not	PART
ajst-25053	53	9	translate	translate	VERB
ajst-25053	53	10	and	and	CCONJ
ajst-25053	53	11	produce	produce	VERB
ajst-25053	53	12	proteins	protein	NOUN
ajst-25053	53	13	after	after	ADP
ajst-25053	53	14	being	be	AUX
ajst-25053	53	15	recognized	recognize	VERB
ajst-25053	53	16	by	by	ADP
ajst-25053	53	17	pattern	pattern	NOUN
ajst-25053	53	18	recognition	recognition	NOUN
ajst-25053	53	19	receptors[3	receptors[3	PROPN
ajst-25053	53	20	]	]	X
ajst-25053	53	21	,	,	PUNCT
ajst-25053	53	22	and	and	CCONJ
ajst-25053	53	23	the	the	DET
ajst-25053	53	24	function	function	NOUN
ajst-25053	53	25	of	of	ADP
ajst-25053	53	26	type	type	NOUN
ajst-25053	53	27	ii	ii	PROPN
ajst-25053	53	28	hat	hat	NOUN
ajst-25053	53	29	structure	structure	NOUN
ajst-25053	53	30	has	have	AUX
ajst-25053	53	31	not	not	PART
ajst-25053	53	32	been	be	AUX
ajst-25053	53	33	explored	explore	VERB
ajst-25053	53	34	.	.	PUNCT
ajst-25053	54	1	therefore	therefore	ADV
ajst-25053	54	2	,	,	PUNCT
ajst-25053	54	3	selecting	select	VERB
ajst-25053	54	4	the	the	DET
ajst-25053	54	5	appropriate	appropriate	ADJ
ajst-25053	54	6	type	type	NOUN
ajst-25053	54	7	i	i	PRON
ajst-25053	54	8	hat	hat	NOUN
ajst-25053	54	9	mode	mode	NOUN
ajst-25053	54	10	can	can	AUX
ajst-25053	54	11	avoid	avoid	VERB
ajst-25053	54	12	inhibiting	inhibit	VERB
ajst-25053	54	13	the	the	DET
ajst-25053	54	14	translation	translation	NOUN
ajst-25053	54	15	efficiency	efficiency	NOUN
ajst-25053	54	16	of	of	ADP
ajst-25053	54	17	mrna	mrna	PROPN
ajst-25053	54	18	due	due	ADP
ajst-25053	54	19	to	to	ADP
ajst-25053	54	20	strong	strong	ADJ
ajst-25053	54	21	immune	immune	ADJ
ajst-25053	54	22	response	response	NOUN
ajst-25053	54	23	.	.	PUNCT
ajst-25053	55	1	there	there	PRON
ajst-25053	55	2	are	be	VERB
ajst-25053	55	3	two	two	NUM
ajst-25053	55	4	kinds	kind	NOUN
ajst-25053	55	5	of	of	ADP
ajst-25053	55	6	mrna	mrna	PROPN
ajst-25053	55	7	cap	cap	PROPN
ajst-25053	55	8	modification	modification	NOUN
ajst-25053	55	9	techniques	technique	NOUN
ajst-25053	55	10	,	,	PUNCT
ajst-25053	55	11	enzyme	enzyme	NOUN
ajst-25053	55	12	based	base	VERB
ajst-25053	55	13	cap	cap	NOUN
ajst-25053	55	14	method	method	NOUN
ajst-25053	55	15	and	and	CCONJ
ajst-25053	55	16	cap	cap	NOUN
ajst-25053	55	17	analogue	analogue	NOUN
ajst-25053	55	18	cotranscription	cotranscription	NOUN
ajst-25053	55	19	method	method	NOUN
ajst-25053	55	20	.	.	PUNCT
ajst-25053	56	1	enzyme	enzyme	NOUN
ajst-25053	56	2	-	-	PUNCT
ajst-25053	56	3	based	base	VERB
ajst-25053	56	4	capping	capping	NOUN
ajst-25053	56	5	method	method	NOUN
ajst-25053	56	6	refers	refer	VERB
ajst-25053	56	7	to	to	ADP
ajst-25053	56	8	in	in	ADP
ajst-25053	56	9	vitro	vitro	X
ajst-25053	56	10	transcription	transcription	NOUN
ajst-25053	56	11	through	through	ADP
ajst-25053	56	12	methyltransferase	methyltransferase	NOUN
ajst-25053	56	13	reaction	reaction	NOUN
ajst-25053	56	14	,	,	PUNCT
ajst-25053	56	15	such	such	ADJ
ajst-25053	56	16	as	as	ADP
ajst-25053	56	17	vaccinia	vaccinia	NOUN
ajst-25053	56	18	virus	virus	NOUN
ajst-25053	56	19	capping	cap	VERB
ajst-25053	56	20	enzyme	enzyme	NOUN
ajst-25053	56	21	developed	develop	VERB
ajst-25053	56	22	by	by	ADP
ajst-25053	56	23	martin	martin	PROPN
ajst-25053	56	24	et	et	PROPN
ajst-25053	56	25	al	al	PROPN
ajst-25053	56	26	.	.	PROPN
ajst-25053	56	27	1975	1975	NUM
ajst-25053	56	28	binding	bind	VERB
ajst-25053	56	29	2	2	NUM
ajst-25053	56	30	'	'	NUM
ajst-25053	56	31	‐o‐	‐o‐	PROPN
ajst-25053	56	32	methyltransferase	methyltransferase	NOUN
ajst-25053	56	33	to	to	PART
ajst-25053	56	34	produce	produce	VERB
ajst-25053	56	35	cap1[4	cap1[4	NOUN
ajst-25053	56	36	]	]	PUNCT
ajst-25053	56	37	.	.	PUNCT
ajst-25053	57	1	however	however	ADV
ajst-25053	57	2	,	,	PUNCT
ajst-25053	57	3	this	this	DET
ajst-25053	57	4	method	method	NOUN
ajst-25053	57	5	also	also	ADV
ajst-25053	57	6	has	have	VERB
ajst-25053	57	7	drawbacks	drawback	NOUN
ajst-25053	57	8	,	,	PUNCT
ajst-25053	57	9	the	the	DET
ajst-25053	57	10	use	use	NOUN
ajst-25053	57	11	of	of	ADP
ajst-25053	57	12	vaccinia	vaccinia	NOUN
ajst-25053	57	13	virus	virus	NOUN
ajst-25053	57	14	capping	cap	VERB
ajst-25053	57	15	enzyme	enzyme	NOUN
ajst-25053	57	16	is	be	AUX
ajst-25053	57	17	expensive	expensive	ADJ
ajst-25053	57	18	,	,	PUNCT
ajst-25053	57	19	enzyme	enzyme	NOUN
ajst-25053	57	20	production	production	NOUN
ajst-25053	57	21	cost	cost	NOUN
ajst-25053	57	22	is	be	AUX
ajst-25053	57	23	high	high	ADJ
ajst-25053	57	24	.	.	PUNCT
ajst-25053	58	1	in	in	ADP
ajst-25053	58	2	addition	addition	NOUN
ajst-25053	58	3	,	,	PUNCT
ajst-25053	58	4	the	the	DET
ajst-25053	58	5	enzyme	enzyme	NOUN
ajst-25053	58	6	cap	cap	NOUN
ajst-25053	58	7	introduces	introduce	VERB
ajst-25053	58	8	additional	additional	ADJ
ajst-25053	58	9	proteins	protein	NOUN
ajst-25053	58	10	,	,	PUNCT
ajst-25053	58	11	resulting	result	VERB
ajst-25053	58	12	in	in	ADP
ajst-25053	58	13	the	the	DET
ajst-25053	58	14	need	need	NOUN
ajst-25053	58	15	for	for	ADP
ajst-25053	58	16	multiple	multiple	ADJ
ajst-25053	58	17	purification	purification	NOUN
ajst-25053	58	18	in	in	ADP
ajst-25053	58	19	the	the	DET
ajst-25053	58	20	preparation.at	preparation.at	X
ajst-25053	58	21	present	present	NOUN
ajst-25053	58	22	,	,	PUNCT
ajst-25053	58	23	hat	hat	NOUN
ajst-25053	58	24	analogs	analog	NOUN
ajst-25053	58	25	cotranscription	cotranscription	NOUN
ajst-25053	58	26	method	method	NOUN
ajst-25053	58	27	is	be	AUX
ajst-25053	58	28	more	more	ADV
ajst-25053	58	29	used	use	VERB
ajst-25053	58	30	,	,	PUNCT
ajst-25053	58	31	that	that	ADV
ajst-25053	58	32	is	is	ADV
ajst-25053	58	33	,	,	PUNCT
ajst-25053	58	34	hat	hat	NOUN
ajst-25053	58	35	analogs	analog	NOUN
ajst-25053	58	36	are	be	AUX
ajst-25053	58	37	directly	directly	ADV
ajst-25053	58	38	transcribed	transcribe	VERB
ajst-25053	58	39	in	in	ADP
ajst-25053	58	40	vitro	vitro	X
ajst-25053	58	41	to	to	PART
ajst-25053	58	42	generate	generate	VERB
ajst-25053	58	43	mrna	mrna	PROPN
ajst-25053	58	44	with	with	ADP
ajst-25053	58	45	hat	hat	NOUN
ajst-25053	58	46	structure	structure	NOUN
ajst-25053	58	47	.	.	PUNCT
ajst-25053	59	1	however	however	ADV
ajst-25053	59	2	,	,	PUNCT
ajst-25053	59	3	studies	study	NOUN
ajst-25053	59	4	have	have	AUX
ajst-25053	59	5	found	find	VERB
ajst-25053	59	6	that	that	SCONJ
ajst-25053	59	7	conventional	conventional	ADJ
ajst-25053	59	8	hat	hat	NOUN
ajst-25053	59	9	analogues	analogue	NOUN
ajst-25053	59	10	bind	bind	VERB
ajst-25053	59	11	mrna	mrna	PROPN
ajst-25053	59	12	sequences	sequence	NOUN
ajst-25053	59	13	in	in	ADP
ajst-25053	59	14	reverse	reverse	NOUN
ajst-25053	59	15	,	,	PUNCT
ajst-25053	59	16	resulting	result	VERB
ajst-25053	59	17	in	in	ADP
ajst-25053	59	18	the	the	DET
ajst-25053	59	19	formation	formation	NOUN
ajst-25053	59	20	of	of	ADP
ajst-25053	59	21	mrna	mrna	PROPN
ajst-25053	59	22	isomers	isomer	NOUN
ajst-25053	59	23	,	,	PUNCT
ajst-25053	59	24	which	which	PRON
ajst-25053	59	25	affect	affect	VERB
ajst-25053	59	26	translation	translation	NOUN
ajst-25053	59	27	efficiency	efficiency	NOUN
ajst-25053	59	28	.	.	PUNCT
ajst-25053	60	1	to	to	PART
ajst-25053	60	2	avoid	avoid	VERB
ajst-25053	60	3	the	the	DET
ajst-25053	60	4	reverse	reverse	ADJ
ajst-25053	60	5	infiltration	infiltration	NOUN
ajst-25053	60	6	of	of	ADP
ajst-25053	60	7	5	5	NUM
ajst-25053	60	8	'	'	NOUN
ajst-25053	60	9	hats	hat	NOUN
ajst-25053	60	10	,	,	PUNCT
ajst-25053	60	11	an	an	DET
ajst-25053	60	12	anti	anti	ADJ
ajst-25053	60	13	-	-	ADJ
ajst-25053	60	14	reverse	reverse	ADJ
ajst-25053	60	15	cap	cap	NOUN
ajst-25053	60	16	analogs	analog	NOUN
ajst-25053	60	17	(	(	PUNCT
ajst-25053	60	18	arca	arca	PROPN
ajst-25053	60	19	)	)	PUNCT
ajst-25053	60	20	has	have	AUX
ajst-25053	60	21	been	be	AUX
ajst-25053	60	22	developed	develop	VERB
ajst-25053	60	23	and	and	CCONJ
ajst-25053	60	24	found	find	VERB
ajst-25053	60	25	to	to	PART
ajst-25053	60	26	be	be	AUX
ajst-25053	60	27	more	more	ADV
ajst-25053	60	28	efficient	efficient	ADJ
ajst-25053	60	29	in	in	ADP
ajst-25053	60	30	translation	translation	NOUN
ajst-25053	60	31	than	than	ADP
ajst-25053	60	32	the	the	DET
ajst-25053	60	33	conventional	conventional	ADJ
ajst-25053	60	34	cap	cap	NOUN
ajst-25053	60	35	approach	approach	NOUN
ajst-25053	60	36	.	.	PUNCT
ajst-25053	61	1	research	research	NOUN
ajst-25053	61	2	on	on	ADP
ajst-25053	61	3	acra	acra	NOUN
ajst-25053	61	4	has	have	AUX
ajst-25053	61	5	been	be	AUX
ajst-25053	61	6	ongoing	ongoing	ADJ
ajst-25053	61	7	in	in	ADP
ajst-25053	61	8	recent	recent	ADJ
ajst-25053	61	9	years	year	NOUN
ajst-25053	61	10	.	.	PUNCT
ajst-25053	62	1	for	for	ADP
ajst-25053	62	2	example	example	NOUN
ajst-25053	62	3	,	,	PUNCT
ajst-25053	62	4	arca	arca	NOUN
ajst-25053	62	5	-	-	PUNCT
ajst-25053	62	6	based	base	VERB
ajst-25053	62	7	thiophosphate	thiophosphate	NOUN
ajst-25053	62	8	modification	modification	NOUN
ajst-25053	62	9	can	can	AUX
ajst-25053	62	10	improve	improve	VERB
ajst-25053	62	11	mrna	mrna	PROPN
ajst-25053	62	12	translation	translation	NOUN
ajst-25053	62	13	efficiency	efficiency	NOUN
ajst-25053	62	14	by	by	ADP
ajst-25053	62	15	increasing	increase	VERB
ajst-25053	62	16	mrna	mrna	PROPN
ajst-25053	62	17	affinity	affinity	NOUN
ajst-25053	62	18	to	to	ADP
ajst-25053	62	19	eif4e	eif4e	VERB
ajst-25053	62	20	.	.	PUNCT
ajst-25053	63	1	in	in	ADP
ajst-25053	63	2	2018	2018	NUM
ajst-25053	63	3	,	,	PUNCT
ajst-25053	63	4	another	another	DET
ajst-25053	63	5	co	co	NOUN
ajst-25053	63	6	-	-	NOUN
ajst-25053	63	7	transcription	transcription	NOUN
ajst-25053	63	8	capping	capping	NOUN
ajst-25053	63	9	method	method	NOUN
ajst-25053	63	10	called	call	VERB
ajst-25053	63	11	"	"	PUNCT
ajst-25053	63	12	cleancap	cleancap	NOUN
ajst-25053	63	13	"	"	PUNCT
ajst-25053	63	14	was	be	AUX
ajst-25053	63	15	developed	develop	VERB
ajst-25053	63	16	,	,	PUNCT
ajst-25053	63	17	which	which	PRON
ajst-25053	63	18	uses	use	VERB
ajst-25053	63	19	an	an	DET
ajst-25053	63	20	initial	initial	ADJ
ajst-25053	63	21	capping	capping	NOUN
ajst-25053	63	22	trimer	trimer	NOUN
ajst-25053	63	23	to	to	PART
ajst-25053	63	24	produce	produce	VERB
ajst-25053	63	25	a	a	DET
ajst-25053	63	26	naturally	naturally	ADV
ajst-25053	63	27	occurring	occur	VERB
ajst-25053	63	28	5	5	NUM
ajst-25053	63	29	'	'	PUNCT
ajst-25053	63	30	end	end	NOUN
ajst-25053	63	31	-	-	PUNCT
ajst-25053	63	32	cap	cap	NOUN
ajst-25053	63	33	structure	structure	NOUN
ajst-25053	63	34	with	with	ADP
ajst-25053	63	35	a	a	DET
ajst-25053	63	36	capping	cap	VERB
ajst-25053	63	37	efficiency	efficiency	NOUN
ajst-25053	63	38	of	of	ADP
ajst-25053	63	39	90	90	NUM
ajst-25053	63	40	%	%	NOUN
ajst-25053	63	41	to	to	PART
ajst-25053	63	42	99	99	NUM
ajst-25053	63	43	%	%	NOUN
ajst-25053	63	44	,	,	PUNCT
ajst-25053	63	45	and	and	CCONJ
ajst-25053	63	46	the	the	DET
ajst-25053	63	47	most	most	ADV
ajst-25053	63	48	mrna	mrna	PROPN
ajst-25053	63	49	companies	company	NOUN
ajst-25053	63	50	are	be	AUX
ajst-25053	63	51	currently	currently	ADV
ajst-25053	63	52	using	use	VERB
ajst-25053	63	53	this	this	DET
ajst-25053	63	54	capping	capping	NOUN
ajst-25053	63	55	strategy	strategy	NOUN
ajst-25053	63	56	.	.	PUNCT
ajst-25053	64	1	2.4	2.4	NUM
ajst-25053	64	2	.	.	PUNCT
ajst-25053	65	1	tail	tail	NOUN
ajst-25053	65	2	poly	poly	NOUN
ajst-25053	65	3	(	(	PUNCT
ajst-25053	65	4	a	a	X
ajst-25053	65	5	)	)	PUNCT
ajst-25053	65	6	tail	tail	NOUN
ajst-25053	65	7	can	can	AUX
ajst-25053	65	8	promote	promote	VERB
ajst-25053	65	9	mrna	mrna	PROPN
ajst-25053	65	10	translation	translation	NOUN
ajst-25053	65	11	efficiency	efficiency	NOUN
ajst-25053	65	12	and	and	CCONJ
ajst-25053	65	13	enhance	enhance	VERB
ajst-25053	65	14	mrna	mrna	PROPN
ajst-25053	65	15	stability	stability	NOUN
ajst-25053	65	16	by	by	ADP
ajst-25053	65	17	reducing	reduce	VERB
ajst-25053	65	18	rna	rna	NOUN
ajst-25053	65	19	exonuclease	exonuclease	NOUN
ajst-25053	65	20	activity	activity	NOUN
ajst-25053	65	21	.	.	PUNCT
ajst-25053	66	1	in	in	ADP
ajst-25053	66	2	addition	addition	NOUN
ajst-25053	66	3	,	,	PUNCT
ajst-25053	66	4	poly	poly	ADJ
ajst-25053	66	5	(	(	PUNCT
ajst-25053	66	6	a	a	NOUN
ajst-25053	66	7	)	)	PUNCT
ajst-25053	66	8	binding	bind	VERB
ajst-25053	66	9	protein	protein	NOUN
ajst-25053	66	10	(	(	PUNCT
ajst-25053	66	11	pabp	pabp	PROPN
ajst-25053	66	12	)	)	PUNCT
ajst-25053	66	13	can	can	AUX
ajst-25053	66	14	help	help	VERB
ajst-25053	66	15	to	to	PART
ajst-25053	66	16	form	form	VERB
ajst-25053	66	17	mrna	mrna	PROPN
ajst-25053	66	18	ring	ring	NOUN
ajst-25053	66	19	structure	structure	NOUN
ajst-25053	66	20	and	and	CCONJ
ajst-25053	66	21	improve	improve	VERB
ajst-25053	66	22	mrna	mrna	PROPN
ajst-25053	66	23	translation	translation	NOUN
ajst-25053	66	24	efficiency	efficiency	NOUN
ajst-25053	66	25	by	by	ADP
ajst-25053	66	26	binding	bind	VERB
ajst-25053	66	27	the	the	DET
ajst-25053	66	28	translation	translation	NOUN
ajst-25053	66	29	initiation	initiation	NOUN
ajst-25053	66	30	factors	factor	VERB
ajst-25053	66	31	elf4	elf4	PROPN
ajst-25053	66	32	g	g	PROPN
ajst-25053	66	33	and	and	CCONJ
ajst-25053	66	34	elf4e	elf4e	PROPN
ajst-25053	66	35	to	to	ADP
ajst-25053	66	36	the	the	DET
ajst-25053	66	37	5	5	NUM
ajst-25053	66	38	-	-	PUNCT
ajst-25053	66	39	terminal	terminal	ADJ
ajst-25053	66	40	cap	cap	NOUN
ajst-25053	66	41	.	.	PUNCT
ajst-25053	67	1	conversely	conversely	ADV
ajst-25053	67	2	,	,	PUNCT
ajst-25053	67	3	pabp	pabp	NOUN
ajst-25053	67	4	can	can	AUX
ajst-25053	67	5	also	also	ADV
ajst-25053	67	6	be	be	AUX
ajst-25053	67	7	combined	combine	VERB
ajst-25053	67	8	with	with	ADP
ajst-25053	67	9	adenosine	adenosine	ADJ
ajst-25053	67	10	compound	compound	NOUN
ajst-25053	67	11	,	,	PUNCT
ajst-25053	67	12	involved	involve	VERB
ajst-25053	67	13	in	in	ADP
ajst-25053	67	14	translation	translation	NOUN
ajst-25053	67	15	of	of	ADP
ajst-25053	67	16	microrna	microrna	PROPN
ajst-25053	67	17	mediated	mediate	VERB
ajst-25053	67	18	inhibition	inhibition	NOUN
ajst-25053	67	19	process[5	process[5	NOUN
ajst-25053	67	20	]	]	PUNCT
ajst-25053	67	21	.	.	PUNCT
ajst-25053	68	1	the	the	DET
ajst-25053	68	2	dual	dual	ADJ
ajst-25053	68	3	role	role	NOUN
ajst-25053	68	4	of	of	ADP
ajst-25053	68	5	pabp	pabp	NOUN
ajst-25053	68	6	in	in	ADP
ajst-25053	68	7	mrna	mrna	PROPN
ajst-25053	68	8	translation	translation	NOUN
ajst-25053	68	9	suggests	suggest	VERB
ajst-25053	68	10	that	that	SCONJ
ajst-25053	68	11	poly	poly	ADJ
ajst-25053	68	12	(	(	PUNCT
ajst-25053	68	13	a	a	X
ajst-25053	68	14	)	)	PUNCT
ajst-25053	68	15	design	design	NOUN
ajst-25053	68	16	should	should	AUX
ajst-25053	68	17	be	be	AUX
ajst-25053	68	18	moderate	moderate	ADJ
ajst-25053	68	19	,	,	PUNCT
ajst-25053	68	20	not	not	PART
ajst-25053	68	21	too	too	ADV
ajst-25053	68	22	long	long	ADJ
ajst-25053	68	23	or	or	CCONJ
ajst-25053	68	24	too	too	ADV
ajst-25053	68	25	short	short	ADJ
ajst-25053	68	26	.	.	PUNCT
ajst-25053	69	1	in	in	ADP
ajst-25053	69	2	2006	2006	NUM
ajst-25053	69	3	,	,	PUNCT
ajst-25053	69	4	holtkamp	holtkamp	PROPN
ajst-25053	69	5	et	et	PROPN
ajst-25053	69	6	al	al	PROPN
ajst-25053	69	7	.	.	PROPN
ajst-25053	69	8	showed	show	VERB
ajst-25053	69	9	that	that	SCONJ
ajst-25053	69	10	a	a	DET
ajst-25053	69	11	poly	poly	ADJ
ajst-25053	69	12	(	(	PUNCT
ajst-25053	69	13	a	a	X
ajst-25053	69	14	)	)	PUNCT
ajst-25053	69	15	tail	tail	NOUN
ajst-25053	69	16	using	use	VERB
ajst-25053	69	17	approximately	approximately	ADV
ajst-25053	69	18	120	120	NUM
ajst-25053	69	19	nucleotides	nucleotide	NOUN
ajst-25053	69	20	in	in	ADP
ajst-25053	69	21	dc	dc	PROPN
ajst-25053	69	22	has	have	VERB
ajst-25053	69	23	better	well	ADJ
ajst-25053	69	24	mrna	mrna	NOUN
ajst-25053	69	25	translation	translation	NOUN
ajst-25053	69	26	efficiency	efficiency	NOUN
ajst-25053	69	27	and	and	CCONJ
ajst-25053	69	28	stability	stability	NOUN
ajst-25053	69	29	compared	compare	VERB
ajst-25053	69	30	to	to	ADP
ajst-25053	69	31	a	a	DET
ajst-25053	69	32	shorter	short	ADJ
ajst-25053	69	33	tail[6	tail[6	ADP
ajst-25053	69	34	]	]	X
ajst-25053	69	35	.	.	PUNCT
ajst-25053	70	1	however	however	ADV
ajst-25053	70	2	,	,	PUNCT
ajst-25053	70	3	lima	lima	PROPN
ajst-25053	70	4	et	et	PROPN
ajst-25053	70	5	al	al	PROPN
ajst-25053	70	6	.	.	PROPN
ajst-25053	70	7	showed	show	VERB
ajst-25053	70	8	that	that	SCONJ
ajst-25053	70	9	mrnas	mrna	NOUN
ajst-25053	70	10	with	with	ADP
ajst-25053	70	11	high	high	ADJ
ajst-25053	70	12	translation	translation	NOUN
ajst-25053	70	13	efficiency	efficiency	NOUN
ajst-25053	70	14	actually	actually	ADV
ajst-25053	70	15	have	have	VERB
ajst-25053	70	16	shorter	short	ADJ
ajst-25053	70	17	poly	poly	ADJ
ajst-25053	70	18	(	(	PUNCT
ajst-25053	70	19	a	a	NOUN
ajst-25053	70	20	)	)	PUNCT
ajst-25053	70	21	sequences	sequence	NOUN
ajst-25053	70	22	(	(	PUNCT
ajst-25053	70	23	33	33	NUM
ajst-25053	70	24	-	-	SYM
ajst-25053	70	25	34	34	NUM
ajst-25053	70	26	nucleotides)[5	nucleotides)[5	NOUN
ajst-25053	70	27	]	]	PUNCT
ajst-25053	70	28	.	.	PUNCT
ajst-25053	71	1	in	in	ADP
ajst-25053	71	2	conclusion	conclusion	NOUN
ajst-25053	71	3	,	,	PUNCT
ajst-25053	71	4	appropriate	appropriate	ADJ
ajst-25053	71	5	poly	poly	ADJ
ajst-25053	71	6	(	(	PUNCT
ajst-25053	71	7	a	a	DET
ajst-25053	71	8	)	)	PUNCT
ajst-25053	71	9	length	length	NOUN
ajst-25053	71	10	should	should	AUX
ajst-25053	71	11	be	be	AUX
ajst-25053	71	12	selected	select	VERB
ajst-25053	71	13	for	for	ADP
ajst-25053	71	14	different	different	ADJ
ajst-25053	71	15	cell	cell	NOUN
ajst-25053	71	16	types	type	NOUN
ajst-25053	71	17	to	to	PART
ajst-25053	71	18	achieve	achieve	VERB
ajst-25053	71	19	the	the	DET
ajst-25053	71	20	best	good	ADJ
ajst-25053	71	21	mrna	mrna	NOUN
ajst-25053	71	22	translation	translation	NOUN
ajst-25053	71	23	efficiency	efficiency	NOUN
ajst-25053	71	24	.	.	PUNCT
ajst-25053	72	1	in	in	ADP
ajst-25053	72	2	general	general	ADJ
ajst-25053	72	3	,	,	PUNCT
ajst-25053	72	4	there	there	PRON
ajst-25053	72	5	are	be	VERB
ajst-25053	72	6	two	two	NUM
ajst-25053	72	7	ways	way	NOUN
ajst-25053	72	8	to	to	PART
ajst-25053	72	9	add	add	VERB
ajst-25053	72	10	poly	poly	ADJ
ajst-25053	72	11	(	(	PUNCT
ajst-25053	72	12	a	a	PRON
ajst-25053	72	13	)	)	PUNCT
ajst-25053	72	14	structures	structure	NOUN
ajst-25053	72	15	,	,	PUNCT
ajst-25053	72	16	pretranscriptional	pretranscriptional	ADJ
ajst-25053	72	17	and	and	CCONJ
ajst-25053	72	18	post	post	ADJ
ajst-25053	72	19	-	-	ADJ
ajst-25053	72	20	transcriptional	transcriptional	ADJ
ajst-25053	72	21	.	.	PUNCT
ajst-25053	73	1	by	by	ADP
ajst-25053	73	2	designing	design	VERB
ajst-25053	73	3	the	the	DET
ajst-25053	73	4	corresponding	correspond	VERB
ajst-25053	73	5	poly	poly	ADJ
ajst-25053	73	6	(	(	PUNCT
ajst-25053	73	7	t	t	NOUN
ajst-25053	73	8	)	)	PUNCT
ajst-25053	73	9	sequence	sequence	NOUN
ajst-25053	73	10	in	in	ADP
ajst-25053	73	11	the	the	DET
ajst-25053	73	12	dna	dna	PROPN
ajst-25053	73	13	template	template	NOUN
ajst-25053	73	14	,	,	PUNCT
ajst-25053	73	15	the	the	DET
ajst-25053	73	16	mrna	mrna	NOUN
ajst-25053	73	17	obtained	obtain	VERB
ajst-25053	73	18	by	by	ADP
ajst-25053	73	19	transcription	transcription	NOUN
ajst-25053	73	20	has	have	VERB
ajst-25053	73	21	the	the	DET
ajst-25053	73	22	tail	tail	NOUN
ajst-25053	73	23	structure	structure	NOUN
ajst-25053	73	24	of	of	ADP
ajst-25053	73	25	specific	specific	ADJ
ajst-25053	73	26	length	length	NOUN
ajst-25053	73	27	directly	directly	ADV
ajst-25053	73	28	.	.	PUNCT
ajst-25053	74	1	post	post	ADJ
ajst-25053	74	2	-	-	ADJ
ajst-25053	74	3	transcription	transcription	NOUN
ajst-25053	74	4	coaxing	coaxing	NOUN
ajst-25053	74	5	is	be	AUX
ajst-25053	74	6	the	the	DET
ajst-25053	74	7	addition	addition	NOUN
ajst-25053	74	8	of	of	ADP
ajst-25053	74	9	poly	poly	ADJ
ajst-25053	74	10	(	(	PUNCT
ajst-25053	74	11	a	a	PRON
ajst-25053	74	12	)	)	PUNCT
ajst-25053	74	13	structure	structure	NOUN
ajst-25053	74	14	by	by	ADP
ajst-25053	74	15	polymerase	polymerase	NOUN
ajst-25053	74	16	polymerase	polymerase	NOUN
ajst-25053	74	17	catalyzing	catalyze	VERB
ajst-25053	74	18	the	the	DET
ajst-25053	74	19	polymerization	polymerization	NOUN
ajst-25053	74	20	of	of	ADP
ajst-25053	74	21	adenylate	adenylate	NOUN
ajst-25053	74	22	in	in	ADP
ajst-25053	74	23	the	the	DET
ajst-25053	74	24	rna	rna	NOUN
ajst-25053	74	25	tail	tail	NOUN
ajst-25053	74	26	.	.	PUNCT
ajst-25053	75	1	compared	compare	VERB
ajst-25053	75	2	with	with	ADP
ajst-25053	75	3	the	the	DET
ajst-25053	75	4	two	two	NUM
ajst-25053	75	5	methods	method	NOUN
ajst-25053	75	6	,	,	PUNCT
ajst-25053	75	7	post	post	ADJ
ajst-25053	75	8	-	-	ADJ
ajst-25053	75	9	transcription	transcription	NOUN
ajst-25053	75	10	coaxing	coaxing	NOUN
ajst-25053	75	11	usually	usually	ADV
ajst-25053	75	12	results	result	VERB
ajst-25053	75	13	in	in	ADP
ajst-25053	75	14	a	a	DET
ajst-25053	75	15	mixture	mixture	NOUN
ajst-25053	75	16	of	of	ADP
ajst-25053	75	17	poly	poly	ADJ
ajst-25053	75	18	(	(	PUNCT
ajst-25053	75	19	a	a	PRON
ajst-25053	75	20	)	)	PUNCT
ajst-25053	75	21	structures	structure	NOUN
ajst-25053	75	22	of	of	ADP
ajst-25053	75	23	different	different	ADJ
ajst-25053	75	24	lengths	length	NOUN
ajst-25053	75	25	,	,	PUNCT
ajst-25053	75	26	while	while	SCONJ
ajst-25053	75	27	pre	pre	ADJ
ajst-25053	75	28	-	-	NOUN
ajst-25053	75	29	transcription	transcription	NOUN
ajst-25053	75	30	coaxing	coax	VERB
ajst-25053	75	31	results	result	NOUN
ajst-25053	75	32	in	in	ADP
ajst-25053	75	33	a	a	DET
ajst-25053	75	34	poly	poly	ADJ
ajst-25053	75	35	(	(	PUNCT
ajst-25053	75	36	a	a	NOUN
ajst-25053	75	37	)	)	PUNCT
ajst-25053	75	38	structure	structure	NOUN
ajst-25053	75	39	of	of	ADP
ajst-25053	75	40	a	a	DET
ajst-25053	75	41	certain	certain	ADJ
ajst-25053	75	42	length	length	NOUN
ajst-25053	75	43	with	with	ADP
ajst-25053	75	44	fewer	few	ADJ
ajst-25053	75	45	enzyme	enzyme	NOUN
ajst-25053	75	46	use	use	NOUN
ajst-25053	75	47	and	and	CCONJ
ajst-25053	75	48	removal	removal	NOUN
ajst-25053	75	49	steps	step	NOUN
ajst-25053	75	50	,	,	PUNCT
ajst-25053	75	51	so	so	SCONJ
ajst-25053	75	52	it	it	PRON
ajst-25053	75	53	is	be	AUX
ajst-25053	75	54	more	more	ADV
ajst-25053	75	55	advantageous	advantageous	ADJ
ajst-25053	75	56	.	.	PUNCT
ajst-25053	76	1	2.5	2.5	NUM
ajst-25053	76	2	.	.	PUNCT
ajst-25053	77	1	nucleotide	nucleotide	NOUN
ajst-25053	77	2	modification	modification	NOUN
ajst-25053	77	3	nucleotide	nucleotide	NOUN
ajst-25053	77	4	modification	modification	NOUN
ajst-25053	77	5	is	be	AUX
ajst-25053	77	6	considered	consider	VERB
ajst-25053	77	7	the	the	DET
ajst-25053	77	8	most	most	ADV
ajst-25053	77	9	important	important	ADJ
ajst-25053	77	10	breakthrough	breakthrough	NOUN
ajst-25053	77	11	in	in	ADP
ajst-25053	77	12	the	the	DET
ajst-25053	77	13	function	function	NOUN
ajst-25053	77	14	of	of	ADP
ajst-25053	77	15	mrna	mrna	PROPN
ajst-25053	77	16	drugs	drug	NOUN
ajst-25053	77	17	in	in	ADP
ajst-25053	77	18	the	the	DET
ajst-25053	77	19	human	human	ADJ
ajst-25053	77	20	body	body	NOUN
ajst-25053	77	21	.	.	PUNCT
ajst-25053	78	1	unmodified	unmodified	ADJ
ajst-25053	78	2	mrna	mrna	PROPN
ajst-25053	78	3	is	be	AUX
ajst-25053	78	4	recognized	recognize	VERB
ajst-25053	78	5	by	by	ADP
ajst-25053	78	6	body	body	NOUN
ajst-25053	78	7	leading	lead	VERB
ajst-25053	78	8	to	to	ADP
ajst-25053	78	9	innate	innate	ADJ
ajst-25053	78	10	immune	immune	ADJ
ajst-25053	78	11	activation	activation	NOUN
ajst-25053	78	12	,	,	PUNCT
ajst-25053	78	13	resulting	result	VERB
ajst-25053	78	14	in	in	ADP
ajst-25053	78	15	significantly	significantly	ADV
ajst-25053	78	16	reduced	reduce	VERB
ajst-25053	78	17	mrna	mrna	PROPN
ajst-25053	78	18	translation	translation	NOUN
ajst-25053	78	19	efficiency	efficiency	NOUN
ajst-25053	78	20	.	.	PUNCT
ajst-25053	79	1	some	some	DET
ajst-25053	79	2	studies	study	NOUN
ajst-25053	79	3	have	have	AUX
ajst-25053	79	4	shown	show	VERB
ajst-25053	79	5	that	that	SCONJ
ajst-25053	79	6	using	use	VERB
ajst-25053	79	7	modified	modify	VERB
ajst-25053	79	8	nucleotides	nucleotide	NOUN
ajst-25053	79	9	such	such	ADJ
ajst-25053	79	10	as	as	ADP
ajst-25053	79	11	pseudouridine	pseudouridine	NOUN
ajst-25053	79	12	instead	instead	ADV
ajst-25053	79	13	of	of	ADP
ajst-25053	79	14	original	original	ADJ
ajst-25053	79	15	nucleotides	nucleotide	NOUN
ajst-25053	79	16	can	can	AUX
ajst-25053	79	17	effectively	effectively	ADV
ajst-25053	79	18	resist	resist	VERB
ajst-25053	79	19	rna	rna	NOUN
ajst-25053	79	20	enzymatic	enzymatic	ADJ
ajst-25053	79	21	358	358	NUM
ajst-25053	79	22	hydrolysis	hydrolysis	NOUN
ajst-25053	79	23	and	and	CCONJ
ajst-25053	79	24	improve	improve	VERB
ajst-25053	79	25	translation	translation	NOUN
ajst-25053	79	26	efficiency	efficiency	NOUN
ajst-25053	79	27	and	and	CCONJ
ajst-25053	79	28	stability	stability	NOUN
ajst-25053	79	29	.	.	PUNCT
ajst-25053	80	1	at	at	ADP
ajst-25053	80	2	the	the	DET
ajst-25053	80	3	same	same	ADJ
ajst-25053	80	4	time	time	NOUN
ajst-25053	80	5	,	,	PUNCT
ajst-25053	80	6	some	some	DET
ajst-25053	80	7	studies	study	NOUN
ajst-25053	80	8	have	have	AUX
ajst-25053	80	9	shown	show	VERB
ajst-25053	80	10	that	that	SCONJ
ajst-25053	80	11	the	the	DET
ajst-25053	80	12	use	use	NOUN
ajst-25053	80	13	of	of	ADP
ajst-25053	80	14	modified	modify	VERB
ajst-25053	80	15	nucleotides	nucleotide	NOUN
ajst-25053	80	16	such	such	ADJ
ajst-25053	80	17	as	as	ADP
ajst-25053	80	18	thiouridine	thiouridine	NOUN
ajst-25053	80	19	and	and	CCONJ
ajst-25053	80	20	5methylcytidine	5methylcytidine	PROPN
ajst-25053	80	21	can	can	AUX
ajst-25053	80	22	reduce	reduce	VERB
ajst-25053	80	23	immunogenicity	immunogenicity	NOUN
ajst-25053	80	24	.	.	PUNCT
ajst-25053	81	1	in	in	ADP
ajst-25053	81	2	addition	addition	NOUN
ajst-25053	81	3	,	,	PUNCT
ajst-25053	81	4	some	some	DET
ajst-25053	81	5	studies	study	NOUN
ajst-25053	81	6	have	have	AUX
ajst-25053	81	7	also	also	ADV
ajst-25053	81	8	mentioned	mention	VERB
ajst-25053	81	9	that	that	SCONJ
ajst-25053	81	10	the	the	DET
ajst-25053	81	11	use	use	NOUN
ajst-25053	81	12	of	of	ADP
ajst-25053	81	13	methylpseuduridine	methylpseuduridine	NOUN
ajst-25053	81	14	is	be	AUX
ajst-25053	81	15	better	well	ADJ
ajst-25053	81	16	than	than	ADP
ajst-25053	81	17	pseuduridine	pseuduridine	ADJ
ajst-25053	81	18	.	.	PUNCT
ajst-25053	82	1	the	the	DET
ajst-25053	82	2	currently	currently	ADV
ajst-25053	82	3	approved	approve	VERB
ajst-25053	82	4	bnt162b2	bnt162b2	NOUN
ajst-25053	82	5	vaccine	vaccine	NOUN
ajst-25053	82	6	from	from	ADP
ajst-25053	82	7	biontech	biontech	NOUN
ajst-25053	82	8	and	and	CCONJ
ajst-25053	82	9	the	the	DET
ajst-25053	82	10	mrna-1273	mrna-1273	ADJ
ajst-25053	82	11	vaccine	vaccine	NOUN
ajst-25053	82	12	from	from	ADP
ajst-25053	82	13	moderna	moderna	PROPN
ajst-25053	82	14	both	both	PRON
ajst-25053	82	15	use	use	VERB
ajst-25053	82	16	methylpseuduridine	methylpseuduridine	NOUN
ajst-25053	82	17	as	as	ADP
ajst-25053	82	18	a	a	DET
ajst-25053	82	19	modified	modified	ADJ
ajst-25053	82	20	nucleotide	nucleotide	NOUN
ajst-25053	82	21	.	.	PUNCT
ajst-25053	83	1	3	3	X
ajst-25053	83	2	.	.	X
ajst-25053	83	3	mrna	mrna	PROPN
ajst-25053	83	4	purification	purification	NOUN
ajst-25053	83	5	it	it	PRON
ajst-25053	83	6	has	have	AUX
ajst-25053	83	7	been	be	AUX
ajst-25053	83	8	confirmed	confirm	VERB
ajst-25053	83	9	that	that	SCONJ
ajst-25053	83	10	mrna	mrna	PROPN
ajst-25053	83	11	produced	produce	VERB
ajst-25053	83	12	by	by	ADP
ajst-25053	83	13	phage	phage	NOUN
ajst-25053	83	14	rna	rna	NOUN
ajst-25053	83	15	polymerase	polymerase	NOUN
ajst-25053	83	16	transcription	transcription	NOUN
ajst-25053	83	17	in	in	ADP
ajst-25053	83	18	vitro	vitro	X
ajst-25053	83	19	contains	contain	VERB
ajst-25053	83	20	a	a	DET
ajst-25053	83	21	variety	variety	NOUN
ajst-25053	83	22	of	of	ADP
ajst-25053	83	23	impurities	impurity	NOUN
ajst-25053	83	24	,	,	PUNCT
ajst-25053	83	25	such	such	ADJ
ajst-25053	83	26	as	as	ADP
ajst-25053	83	27	short	short	ADJ
ajst-25053	83	28	rna	rna	NOUN
ajst-25053	83	29	generated	generate	VERB
ajst-25053	83	30	by	by	ADP
ajst-25053	83	31	transcription	transcription	NOUN
ajst-25053	83	32	interruption	interruption	NOUN
ajst-25053	83	33	,	,	PUNCT
ajst-25053	83	34	oligodeoxynucleotides	oligodeoxynucleotide	NOUN
ajst-25053	83	35	,	,	PUNCT
ajst-25053	83	36	dsrna	dsrna	NOUN
ajst-25053	83	37	catalyzed	catalyze	VERB
ajst-25053	83	38	by	by	ADP
ajst-25053	83	39	rna	rna	NOUN
ajst-25053	83	40	-	-	PUNCT
ajst-25053	83	41	dependent	dependent	ADJ
ajst-25053	83	42	rna	rna	NOUN
ajst-25053	83	43	polymerase	polymerase	NOUN
ajst-25053	83	44	,	,	PUNCT
ajst-25053	83	45	and	and	CCONJ
ajst-25053	83	46	proteins	protein	NOUN
ajst-25053	83	47	,	,	PUNCT
ajst-25053	83	48	which	which	PRON
ajst-25053	83	49	may	may	AUX
ajst-25053	83	50	lead	lead	VERB
ajst-25053	83	51	to	to	ADP
ajst-25053	83	52	low	low	ADJ
ajst-25053	83	53	levels	level	NOUN
ajst-25053	83	54	of	of	ADP
ajst-25053	83	55	immune	immune	ADJ
ajst-25053	83	56	rejection	rejection	NOUN
ajst-25053	83	57	.	.	PUNCT
ajst-25053	84	1	efficient	efficient	ADJ
ajst-25053	84	2	mrna	mrna	PROPN
ajst-25053	84	3	purification	purification	NOUN
ajst-25053	84	4	can	can	AUX
ajst-25053	84	5	not	not	PART
ajst-25053	84	6	only	only	ADV
ajst-25053	84	7	remove	remove	VERB
ajst-25053	84	8	the	the	DET
ajst-25053	84	9	impurity	impurity	NOUN
ajst-25053	84	10	rna	rna	NOUN
ajst-25053	84	11	contamination	contamination	NOUN
ajst-25053	84	12	that	that	PRON
ajst-25053	84	13	causes	cause	VERB
ajst-25053	84	14	immune	immune	ADJ
ajst-25053	84	15	rejection	rejection	NOUN
ajst-25053	84	16	,	,	PUNCT
ajst-25053	84	17	but	but	CCONJ
ajst-25053	84	18	also	also	ADV
ajst-25053	84	19	improve	improve	VERB
ajst-25053	84	20	the	the	DET
ajst-25053	84	21	efficiency	efficiency	NOUN
ajst-25053	84	22	of	of	ADP
ajst-25053	84	23	mrna	mrna	PROPN
ajst-25053	84	24	translation	translation	PROPN
ajst-25053	84	25	.	.	PUNCT
ajst-25053	85	1	licl	licl	ADJ
ajst-25053	85	2	-	-	PUNCT
ajst-25053	85	3	ethanol	ethanol	NOUN
ajst-25053	85	4	precipitation	precipitation	NOUN
ajst-25053	85	5	method	method	NOUN
ajst-25053	85	6	is	be	AUX
ajst-25053	85	7	commonly	commonly	ADV
ajst-25053	85	8	used	use	VERB
ajst-25053	85	9	to	to	PART
ajst-25053	85	10	remove	remove	VERB
ajst-25053	85	11	impurities	impurity	NOUN
ajst-25053	85	12	,	,	PUNCT
ajst-25053	85	13	licl	licl	ADJ
ajst-25053	85	14	precipitation	precipitation	NOUN
ajst-25053	85	15	has	have	VERB
ajst-25053	85	16	greater	great	ADJ
ajst-25053	85	17	advantages	advantage	NOUN
ajst-25053	85	18	than	than	ADP
ajst-25053	85	19	other	other	ADJ
ajst-25053	85	20	rna	rna	NOUN
ajst-25053	85	21	precipitation	precipitation	NOUN
ajst-25053	85	22	methods	method	NOUN
ajst-25053	85	23	,	,	PUNCT
ajst-25053	85	24	and	and	CCONJ
ajst-25053	85	25	its	its	PRON
ajst-25053	85	26	efficiency	efficiency	NOUN
ajst-25053	85	27	is	be	AUX
ajst-25053	85	28	higher	high	ADJ
ajst-25053	85	29	to	to	PART
ajst-25053	85	30	precipitate	precipitate	VERB
ajst-25053	85	31	dna	dna	NOUN
ajst-25053	85	32	and	and	CCONJ
ajst-25053	85	33	protein	protein	NOUN
ajst-25053	85	34	,	,	PUNCT
ajst-25053	85	35	and	and	CCONJ
ajst-25053	85	36	then	then	ADV
ajst-25053	85	37	the	the	DET
ajst-25053	85	38	target	target	NOUN
ajst-25053	85	39	mrna	mrna	PROPN
ajst-25053	85	40	was	be	AUX
ajst-25053	85	41	separated	separate	VERB
ajst-25053	85	42	from	from	ADP
ajst-25053	85	43	other	other	ADJ
ajst-25053	85	44	mrna	mrna	PROPN
ajst-25053	85	45	impurities	impurity	NOUN
ajst-25053	85	46	in	in	ADP
ajst-25053	85	47	the	the	DET
ajst-25053	85	48	system	system	NOUN
ajst-25053	85	49	by	by	ADP
ajst-25053	85	50	high	high	ADJ
ajst-25053	85	51	performance	performance	NOUN
ajst-25053	85	52	liquid	liquid	NOUN
ajst-25053	85	53	chromatography	chromatography	NOUN
ajst-25053	85	54	(	(	PUNCT
ajst-25053	85	55	hplc	hplc	PROPN
ajst-25053	85	56	)	)	PUNCT
ajst-25053	85	57	.	.	PUNCT
ajst-25053	86	1	4	4	X
ajst-25053	86	2	.	.	X
ajst-25053	86	3	mrna	mrna	PROPN
ajst-25053	86	4	drug	drug	PROPN
ajst-25053	86	5	delivery	delivery	NOUN
ajst-25053	86	6	system	system	NOUN
ajst-25053	86	7	exogenous	exogenous	ADJ
ajst-25053	86	8	mrna	mrna	PROPN
ajst-25053	86	9	must	must	AUX
ajst-25053	86	10	reach	reach	VERB
ajst-25053	86	11	the	the	DET
ajst-25053	86	12	cytoplasm	cytoplasm	NOUN
ajst-25053	86	13	through	through	ADP
ajst-25053	86	14	the	the	DET
ajst-25053	86	15	cell	cell	NOUN
ajst-25053	86	16	membrane	membrane	NOUN
ajst-25053	86	17	in	in	ADP
ajst-25053	86	18	order	order	NOUN
ajst-25053	86	19	to	to	PART
ajst-25053	86	20	translate	translate	VERB
ajst-25053	86	21	the	the	DET
ajst-25053	86	22	protein	protein	NOUN
ajst-25053	86	23	.	.	PUNCT
ajst-25053	87	1	because	because	SCONJ
ajst-25053	87	2	mrna	mrna	PROPN
ajst-25053	87	3	molecules	molecule	NOUN
ajst-25053	87	4	are	be	AUX
ajst-25053	87	5	large	large	ADJ
ajst-25053	87	6	and	and	CCONJ
ajst-25053	87	7	negatively	negatively	ADV
ajst-25053	87	8	charged	charge	VERB
ajst-25053	87	9	,	,	PUNCT
ajst-25053	87	10	they	they	PRON
ajst-25053	87	11	repel	repel	VERB
ajst-25053	87	12	the	the	DET
ajst-25053	87	13	anionic	anionic	ADJ
ajst-25053	87	14	lipid	lipid	NOUN
ajst-25053	87	15	bilayer	bilayer	NOUN
ajst-25053	87	16	on	on	ADP
ajst-25053	87	17	the	the	DET
ajst-25053	87	18	cell	cell	NOUN
ajst-25053	87	19	membrane	membrane	NOUN
ajst-25053	87	20	and	and	CCONJ
ajst-25053	87	21	thus	thus	ADV
ajst-25053	87	22	can	can	AUX
ajst-25053	87	23	not	not	PART
ajst-25053	87	24	effectively	effectively	ADV
ajst-25053	87	25	enter	enter	VERB
ajst-25053	87	26	the	the	DET
ajst-25053	87	27	cell	cell	NOUN
ajst-25053	87	28	to	to	PART
ajst-25053	87	29	perform	perform	VERB
ajst-25053	87	30	functions	function	NOUN
ajst-25053	87	31	.	.	PUNCT
ajst-25053	88	1	in	in	ADP
ajst-25053	88	2	addition	addition	NOUN
ajst-25053	88	3	,	,	PUNCT
ajst-25053	88	4	mrna	mrna	PROPN
ajst-25053	88	5	is	be	AUX
ajst-25053	88	6	easily	easily	ADV
ajst-25053	88	7	engulfed	engulf	VERB
ajst-25053	88	8	by	by	ADP
ajst-25053	88	9	immune	immune	ADJ
ajst-25053	88	10	cells	cell	NOUN
ajst-25053	88	11	in	in	ADP
ajst-25053	88	12	the	the	DET
ajst-25053	88	13	body	body	NOUN
ajst-25053	88	14	or	or	CCONJ
ajst-25053	88	15	degraded	degrade	VERB
ajst-25053	88	16	by	by	ADP
ajst-25053	88	17	nucleases	nuclease	NOUN
ajst-25053	88	18	in	in	ADP
ajst-25053	88	19	the	the	DET
ajst-25053	88	20	environment	environment	NOUN
ajst-25053	88	21	.	.	PUNCT
ajst-25053	89	1	an	an	DET
ajst-25053	89	2	efficient	efficient	ADJ
ajst-25053	89	3	mrna	mrna	NOUN
ajst-25053	89	4	delivery	delivery	NOUN
ajst-25053	89	5	system	system	NOUN
ajst-25053	89	6	is	be	AUX
ajst-25053	89	7	therefore	therefore	ADV
ajst-25053	89	8	critical	critical	ADJ
ajst-25053	89	9	to	to	ADP
ajst-25053	89	10	achieving	achieve	VERB
ajst-25053	89	11	therapeutic	therapeutic	ADJ
ajst-25053	89	12	relevance	relevance	NOUN
ajst-25053	89	13	.	.	PUNCT
ajst-25053	90	1	at	at	ADP
ajst-25053	90	2	present	present	ADJ
ajst-25053	90	3	,	,	PUNCT
ajst-25053	90	4	there	there	PRON
ajst-25053	90	5	are	be	VERB
ajst-25053	90	6	several	several	ADJ
ajst-25053	90	7	main	main	ADJ
ajst-25053	90	8	delivery	delivery	NOUN
ajst-25053	90	9	methods	method	NOUN
ajst-25053	90	10	of	of	ADP
ajst-25053	90	11	mrna	mrna	PROPN
ajst-25053	90	12	,	,	PUNCT
ajst-25053	90	13	among	among	ADP
ajst-25053	90	14	which	which	PRON
ajst-25053	90	15	nano	nano	NOUN
ajst-25053	90	16	lipid	lipid	NOUN
ajst-25053	90	17	particles	particle	NOUN
ajst-25053	90	18	are	be	AUX
ajst-25053	90	19	the	the	DET
ajst-25053	90	20	most	most	ADV
ajst-25053	90	21	promising	promising	ADJ
ajst-25053	90	22	method	method	NOUN
ajst-25053	90	23	at	at	ADP
ajst-25053	90	24	present	present	NOUN
ajst-25053	90	25	.	.	PUNCT
ajst-25053	91	1	4.1	4.1	NUM
ajst-25053	91	2	.	.	PUNCT
ajst-25053	92	1	naked	naked	ADJ
ajst-25053	92	2	mrna	mrna	PROPN
ajst-25053	92	3	injection	injection	NOUN
ajst-25053	92	4	that	that	PRON
ajst-25053	92	5	is	be	AUX
ajst-25053	92	6	,	,	PUNCT
ajst-25053	92	7	mrna	mrna	PROPN
ajst-25053	92	8	is	be	AUX
ajst-25053	92	9	directly	directly	ADV
ajst-25053	92	10	injected	inject	VERB
ajst-25053	92	11	into	into	ADP
ajst-25053	92	12	the	the	DET
ajst-25053	92	13	tissue	tissue	NOUN
ajst-25053	92	14	without	without	ADP
ajst-25053	92	15	packaging	packaging	NOUN
ajst-25053	92	16	,	,	PUNCT
ajst-25053	92	17	and	and	CCONJ
ajst-25053	92	18	the	the	DET
ajst-25053	92	19	buffer	buffer	NOUN
ajst-25053	92	20	is	be	AUX
ajst-25053	92	21	usually	usually	ADV
ajst-25053	92	22	diluted	dilute	VERB
ajst-25053	92	23	before	before	ADP
ajst-25053	92	24	injection	injection	NOUN
ajst-25053	92	25	.	.	PUNCT
ajst-25053	93	1	commonly	commonly	ADV
ajst-25053	93	2	used	use	VERB
ajst-25053	93	3	buffer	buffer	NOUN
ajst-25053	93	4	solutions	solution	NOUN
ajst-25053	93	5	include	include	VERB
ajst-25053	93	6	sucrose	sucrose	VERB
ajst-25053	93	7	solution	solution	NOUN
ajst-25053	93	8	,	,	PUNCT
ajst-25053	93	9	lactate	lactate	NOUN
ajst-25053	93	10	ringer	ringer	NOUN
ajst-25053	93	11	's	's	PART
ajst-25053	93	12	test	test	NOUN
ajst-25053	93	13	solution	solution	NOUN
ajst-25053	93	14	,	,	PUNCT
ajst-25053	93	15	phosphate	phosphate	NOUN
ajst-25053	93	16	buffer	buffer	NOUN
ajst-25053	93	17	solution	solution	NOUN
ajst-25053	93	18	,	,	PUNCT
ajst-25053	93	19	trehalose	trehalose	ADJ
ajst-25053	93	20	solution	solution	NOUN
ajst-25053	93	21	,	,	PUNCT
ajst-25053	93	22	etc	etc	X
ajst-25053	93	23	.	.	X
ajst-25053	93	24	in	in	ADP
ajst-25053	93	25	1990	1990	NUM
ajst-25053	93	26	,	,	PUNCT
ajst-25053	93	27	wolff	wolff	PROPN
ajst-25053	93	28	et	et	PROPN
ajst-25053	93	29	al	al	PROPN
ajst-25053	93	30	.	.	PROPN
ajst-25053	93	31	found	find	VERB
ajst-25053	93	32	for	for	ADP
ajst-25053	93	33	the	the	DET
ajst-25053	93	34	first	first	ADJ
ajst-25053	93	35	time	time	NOUN
ajst-25053	93	36	that	that	PRON
ajst-25053	93	37	direct	direct	ADJ
ajst-25053	93	38	injection	injection	NOUN
ajst-25053	93	39	of	of	ADP
ajst-25053	93	40	mrna	mrna	PROPN
ajst-25053	93	41	in	in	ADP
ajst-25053	93	42	mice	mouse	NOUN
ajst-25053	93	43	could	could	AUX
ajst-25053	93	44	also	also	ADV
ajst-25053	93	45	achieve	achieve	VERB
ajst-25053	93	46	normal	normal	ADJ
ajst-25053	93	47	expression	expression	NOUN
ajst-25053	93	48	of	of	ADP
ajst-25053	93	49	reporter	reporter	NOUN
ajst-25053	93	50	genes	gene	NOUN
ajst-25053	93	51	in	in	ADP
ajst-25053	93	52	muscle	muscle	NOUN
ajst-25053	93	53	cells	cell	NOUN
ajst-25053	93	54	,	,	PUNCT
ajst-25053	93	55	and	and	CCONJ
ajst-25053	93	56	the	the	DET
ajst-25053	93	57	more	more	ADJ
ajst-25053	93	58	mrna	mrna	PROPN
ajst-25053	93	59	injected	inject	VERB
ajst-25053	93	60	,	,	PUNCT
ajst-25053	93	61	the	the	PRON
ajst-25053	93	62	higher	high	ADJ
ajst-25053	93	63	the	the	DET
ajst-25053	93	64	protein	protein	NOUN
ajst-25053	93	65	expression[2	expression[2	PROPN
ajst-25053	93	66	]	]	PUNCT
ajst-25053	93	67	.	.	PUNCT
ajst-25053	94	1	in	in	ADP
ajst-25053	94	2	2000	2000	NUM
ajst-25053	94	3	,	,	PUNCT
ajst-25053	94	4	ingmar	ingmar	PROPN
ajst-25053	94	5	et	et	PROPN
ajst-25053	94	6	al	al	PROPN
ajst-25053	94	7	.	.	PROPN
ajst-25053	94	8	directly	directly	ADV
ajst-25053	94	9	injected	inject	VERB
ajst-25053	94	10	naked	naked	ADJ
ajst-25053	94	11	mrna	mrna	NOUN
ajst-25053	94	12	into	into	ADP
ajst-25053	94	13	mice	mouse	NOUN
ajst-25053	94	14	,	,	PUNCT
ajst-25053	94	15	and	and	CCONJ
ajst-25053	94	16	after	after	ADP
ajst-25053	94	17	2	2	NUM
ajst-25053	94	18	weeks	week	NOUN
ajst-25053	94	19	,	,	PUNCT
ajst-25053	94	20	specific	specific	ADJ
ajst-25053	94	21	anti	anti	ADJ
ajst-25053	94	22	-	-	ADJ
ajst-25053	94	23	β	β	ADJ
ajst-25053	94	24	-	-	ADJ
ajst-25053	94	25	glycosidase	glycosidase	ADJ
ajst-25053	94	26	igg	igg	NOUN
ajst-25053	94	27	could	could	AUX
ajst-25053	94	28	be	be	AUX
ajst-25053	94	29	detected	detect	VERB
ajst-25053	94	30	in	in	ADP
ajst-25053	94	31	mice	mouse	NOUN
ajst-25053	94	32	,	,	PUNCT
ajst-25053	94	33	and	and	CCONJ
ajst-25053	94	34	glycosidase	glycosidase	NOUN
ajst-25053	94	35	-	-	PUNCT
ajst-25053	94	36	specific	specific	ADJ
ajst-25053	94	37	ctl	ctl	NOUN
ajst-25053	94	38	response	response	NOUN
ajst-25053	94	39	could	could	AUX
ajst-25053	94	40	also	also	ADV
ajst-25053	94	41	be	be	AUX
ajst-25053	94	42	triggered	trigger	VERB
ajst-25053	94	43	,	,	PUNCT
ajst-25053	94	44	indicating	indicate	VERB
ajst-25053	94	45	that	that	SCONJ
ajst-25053	94	46	injection	injection	NOUN
ajst-25053	94	47	of	of	ADP
ajst-25053	94	48	naked	naked	ADJ
ajst-25053	94	49	mrna	mrna	NOUN
ajst-25053	94	50	in	in	ADP
ajst-25053	94	51	mice	mouse	NOUN
ajst-25053	94	52	could	could	AUX
ajst-25053	94	53	trigger	trigger	VERB
ajst-25053	94	54	humoral	humoral	ADJ
ajst-25053	94	55	and	and	CCONJ
ajst-25053	94	56	cellular	cellular	ADJ
ajst-25053	94	57	immunity	immunity	NOUN
ajst-25053	94	58	specific	specific	ADJ
ajst-25053	94	59	to	to	ADP
ajst-25053	94	60	glycosidase[7	glycosidase[7	NOUN
ajst-25053	94	61	]	]	PUNCT
ajst-25053	94	62	.	.	PUNCT
ajst-25053	95	1	in	in	ADP
ajst-25053	95	2	2004	2004	NUM
ajst-25053	95	3	,	,	PUNCT
ajst-25053	95	4	carralot	carralot	NOUN
ajst-25053	95	5	et	et	PROPN
ajst-25053	95	6	al	al	PROPN
ajst-25053	95	7	.	.	PROPN
ajst-25053	95	8	also	also	ADV
ajst-25053	95	9	found	find	VERB
ajst-25053	95	10	that	that	SCONJ
ajst-25053	95	11	injecting	inject	VERB
ajst-25053	95	12	naked	naked	ADJ
ajst-25053	95	13	mrna	mrna	PROPN
ajst-25053	95	14	encoding	encoding	NOUN
ajst-25053	95	15	glycosidase	glycosidase	NOUN
ajst-25053	95	16	in	in	ADP
ajst-25053	95	17	mice	mouse	NOUN
ajst-25053	95	18	could	could	AUX
ajst-25053	95	19	detect	detect	VERB
ajst-25053	95	20	normal	normal	ADJ
ajst-25053	95	21	expression	expression	NOUN
ajst-25053	95	22	of	of	ADP
ajst-25053	95	23	glycosidase	glycosidase	NOUN
ajst-25053	95	24	in	in	ADP
ajst-25053	95	25	mice[8	mice[8	NOUN
ajst-25053	95	26	]	]	PUNCT
ajst-25053	95	27	.	.	PUNCT
ajst-25053	96	1	regarding	regard	VERB
ajst-25053	96	2	the	the	DET
ajst-25053	96	3	uptake	uptake	ADJ
ajst-25053	96	4	mechanism	mechanism	NOUN
ajst-25053	96	5	of	of	ADP
ajst-25053	96	6	naked	naked	ADJ
ajst-25053	96	7	mrna	mrna	NOUN
ajst-25053	96	8	,	,	PUNCT
ajst-25053	96	9	some	some	DET
ajst-25053	96	10	studies	study	NOUN
ajst-25053	96	11	believe	believe	VERB
ajst-25053	96	12	that	that	SCONJ
ajst-25053	96	13	exogenous	exogenous	ADJ
ajst-25053	96	14	rna	rna	NOUN
ajst-25053	96	15	is	be	AUX
ajst-25053	96	16	taken	take	VERB
ajst-25053	96	17	up	up	ADP
ajst-25053	96	18	by	by	ADP
ajst-25053	96	19	dc	dc	PROPN
ajst-25053	96	20	under	under	ADP
ajst-25053	96	21	the	the	DET
ajst-25053	96	22	action	action	NOUN
ajst-25053	96	23	of	of	ADP
ajst-25053	96	24	macrophages	macrophage	NOUN
ajst-25053	96	25	and	and	CCONJ
ajst-25053	96	26	obtained	obtain	VERB
ajst-25053	96	27	expression	expression	NOUN
ajst-25053	96	28	.	.	PUNCT
ajst-25053	97	1	other	other	ADJ
ajst-25053	97	2	studies	study	NOUN
ajst-25053	97	3	have	have	AUX
ajst-25053	97	4	shown	show	VERB
ajst-25053	97	5	that	that	SCONJ
ajst-25053	97	6	the	the	DET
ajst-25053	97	7	delivery	delivery	NOUN
ajst-25053	97	8	efficiency	efficiency	NOUN
ajst-25053	97	9	of	of	ADP
ajst-25053	97	10	mrna	mrna	PROPN
ajst-25053	97	11	is	be	AUX
ajst-25053	97	12	affected	affect	VERB
ajst-25053	97	13	by	by	ADP
ajst-25053	97	14	the	the	DET
ajst-25053	97	15	type	type	NOUN
ajst-25053	97	16	of	of	ADP
ajst-25053	97	17	buffer	buffer	NOUN
ajst-25053	97	18	and	and	CCONJ
ajst-25053	97	19	the	the	DET
ajst-25053	97	20	concentration	concentration	NOUN
ajst-25053	97	21	of	of	ADP
ajst-25053	97	22	ions	ion	NOUN
ajst-25053	97	23	in	in	ADP
ajst-25053	97	24	the	the	DET
ajst-25053	97	25	buffer	buffer	NOUN
ajst-25053	97	26	.	.	PUNCT
ajst-25053	98	1	this	this	DET
ajst-25053	98	2	delivery	delivery	NOUN
ajst-25053	98	3	method	method	NOUN
ajst-25053	98	4	has	have	VERB
ajst-25053	98	5	the	the	DET
ajst-25053	98	6	advantages	advantage	NOUN
ajst-25053	98	7	of	of	ADP
ajst-25053	98	8	low	low	ADJ
ajst-25053	98	9	cost	cost	NOUN
ajst-25053	98	10	,	,	PUNCT
ajst-25053	98	11	convenience	convenience	NOUN
ajst-25053	98	12	and	and	CCONJ
ajst-25053	98	13	fast	fast	ADJ
ajst-25053	98	14	,	,	PUNCT
ajst-25053	98	15	but	but	CCONJ
ajst-25053	98	16	due	due	ADP
ajst-25053	98	17	to	to	ADP
ajst-25053	98	18	the	the	DET
ajst-25053	98	19	instability	instability	NOUN
ajst-25053	98	20	of	of	ADP
ajst-25053	98	21	mrna	mrna	PROPN
ajst-25053	98	22	and	and	CCONJ
ajst-25053	98	23	the	the	DET
ajst-25053	98	24	complex	complex	ADJ
ajst-25053	98	25	physiological	physiological	ADJ
ajst-25053	98	26	environment	environment	NOUN
ajst-25053	98	27	in	in	ADP
ajst-25053	98	28	the	the	DET
ajst-25053	98	29	human	human	ADJ
ajst-25053	98	30	body	body	NOUN
ajst-25053	98	31	,	,	PUNCT
ajst-25053	98	32	rna	rna	NOUN
ajst-25053	98	33	is	be	AUX
ajst-25053	98	34	easy	easy	ADJ
ajst-25053	98	35	to	to	PART
ajst-25053	98	36	degrade	degrade	VERB
ajst-25053	98	37	and	and	CCONJ
ajst-25053	98	38	lose	lose	VERB
ajst-25053	98	39	its	its	PRON
ajst-25053	98	40	role	role	NOUN
ajst-25053	98	41	.	.	PUNCT
ajst-25053	99	1	4.2	4.2	NUM
ajst-25053	99	2	.	.	X
ajst-25053	100	1	dc	dc	PROPN
ajst-25053	100	2	load	load	VERB
ajst-25053	100	3	dc	dc	PROPN
ajst-25053	100	4	,	,	PUNCT
ajst-25053	100	5	as	as	ADP
ajst-25053	100	6	the	the	DET
ajst-25053	100	7	most	most	ADV
ajst-25053	100	8	powerful	powerful	ADJ
ajst-25053	100	9	antigen	antigen	NOUN
ajst-25053	100	10	presenting	present	VERB
ajst-25053	100	11	cell	cell	NOUN
ajst-25053	100	12	in	in	ADP
ajst-25053	100	13	the	the	DET
ajst-25053	100	14	human	human	ADJ
ajst-25053	100	15	body	body	NOUN
ajst-25053	100	16	,	,	PUNCT
ajst-25053	100	17	plays	play	VERB
ajst-25053	100	18	a	a	DET
ajst-25053	100	19	key	key	ADJ
ajst-25053	100	20	role	role	NOUN
ajst-25053	100	21	in	in	ADP
ajst-25053	100	22	the	the	DET
ajst-25053	100	23	immune	immune	ADJ
ajst-25053	100	24	system	system	NOUN
ajst-25053	100	25	and	and	CCONJ
ajst-25053	100	26	is	be	AUX
ajst-25053	100	27	considered	consider	VERB
ajst-25053	100	28	to	to	PART
ajst-25053	100	29	be	be	AUX
ajst-25053	100	30	a	a	DET
ajst-25053	100	31	very	very	ADV
ajst-25053	100	32	promising	promising	ADJ
ajst-25053	100	33	strategy	strategy	NOUN
ajst-25053	100	34	in	in	ADP
ajst-25053	100	35	anti	anti	ADJ
ajst-25053	100	36	-	-	ADJ
ajst-25053	100	37	cancer	cancer	ADJ
ajst-25053	100	38	immunotherapy	immunotherapy	NOUN
ajst-25053	100	39	.	.	PUNCT
ajst-25053	101	1	dc	dc	PROPN
ajst-25053	101	2	can	can	AUX
ajst-25053	101	3	load	load	VERB
ajst-25053	101	4	the	the	DET
ajst-25053	101	5	mrna	mrna	NOUN
ajst-25053	101	6	encoding	encode	VERB
ajst-25053	101	7	the	the	DET
ajst-25053	101	8	desired	desire	VERB
ajst-25053	101	9	antigen	antigen	NOUN
ajst-25053	101	10	and	and	CCONJ
ajst-25053	101	11	cause	cause	VERB
ajst-25053	101	12	cellular	cellular	ADJ
ajst-25053	101	13	immunity	immunity	NOUN
ajst-25053	101	14	.	.	PUNCT
ajst-25053	102	1	the	the	DET
ajst-25053	102	2	study	study	NOUN
ajst-25053	102	3	shows	show	VERB
ajst-25053	102	4	that	that	SCONJ
ajst-25053	102	5	electroporation	electroporation	NOUN
ajst-25053	102	6	is	be	AUX
ajst-25053	102	7	an	an	DET
ajst-25053	102	8	efficient	efficient	ADJ
ajst-25053	102	9	method	method	NOUN
ajst-25053	102	10	to	to	PART
ajst-25053	102	11	introduce	introduce	VERB
ajst-25053	102	12	mrna	mrna	PROPN
ajst-25053	102	13	into	into	ADP
ajst-25053	102	14	dc	dc	PROPN
ajst-25053	102	15	.	.	PUNCT
ajst-25053	103	1	currently	currently	ADV
ajst-25053	103	2	,	,	PUNCT
ajst-25053	103	3	an	an	DET
ajst-25053	103	4	example	example	NOUN
ajst-25053	103	5	of	of	ADP
ajst-25053	103	6	a	a	DET
ajst-25053	103	7	dc	dc	PROPN
ajst-25053	103	8	-	-	PUNCT
ajst-25053	103	9	loaded	load	VERB
ajst-25053	103	10	mrna	mrna	NOUN
ajst-25053	103	11	vaccine	vaccine	NOUN
ajst-25053	103	12	is	be	AUX
ajst-25053	103	13	the	the	DET
ajst-25053	103	14	trimix	trimix	PROPN
ajst-25053	103	15	dc	dc	PROPN
ajst-25053	103	16	-	-	PUNCT
ajst-25053	103	17	mel	mel	PROPN
ajst-25053	103	18	vaccine	vaccine	NOUN
ajst-25053	103	19	given	give	VERB
ajst-25053	103	20	to	to	ADP
ajst-25053	103	21	melanoma	melanoma	NOUN
ajst-25053	103	22	patients	patient	NOUN
ajst-25053	103	23	.	.	PUNCT
ajst-25053	104	1	the	the	DET
ajst-25053	104	2	vaccine	vaccine	NOUN
ajst-25053	104	3	is	be	AUX
ajst-25053	104	4	loaded	load	VERB
ajst-25053	104	5	with	with	ADP
ajst-25053	104	6	four	four	NUM
ajst-25053	104	7	mrnas	mrna	NOUN
ajst-25053	104	8	,	,	PUNCT
ajst-25053	104	9	tumor	tumor	NOUN
ajst-25053	104	10	antigens	antigen	NOUN
ajst-25053	104	11	,	,	PUNCT
ajst-25053	104	12	cd40l	cd40l	NOUN
ajst-25053	104	13	,	,	PUNCT
ajst-25053	104	14	cd70	cd70	PROPN
ajst-25053	104	15	and	and	CCONJ
ajst-25053	104	16	active	active	ADJ
ajst-25053	104	17	tlr4	tlr4	NOUN
ajst-25053	104	18	,	,	PUNCT
ajst-25053	104	19	and	and	CCONJ
ajst-25053	104	20	has	have	AUX
ajst-25053	104	21	been	be	AUX
ajst-25053	104	22	shown	show	VERB
ajst-25053	104	23	to	to	PART
ajst-25053	104	24	be	be	AUX
ajst-25053	104	25	effective	effective	ADJ
ajst-25053	104	26	in	in	ADP
ajst-25053	104	27	clinical	clinical	ADJ
ajst-25053	104	28	trials[9	trials[9	NOUN
ajst-25053	104	29	]	]	PUNCT
ajst-25053	104	30	.	.	PUNCT
ajst-25053	105	1	although	although	SCONJ
ajst-25053	105	2	the	the	DET
ajst-25053	105	3	efficiency	efficiency	NOUN
ajst-25053	105	4	of	of	ADP
ajst-25053	105	5	mrna	mrna	PROPN
ajst-25053	105	6	transfection	transfection	NOUN
ajst-25053	105	7	with	with	ADP
ajst-25053	105	8	dc	dc	PROPN
ajst-25053	105	9	is	be	AUX
ajst-25053	105	10	low	low	ADJ
ajst-25053	105	11	,	,	PUNCT
ajst-25053	105	12	and	and	CCONJ
ajst-25053	105	13	the	the	DET
ajst-25053	105	14	long	long	ADJ
ajst-25053	105	15	preparation	preparation	NOUN
ajst-25053	105	16	time	time	NOUN
ajst-25053	105	17	may	may	AUX
ajst-25053	105	18	lead	lead	VERB
ajst-25053	105	19	to	to	ADP
ajst-25053	105	20	the	the	DET
ajst-25053	105	21	loss	loss	NOUN
ajst-25053	105	22	of	of	ADP
ajst-25053	105	23	the	the	DET
ajst-25053	105	24	mrna	mrna	NOUN
ajst-25053	105	25	-	-	PUNCT
ajst-25053	105	26	induced	induce	VERB
ajst-25053	105	27	immune	immune	ADJ
ajst-25053	105	28	response	response	NOUN
ajst-25053	105	29	,	,	PUNCT
ajst-25053	105	30	based	base	VERB
ajst-25053	105	31	on	on	ADP
ajst-25053	105	32	the	the	DET
ajst-25053	105	33	important	important	ADJ
ajst-25053	105	34	position	position	NOUN
ajst-25053	105	35	of	of	ADP
ajst-25053	105	36	dc	dc	PROPN
ajst-25053	105	37	in	in	ADP
ajst-25053	105	38	the	the	DET
ajst-25053	105	39	immune	immune	ADJ
ajst-25053	105	40	system	system	NOUN
ajst-25053	105	41	,	,	PUNCT
ajst-25053	105	42	dc	dc	PROPN
ajst-25053	105	43	-	-	PUNCT
ajst-25053	105	44	loaded	load	VERB
ajst-25053	105	45	mrna	mrna	NOUN
ajst-25053	105	46	can	can	AUX
ajst-25053	105	47	still	still	ADV
ajst-25053	105	48	be	be	AUX
ajst-25053	105	49	an	an	DET
ajst-25053	105	50	alternative	alternative	ADJ
ajst-25053	105	51	direction	direction	NOUN
ajst-25053	105	52	for	for	ADP
ajst-25053	105	53	future	future	ADJ
ajst-25053	105	54	immunotherapy	immunotherapy	NOUN
ajst-25053	105	55	research	research	NOUN
ajst-25053	105	56	,	,	PUNCT
ajst-25053	105	57	especially	especially	ADV
ajst-25053	105	58	the	the	DET
ajst-25053	105	59	combination	combination	NOUN
ajst-25053	105	60	immunotherapy	immunotherapy	NOUN
ajst-25053	105	61	strategy	strategy	NOUN
ajst-25053	105	62	of	of	ADP
ajst-25053	105	63	combining	combine	VERB
ajst-25053	105	64	dc	dc	PROPN
ajst-25053	105	65	-	-	PUNCT
ajst-25053	105	66	based	base	VERB
ajst-25053	105	67	vaccines	vaccine	NOUN
ajst-25053	105	68	with	with	ADP
ajst-25053	105	69	other	other	ADJ
ajst-25053	105	70	cancer	cancer	NOUN
ajst-25053	105	71	therapies	therapy	NOUN
ajst-25053	105	72	.	.	PUNCT
ajst-25053	106	1	4.3	4.3	NUM
ajst-25053	106	2	.	.	PUNCT
ajst-25053	106	3	cationic	cationic	ADJ
ajst-25053	106	4	peptide	peptide	NOUN
ajst-25053	106	5	protamine	protamine	NOUN
ajst-25053	106	6	is	be	AUX
ajst-25053	106	7	a	a	DET
ajst-25053	106	8	naturally	naturally	ADV
ajst-25053	106	9	occurring	occur	VERB
ajst-25053	106	10	protein	protein	NOUN
ajst-25053	106	11	that	that	PRON
ajst-25053	106	12	,	,	PUNCT
ajst-25053	106	13	due	due	ADP
ajst-25053	106	14	to	to	ADP
ajst-25053	106	15	its	its	PRON
ajst-25053	106	16	large	large	ADJ
ajst-25053	106	17	amount	amount	NOUN
ajst-25053	106	18	of	of	ADP
ajst-25053	106	19	cationic	cationic	ADJ
ajst-25053	106	20	l	l	NOUN
ajst-25053	106	21	-	-	NOUN
ajst-25053	106	22	arginine	arginine	NOUN
ajst-25053	106	23	,	,	PUNCT
ajst-25053	106	24	can	can	AUX
ajst-25053	106	25	form	form	VERB
ajst-25053	106	26	complexes	complex	NOUN
ajst-25053	106	27	with	with	ADP
ajst-25053	106	28	negatively	negatively	ADV
ajst-25053	106	29	charged	charge	VERB
ajst-25053	106	30	mrna	mrna	NOUN
ajst-25053	106	31	to	to	PART
ajst-25053	106	32	protect	protect	VERB
ajst-25053	106	33	nucleic	nucleic	ADJ
ajst-25053	106	34	acids	acid	NOUN
ajst-25053	106	35	from	from	ADP
ajst-25053	106	36	enzymatic	enzymatic	ADJ
ajst-25053	106	37	degradation	degradation	NOUN
ajst-25053	106	38	.	.	PUNCT
ajst-25053	107	1	an	an	DET
ajst-25053	107	2	mrna	mrna	PROPN
ajst-25053	107	3	vaccine	vaccine	NOUN
ajst-25053	107	4	delivery	delivery	NOUN
ajst-25053	107	5	system	system	NOUN
ajst-25053	107	6	for	for	ADP
ajst-25053	107	7	rabies	rabie	NOUN
ajst-25053	107	8	developed	develop	VERB
ajst-25053	107	9	by	by	ADP
ajst-25053	107	10	curevac	curevac	NOUN
ajst-25053	107	11	using	use	VERB
ajst-25053	107	12	protamine	protamine	NOUN
ajst-25053	107	13	has	have	AUX
ajst-25053	107	14	proven	prove	VERB
ajst-25053	107	15	to	to	PART
ajst-25053	107	16	be	be	AUX
ajst-25053	107	17	effective[10	effective[10	VERB
ajst-25053	107	18	]	]	PUNCT
ajst-25053	107	19	.	.	PUNCT
ajst-25053	108	1	even	even	ADV
ajst-25053	108	2	though	though	SCONJ
ajst-25053	108	3	the	the	DET
ajst-25053	108	4	efficiency	efficiency	NOUN
ajst-25053	108	5	of	of	ADP
ajst-25053	108	6	protamine	protamine	PROPN
ajst-25053	108	7	transfection	transfection	PROPN
ajst-25053	108	8	mrna	mrna	PROPN
ajst-25053	108	9	needs	need	VERB
ajst-25053	108	10	to	to	PART
ajst-25053	108	11	be	be	AUX
ajst-25053	108	12	improved	improve	VERB
ajst-25053	108	13	,	,	PUNCT
ajst-25053	108	14	due	due	ADP
ajst-25053	108	15	to	to	ADP
ajst-25053	108	16	its	its	PRON
ajst-25053	108	17	clinical	clinical	ADJ
ajst-25053	108	18	safety	safety	NOUN
ajst-25053	108	19	,	,	PUNCT
ajst-25053	108	20	it	it	PRON
ajst-25053	108	21	can	can	AUX
ajst-25053	108	22	still	still	ADV
ajst-25053	108	23	be	be	AUX
ajst-25053	108	24	used	use	VERB
ajst-25053	108	25	as	as	ADP
ajst-25053	108	26	a	a	DET
ajst-25053	108	27	feasible	feasible	ADJ
ajst-25053	108	28	research	research	NOUN
ajst-25053	108	29	direction	direction	NOUN
ajst-25053	108	30	for	for	ADP
ajst-25053	108	31	mrna	mrna	PROPN
ajst-25053	108	32	delivery	delivery	NOUN
ajst-25053	108	33	systems	system	NOUN
ajst-25053	108	34	.	.	PUNCT
ajst-25053	109	1	4.4	4.4	NUM
ajst-25053	109	2	.	.	PUNCT
ajst-25053	110	1	cationic	cationic	ADJ
ajst-25053	110	2	nanoemulsion	nanoemulsion	NOUN
ajst-25053	110	3	cationic	cationic	ADJ
ajst-25053	110	4	nanoemulsion	nanoemulsion	NOUN
ajst-25053	110	5	is	be	AUX
ajst-25053	110	6	an	an	DET
ajst-25053	110	7	oil	oil	NOUN
ajst-25053	110	8	-	-	PUNCT
ajst-25053	110	9	in	in	ADP
ajst-25053	110	10	-	-	PUNCT
ajst-25053	110	11	water	water	NOUN
ajst-25053	110	12	delivery	delivery	NOUN
ajst-25053	110	13	method	method	NOUN
ajst-25053	110	14	,	,	PUNCT
ajst-25053	110	15	usually	usually	ADV
ajst-25053	110	16	consisting	consist	VERB
ajst-25053	110	17	of	of	ADP
ajst-25053	110	18	squalene	squalene	NOUN
ajst-25053	110	19	,	,	PUNCT
ajst-25053	110	20	indicating	indicate	VERB
ajst-25053	110	21	an	an	DET
ajst-25053	110	22	active	active	ADJ
ajst-25053	110	23	agent	agent	NOUN
ajst-25053	110	24	and	and	CCONJ
ajst-25053	110	25	a	a	DET
ajst-25053	110	26	buffer	buffer	NOUN
ajst-25053	110	27	,	,	PUNCT
ajst-25053	110	28	mf59	mf59	PROPN
ajst-25053	110	29	and	and	CCONJ
ajst-25053	110	30	as03	as03	PROPN
ajst-25053	110	31	are	be	AUX
ajst-25053	110	32	two	two	NUM
ajst-25053	110	33	examples	example	NOUN
ajst-25053	110	34	of	of	ADP
ajst-25053	110	35	adjuvant	adjuvant	ADJ
ajst-25053	110	36	systems	system	NOUN
ajst-25053	110	37	,	,	PUNCT
ajst-25053	110	38	of	of	ADP
ajst-25053	110	39	which	which	PRON
ajst-25053	110	40	mf59	mf59	PROPN
ajst-25053	110	41	is	be	AUX
ajst-25053	110	42	permitted	permit	VERB
ajst-25053	110	43	in	in	ADP
ajst-25053	110	44	many	many	ADJ
ajst-25053	110	45	countries	country	NOUN
ajst-25053	110	46	for	for	ADP
ajst-25053	110	47	pandemic	pandemic	ADJ
ajst-25053	110	48	and	and	CCONJ
ajst-25053	110	49	seasonal	seasonal	ADJ
ajst-25053	110	50	influenza	influenza	NOUN
ajst-25053	110	51	vaccines	vaccine	NOUN
ajst-25053	110	52	due	due	ADP
ajst-25053	110	53	to	to	ADP
ajst-25053	110	54	its	its	PRON
ajst-25053	110	55	safety	safety	NOUN
ajst-25053	110	56	.	.	PUNCT
ajst-25053	111	1	as03	as03	PROPN
ajst-25053	111	2	has	have	AUX
ajst-25053	111	3	been	be	AUX
ajst-25053	111	4	shown	show	VERB
ajst-25053	111	5	to	to	PART
ajst-25053	111	6	activate	activate	VERB
ajst-25053	111	7	the	the	DET
ajst-25053	111	8	immune	immune	ADJ
ajst-25053	111	9	system	system	NOUN
ajst-25053	111	10	to	to	PART
ajst-25053	111	11	increase	increase	VERB
ajst-25053	111	12	antigen	antigen	ADV
ajst-25053	111	13	uptake	uptake	NOUN
ajst-25053	111	14	and	and	CCONJ
ajst-25053	111	15	presentation	presentation	NOUN
ajst-25053	111	16	,	,	PUNCT
ajst-25053	111	17	making	make	VERB
ajst-25053	111	18	it	it	PRON
ajst-25053	111	19	a	a	DET
ajst-25053	111	20	promising	promising	ADJ
ajst-25053	111	21	direction	direction	NOUN
ajst-25053	111	22	for	for	ADP
ajst-25053	111	23	future	future	ADJ
ajst-25053	111	24	research	research	NOUN
ajst-25053	111	25	in	in	ADP
ajst-25053	111	26	this	this	DET
ajst-25053	111	27	area[11,12	area[11,12	NOUN
ajst-25053	111	28	]	]	PUNCT
ajst-25053	111	29	.	.	PUNCT
ajst-25053	112	1	the	the	DET
ajst-25053	112	2	cationic	cationic	ADJ
ajst-25053	112	3	nanoemulsion	nanoemulsion	NOUN
ajst-25053	112	4	based	base	VERB
ajst-25053	112	5	on	on	ADP
ajst-25053	112	6	the	the	DET
ajst-25053	112	7	adjuvant	adjuvant	ADJ
ajst-25053	112	8	mf59	mf59	PROPN
ajst-25053	112	9	contains	contain	VERB
ajst-25053	112	10	a	a	DET
ajst-25053	112	11	key	key	ADJ
ajst-25053	112	12	ingredient	ingredient	NOUN
ajst-25053	112	13	that	that	PRON
ajst-25053	112	14	combines	combine	VERB
ajst-25053	112	15	mrna	mrna	NOUN
ajst-25053	112	16	in	in	ADP
ajst-25053	112	17	the	the	DET
ajst-25053	112	18	oil	oil	NOUN
ajst-25053	112	19	phase	phase	NOUN
ajst-25053	112	20	to	to	PART
ajst-25053	112	21	protect	protect	VERB
ajst-25053	112	22	it	it	PRON
ajst-25053	112	23	from	from	ADP
ajst-25053	112	24	degradation	degradation	NOUN
ajst-25053	112	25	.	.	PUNCT
ajst-25053	113	1	gennova	gennova	PROPN
ajst-25053	113	2	biopharmaceuticals	biopharmaceutical	NOUN
ajst-25053	113	3	ltd	ltd	PROPN
ajst-25053	113	4	and	and	CCONJ
ajst-25053	113	5	hdt	hdt	PROPN
ajst-25053	113	6	biotech	biotech	PROPN
ajst-25053	113	7	corporation	corporation	NOUN
ajst-25053	113	8	have	have	AUX
ajst-25053	113	9	jointly	jointly	ADV
ajst-25053	113	10	developed	develop	VERB
ajst-25053	113	11	a	a	DET
ajst-25053	113	12	lipid	lipid	NOUN
ajst-25053	113	13	inorganic	inorganic	ADJ
ajst-25053	113	14	nanoparticle	nanoparticle	NOUN
ajst-25053	113	15	for	for	ADP
ajst-25053	113	16	the	the	DET
ajst-25053	113	17	delivery	delivery	NOUN
ajst-25053	113	18	of	of	ADP
ajst-25053	113	19	the	the	DET
ajst-25053	113	20	sars	sar	NOUN
ajst-25053	113	21	-	-	PUNCT
ajst-25053	113	22	cov2	cov2	PROPN
ajst-25053	113	23	vaccine	vaccine	NOUN
ajst-25053	113	24	hgco10	hgco10	VERB
ajst-25053	113	25	,	,	PUNCT
ajst-25053	113	26	a	a	DET
ajst-25053	113	27	material	material	NOUN
ajst-25053	113	28	similar	similar	ADJ
ajst-25053	113	29	to	to	ADP
ajst-25053	113	30	cationic	cationic	ADJ
ajst-25053	113	31	nanomilk	nanomilk	NOUN
ajst-25053	113	32	.	.	PUNCT
ajst-25053	114	1	the	the	DET
ajst-25053	114	2	superparamagnetic	superparamagnetic	ADJ
ajst-25053	114	3	iron	iron	NOUN
ajst-25053	114	4	oxide	oxide	NOUN
ajst-25053	114	5	(	(	PUNCT
ajst-25053	114	6	fe3o4	fe3o4	NOUN
ajst-25053	114	7	)	)	PUNCT
ajst-25053	114	8	can	can	AUX
ajst-25053	114	9	achieve	achieve	VERB
ajst-25053	114	10	therapeutic	therapeutic	ADJ
ajst-25053	114	11	and	and	CCONJ
ajst-25053	114	12	imaging	imaging	NOUN
ajst-25053	114	13	functions	function	NOUN
ajst-25053	114	14	,	,	PUNCT
ajst-25053	114	15	and	and	CCONJ
ajst-25053	114	16	the	the	DET
ajst-25053	114	17	colloidal	colloidal	NOUN
ajst-25053	114	18	stability	stability	NOUN
ajst-25053	114	19	of	of	ADP
ajst-25053	114	20	this	this	DET
ajst-25053	114	21	preparation	preparation	NOUN
ajst-25053	114	22	is	be	AUX
ajst-25053	114	23	far	far	ADV
ajst-25053	114	24	better	well	ADJ
ajst-25053	114	25	than	than	ADP
ajst-25053	114	26	that	that	PRON
ajst-25053	114	27	of	of	ADP
ajst-25053	114	28	the	the	DET
ajst-25053	114	29	currently	currently	ADV
ajst-25053	114	30	used	use	VERB
ajst-25053	114	31	sars	sar	NOUN
ajst-25053	114	32	-	-	PUNCT
ajst-25053	114	33	cov2mrna	cov2mrna	PROPN
ajst-25053	114	34	vaccine[13	vaccine[13	NOUN
ajst-25053	114	35	]	]	X
ajst-25053	114	36	.	.	PUNCT
ajst-25053	115	1	4.5	4.5	NUM
ajst-25053	115	2	.	.	PUNCT
ajst-25053	116	1	lnp	lnp	PROPN
ajst-25053	116	2	lipid	lipid	PROPN
ajst-25053	116	3	nanoparticles(lnp	nanoparticles(lnp	PROPN
ajst-25053	116	4	)	)	PUNCT
ajst-25053	116	5	is	be	AUX
ajst-25053	116	6	the	the	DET
ajst-25053	116	7	most	most	ADV
ajst-25053	116	8	advanced	advanced	ADJ
ajst-25053	116	9	mrna	mrna	NOUN
ajst-25053	116	10	drug	drug	NOUN
ajst-25053	116	11	delivery	delivery	NOUN
ajst-25053	116	12	method	method	NOUN
ajst-25053	116	13	in	in	ADP
ajst-25053	116	14	the	the	DET
ajst-25053	116	15	clinic	clinic	NOUN
ajst-25053	116	16	,	,	PUNCT
ajst-25053	116	17	which	which	PRON
ajst-25053	116	18	has	have	AUX
ajst-25053	116	19	been	be	AUX
ajst-25053	116	20	demonstrated	demonstrate	VERB
ajst-25053	116	21	in	in	ADP
ajst-25053	116	22	the	the	DET
ajst-25053	116	23	lnp	lnp	PROPN
ajst-25053	116	24	-	-	PUNCT
ajst-25053	116	25	mrna	mrna	PROPN
ajst-25053	116	26	vaccines	vaccine	NOUN
ajst-25053	116	27	moderna	moderna	PROPN
ajst-25053	116	28	and	and	CCONJ
ajst-25053	116	29	pfebiontech	pfebiontech	ADJ
ajst-25053	116	30	in	in	ADP
ajst-25053	116	31	covid-19	covid-19	PROPN
ajst-25053	116	32	.	.	PUNCT
ajst-25053	117	1	lnp	lnp	PROPN
ajst-25053	117	2	includes	include	VERB
ajst-25053	117	3	cationic	cationic	ADJ
ajst-25053	117	4	ionizable	ionizable	ADJ
ajst-25053	117	5	lipids	lipid	NOUN
ajst-25053	117	6	,	,	PUNCT
ajst-25053	117	7	cholesterol	cholesterol	NOUN
ajst-25053	117	8	,	,	PUNCT
ajst-25053	117	9	helper	helper	NOUN
ajst-25053	117	10	phospholipids	phospholipid	NOUN
ajst-25053	117	11	,	,	PUNCT
ajst-25053	117	12	and	and	CCONJ
ajst-25053	117	13	polyethylene	polyethylene	NOUN
ajst-25053	117	14	glycol	glycol	NOUN
ajst-25053	117	15	lipids	lipid	NOUN
ajst-25053	117	16	.	.	PUNCT
ajst-25053	118	1	the	the	DET
ajst-25053	118	2	ionizable	ionizable	ADJ
ajst-25053	118	3	lipids	lipids	ADJ
ajst-25053	118	4	envelope	envelope	NOUN
ajst-25053	118	5	the	the	DET
ajst-25053	118	6	negatively	negatively	ADV
ajst-25053	118	7	charged	charge	VERB
ajst-25053	118	8	mrna	mrna	NOUN
ajst-25053	118	9	through	through	ADP
ajst-25053	118	10	a	a	DET
ajst-25053	118	11	combination	combination	NOUN
ajst-25053	118	12	of	of	ADP
ajst-25053	118	13	electrostatic	electrostatic	ADJ
ajst-25053	118	14	attraction	attraction	NOUN
ajst-25053	118	15	and	and	CCONJ
ajst-25053	118	16	hydrophobic	hydrophobic	NOUN
ajst-25053	118	17	interaction	interaction	NOUN
ajst-25053	118	18	.	.	PUNCT
ajst-25053	119	1	cholesterol	cholesterol	NOUN
ajst-25053	119	2	as	as	ADP
ajst-25053	119	3	a	a	DET
ajst-25053	119	4	359	359	NUM
ajst-25053	119	5	neutral	neutral	ADJ
ajst-25053	119	6	lipid	lipid	NOUN
ajst-25053	119	7	can	can	AUX
ajst-25053	119	8	not	not	PART
ajst-25053	119	9	only	only	ADV
ajst-25053	119	10	enhance	enhance	VERB
ajst-25053	119	11	particle	particle	NOUN
ajst-25053	119	12	stability	stability	NOUN
ajst-25053	119	13	,	,	PUNCT
ajst-25053	119	14	but	but	CCONJ
ajst-25053	119	15	also	also	ADV
ajst-25053	119	16	improve	improve	VERB
ajst-25053	119	17	transfection	transfection	NOUN
ajst-25053	119	18	efficiency	efficiency	NOUN
ajst-25053	119	19	.	.	PUNCT
ajst-25053	120	1	polyethylene	polyethylene	NOUN
ajst-25053	120	2	glycol	glycol	NOUN
ajst-25053	120	3	lipids	lipid	NOUN
ajst-25053	120	4	reduce	reduce	VERB
ajst-25053	120	5	antibody	antibody	NOUN
ajst-25053	120	6	binding	bind	VERB
ajst-25053	120	7	of	of	ADP
ajst-25053	120	8	serum	serum	NOUN
ajst-25053	120	9	proteins	protein	NOUN
ajst-25053	120	10	and	and	CCONJ
ajst-25053	120	11	clearance	clearance	NOUN
ajst-25053	120	12	of	of	ADP
ajst-25053	120	13	phagocytes	phagocyte	NOUN
ajst-25053	120	14	,	,	PUNCT
ajst-25053	120	15	thereby	thereby	ADV
ajst-25053	120	16	extending	extend	VERB
ajst-25053	120	17	systemic	systemic	ADJ
ajst-25053	120	18	circulation	circulation	NOUN
ajst-25053	120	19	time	time	NOUN
ajst-25053	120	20	.	.	PUNCT
ajst-25053	121	1	auxiliary	auxiliary	ADJ
ajst-25053	121	2	phospholipids	phospholipid	NOUN
ajst-25053	121	3	can	can	AUX
ajst-25053	121	4	provide	provide	VERB
ajst-25053	121	5	a	a	DET
ajst-25053	121	6	bilayer	bilayer	NOUN
ajst-25053	121	7	stable	stable	ADJ
ajst-25053	121	8	structure	structure	NOUN
ajst-25053	121	9	,	,	PUNCT
ajst-25053	121	10	and	and	CCONJ
ajst-25053	121	11	it	it	PRON
ajst-25053	121	12	has	have	AUX
ajst-25053	121	13	also	also	ADV
ajst-25053	121	14	been	be	AUX
ajst-25053	121	15	demonstrated	demonstrate	VERB
ajst-25053	121	16	that	that	SCONJ
ajst-25053	121	17	the	the	DET
ajst-25053	121	18	chemical	chemical	ADJ
ajst-25053	121	19	properties	property	NOUN
ajst-25053	121	20	of	of	ADP
ajst-25053	121	21	phosphoric	phosphoric	NOUN
ajst-25053	121	22	acid	acid	NOUN
ajst-25053	121	23	play	play	VERB
ajst-25053	121	24	an	an	DET
ajst-25053	121	25	important	important	ADJ
ajst-25053	121	26	role	role	NOUN
ajst-25053	121	27	in	in	ADP
ajst-25053	121	28	endosome	endosome	PROPN
ajst-25053	121	29	escape[14	escape[14	PROPN
ajst-25053	121	30	]	]	PUNCT
ajst-25053	121	31	.	.	PUNCT
ajst-25053	122	1	in	in	ADP
ajst-25053	122	2	addition	addition	NOUN
ajst-25053	122	3	,	,	PUNCT
ajst-25053	122	4	there	there	PRON
ajst-25053	122	5	have	have	AUX
ajst-25053	122	6	also	also	ADV
ajst-25053	122	7	been	be	AUX
ajst-25053	122	8	reports	report	NOUN
ajst-25053	122	9	of	of	ADP
ajst-25053	122	10	adverse	adverse	ADJ
ajst-25053	122	11	events	event	NOUN
ajst-25053	122	12	related	relate	VERB
ajst-25053	122	13	to	to	ADP
ajst-25053	122	14	mrna	mrna	PROPN
ajst-25053	122	15	-	-	PUNCT
ajst-25053	122	16	lnp	lnp	PROPN
ajst-25053	122	17	,	,	PUNCT
ajst-25053	122	18	inflammatory	inflammatory	ADJ
ajst-25053	122	19	reactions	reaction	NOUN
ajst-25053	122	20	in	in	ADP
ajst-25053	122	21	the	the	DET
ajst-25053	122	22	body	body	NOUN
ajst-25053	122	23	,	,	PUNCT
ajst-25053	122	24	and	and	CCONJ
ajst-25053	122	25	human	human	ADJ
ajst-25053	122	26	tolerance	tolerance	NOUN
ajst-25053	122	27	to	to	ADP
ajst-25053	122	28	drugs[15	drugs[15	NOUN
ajst-25053	122	29	]	]	PUNCT
ajst-25053	122	30	,	,	PUNCT
ajst-25053	122	31	and	and	CCONJ
ajst-25053	122	32	further	further	ADJ
ajst-25053	122	33	pharmacological	pharmacological	ADJ
ajst-25053	122	34	and	and	CCONJ
ajst-25053	122	35	immunological	immunological	ADJ
ajst-25053	122	36	studies	study	NOUN
ajst-25053	122	37	on	on	ADP
ajst-25053	122	38	lnp	lnp	PROPN
ajst-25053	122	39	components	component	NOUN
ajst-25053	122	40	are	be	AUX
ajst-25053	122	41	needed	need	VERB
ajst-25053	122	42	to	to	PART
ajst-25053	122	43	achieve	achieve	VERB
ajst-25053	122	44	safe	safe	ADJ
ajst-25053	122	45	and	and	CCONJ
ajst-25053	122	46	effective	effective	ADJ
ajst-25053	122	47	mrna	mrna	PROPN
ajst-25053	122	48	delivery	delivery	NOUN
ajst-25053	122	49	.	.	PUNCT
ajst-25053	123	1	the	the	DET
ajst-25053	123	2	in	in	ADP
ajst-25053	123	3	-	-	PUNCT
ajst-25053	123	4	depth	depth	NOUN
ajst-25053	123	5	research	research	NOUN
ajst-25053	123	6	on	on	ADP
ajst-25053	123	7	mrna	mrna	PROPN
ajst-25053	123	8	-	-	PUNCT
ajst-25053	123	9	lnp	lnp	PROPN
ajst-25053	123	10	has	have	AUX
ajst-25053	123	11	become	become	VERB
ajst-25053	123	12	a	a	DET
ajst-25053	123	13	hot	hot	ADJ
ajst-25053	123	14	spot	spot	NOUN
ajst-25053	123	15	in	in	ADP
ajst-25053	123	16	the	the	DET
ajst-25053	123	17	future	future	ADJ
ajst-25053	123	18	treatment	treatment	NOUN
ajst-25053	123	19	of	of	ADP
ajst-25053	123	20	cancer	cancer	NOUN
ajst-25053	123	21	or	or	CCONJ
ajst-25053	123	22	infectious	infectious	ADJ
ajst-25053	123	23	diseases	disease	NOUN
ajst-25053	123	24	.	.	PUNCT
ajst-25053	124	1	5	5	X
ajst-25053	124	2	.	.	X
ajst-25053	124	3	sarna	sarna	PROPN
ajst-25053	124	4	in	in	ADP
ajst-25053	124	5	addition	addition	NOUN
ajst-25053	124	6	to	to	ADP
ajst-25053	124	7	the	the	DET
ajst-25053	124	8	traditional	traditional	ADJ
ajst-25053	124	9	non	non	ADJ
ajst-25053	124	10	-	-	ADJ
ajst-25053	124	11	replicating	replicate	VERB
ajst-25053	124	12	mrna	mrna	NOUN
ajst-25053	124	13	,	,	PUNCT
ajst-25053	124	14	there	there	PRON
ajst-25053	124	15	is	be	VERB
ajst-25053	124	16	also	also	ADV
ajst-25053	124	17	a	a	DET
ajst-25053	124	18	self	self	NOUN
ajst-25053	124	19	-	-	PUNCT
ajst-25053	124	20	amplifying	amplify	VERB
ajst-25053	124	21	mrna	mrna	NOUN
ajst-25053	124	22	,	,	PUNCT
ajst-25053	124	23	which	which	PRON
ajst-25053	124	24	is	be	AUX
ajst-25053	124	25	based	base	VERB
ajst-25053	124	26	on	on	ADP
ajst-25053	124	27	the	the	DET
ajst-25053	124	28	original	original	ADJ
ajst-25053	124	29	mrna	mrna	NOUN
ajst-25053	124	30	,	,	PUNCT
ajst-25053	124	31	and	and	CCONJ
ajst-25053	124	32	there	there	PRON
ajst-25053	124	33	is	be	VERB
ajst-25053	124	34	an	an	DET
ajst-25053	124	35	open	open	ADJ
ajst-25053	124	36	reading	reading	NOUN
ajst-25053	124	37	frame	frame	NOUN
ajst-25053	124	38	at	at	ADP
ajst-25053	124	39	the	the	DET
ajst-25053	124	40	five	five	NUM
ajst-25053	124	41	ends	end	NOUN
ajst-25053	124	42	,	,	PUNCT
ajst-25053	124	43	encoding	encode	VERB
ajst-25053	124	44	the	the	DET
ajst-25053	124	45	four	four	NUM
ajst-25053	124	46	non	non	ADJ
ajst-25053	124	47	-	-	ADJ
ajst-25053	124	48	structural	structural	ADJ
ajst-25053	124	49	proteins	protein	NOUN
ajst-25053	124	50	(	(	PUNCT
ajst-25053	124	51	nsps	nsps	NOUN
ajst-25053	124	52	)	)	PUNCT
ajst-25053	124	53	of	of	ADP
ajst-25053	124	54	the	the	DET
ajst-25053	124	55	specific	specific	ADJ
ajst-25053	124	56	virus	virus	NOUN
ajst-25053	124	57	.	.	PUNCT
ajst-25053	125	1	the	the	DET
ajst-25053	125	2	structural	structural	ADJ
ajst-25053	125	3	protein	protein	NOUN
ajst-25053	125	4	virus	virus	NOUN
ajst-25053	125	5	gene	gene	NOUN
ajst-25053	125	6	behind	behind	ADP
ajst-25053	125	7	the	the	DET
ajst-25053	125	8	subgenomic	subgenomic	ADJ
ajst-25053	125	9	promoter	promoter	NOUN
ajst-25053	125	10	(	(	PUNCT
ajst-25053	125	11	sgp	sgp	PROPN
ajst-25053	125	12	)	)	PUNCT
ajst-25053	125	13	was	be	AUX
ajst-25053	125	14	replaced	replace	VERB
ajst-25053	125	15	with	with	ADP
ajst-25053	125	16	a	a	DET
ajst-25053	125	17	heterogenic	heterogenic	ADJ
ajst-25053	125	18	gene	gene	NOUN
ajst-25053	125	19	encoding	encode	VERB
ajst-25053	125	20	the	the	DET
ajst-25053	125	21	target	target	NOUN
ajst-25053	125	22	protein	protein	NOUN
ajst-25053	125	23	.	.	PUNCT
ajst-25053	126	1	after	after	SCONJ
ajst-25053	126	2	the	the	DET
ajst-25053	126	3	sarna	sarna	PROPN
ajst-25053	126	4	enters	enter	VERB
ajst-25053	126	5	the	the	DET
ajst-25053	126	6	host	host	NOUN
ajst-25053	126	7	cytoplasm	cytoplasm	NOUN
ajst-25053	126	8	,	,	PUNCT
ajst-25053	126	9	the	the	DET
ajst-25053	126	10	four	four	NUM
ajst-25053	126	11	non	non	ADJ
ajst-25053	126	12	-	-	ADJ
ajst-25053	126	13	structural	structural	ADJ
ajst-25053	126	14	proteins	protein	NOUN
ajst-25053	126	15	form	form	VERB
ajst-25053	126	16	an	an	DET
ajst-25053	126	17	rna	rna	NOUN
ajst-25053	126	18	-	-	PUNCT
ajst-25053	126	19	dependent	dependent	ADJ
ajst-25053	126	20	rna	rna	NOUN
ajst-25053	126	21	polymerase	polymerase	NOUN
ajst-25053	126	22	(	(	PUNCT
ajst-25053	126	23	rdrp	rdrp	PROPN
ajst-25053	126	24	)	)	PUNCT
ajst-25053	126	25	through	through	ADP
ajst-25053	126	26	a	a	DET
ajst-25053	126	27	complex	complex	ADJ
ajst-25053	126	28	multi	multi	ADJ
ajst-25053	126	29	-	-	ADJ
ajst-25053	126	30	step	step	ADJ
ajst-25053	126	31	polymerization	polymerization	NOUN
ajst-25053	126	32	process	process	NOUN
ajst-25053	126	33	that	that	PRON
ajst-25053	126	34	guides	guide	VERB
ajst-25053	126	35	durable	durable	ADJ
ajst-25053	126	36	and	and	CCONJ
ajst-25053	126	37	efficient	efficient	ADJ
ajst-25053	126	38	antigen	antigen	ADJ
ajst-25053	126	39	expression	expression	NOUN
ajst-25053	126	40	.	.	PUNCT
ajst-25053	127	1	due	due	ADP
ajst-25053	127	2	to	to	ADP
ajst-25053	127	3	its	its	PRON
ajst-25053	127	4	selfreplicating	selfreplicating	NOUN
ajst-25053	127	5	properties	property	NOUN
ajst-25053	127	6	,	,	PUNCT
ajst-25053	127	7	sarna	sarna	PROPN
ajst-25053	127	8	can	can	AUX
ajst-25053	127	9	be	be	AUX
ajst-25053	127	10	delivered	deliver	VERB
ajst-25053	127	11	at	at	ADP
ajst-25053	127	12	lower	low	ADJ
ajst-25053	127	13	concentrations	concentration	NOUN
ajst-25053	127	14	than	than	ADP
ajst-25053	127	15	conventional	conventional	ADJ
ajst-25053	127	16	mrna	mrna	NOUN
ajst-25053	127	17	to	to	PART
ajst-25053	127	18	achieve	achieve	VERB
ajst-25053	127	19	comparable	comparable	ADJ
ajst-25053	127	20	antigen	antigen	ADJ
ajst-25053	127	21	expression	expression	NOUN
ajst-25053	127	22	.	.	PUNCT
ajst-25053	128	1	arct-145	arct-145	NOUN
ajst-25053	128	2	is	be	AUX
ajst-25053	128	3	the	the	DET
ajst-25053	128	4	world	world	NOUN
ajst-25053	128	5	's	's	PART
ajst-25053	128	6	first	first	ADJ
ajst-25053	128	7	commercially	commercially	ADV
ajst-25053	128	8	available	available	ADJ
ajst-25053	128	9	sarna	sarna	PROPN
ajst-25053	128	10	vaccine	vaccine	NOUN
ajst-25053	128	11	.	.	PUNCT
ajst-25053	129	1	with	with	ADP
ajst-25053	129	2	the	the	DET
ajst-25053	129	3	development	development	NOUN
ajst-25053	129	4	of	of	ADP
ajst-25053	129	5	rna	rna	PROPN
ajst-25053	129	6	technology	technology	NOUN
ajst-25053	129	7	,	,	PUNCT
ajst-25053	129	8	innovative	innovative	ADJ
ajst-25053	129	9	changes	change	NOUN
ajst-25053	129	10	related	relate	VERB
ajst-25053	129	11	to	to	ADP
ajst-25053	129	12	sarna	sarna	PROPN
ajst-25053	129	13	technology	technology	PROPN
ajst-25053	129	14	are	be	AUX
ajst-25053	129	15	also	also	ADV
ajst-25053	129	16	emerging	emerge	VERB
ajst-25053	129	17	,	,	PUNCT
ajst-25053	129	18	such	such	ADJ
ajst-25053	129	19	as	as	ADP
ajst-25053	129	20	tarna	tarna	NOUN
ajst-25053	129	21	and	and	CCONJ
ajst-25053	129	22	induced	induce	VERB
ajst-25053	129	23	pluripotent	pluripotent	ADJ
ajst-25053	129	24	stem	stem	NOUN
ajst-25053	129	25	cells	cell	NOUN
ajst-25053	129	26	.	.	PUNCT
ajst-25053	130	1	despite	despite	SCONJ
ajst-25053	130	2	some	some	DET
ajst-25053	130	3	limitations	limitation	NOUN
ajst-25053	130	4	,	,	PUNCT
ajst-25053	130	5	sarna	sarna	PROPN
ajst-25053	130	6	technology	technology	PROPN
ajst-25053	130	7	still	still	ADV
ajst-25053	130	8	has	have	VERB
ajst-25053	130	9	a	a	DET
ajst-25053	130	10	wide	wide	ADJ
ajst-25053	130	11	range	range	NOUN
ajst-25053	130	12	of	of	ADP
ajst-25053	130	13	application	application	NOUN
ajst-25053	130	14	prospects	prospect	NOUN
ajst-25053	130	15	and	and	CCONJ
ajst-25053	130	16	is	be	AUX
ajst-25053	130	17	expected	expect	VERB
ajst-25053	130	18	to	to	PART
ajst-25053	130	19	become	become	VERB
ajst-25053	130	20	a	a	DET
ajst-25053	130	21	rising	rise	VERB
ajst-25053	130	22	star	star	NOUN
ajst-25053	130	23	in	in	ADP
ajst-25053	130	24	mrna	mrna	PROPN
ajst-25053	130	25	technology	technology	PROPN
ajst-25053	130	26	.	.	PUNCT
ajst-25053	131	1	6	6	X
ajst-25053	131	2	.	.	X
ajst-25053	131	3	circrna	circrna	NOUN
ajst-25053	131	4	another	another	DET
ajst-25053	131	5	promising	promising	ADJ
ajst-25053	131	6	mrna	mrna	PROPN
ajst-25053	131	7	is	be	AUX
ajst-25053	131	8	circular	circular	ADJ
ajst-25053	131	9	mrna	mrna	NOUN
ajst-25053	131	10	,	,	PUNCT
ajst-25053	131	11	a	a	DET
ajst-25053	131	12	singlestranded	singlestrande	VERB
ajst-25053	131	13	rna	rna	NOUN
ajst-25053	131	14	that	that	PRON
ajst-25053	131	15	presents	present	VERB
ajst-25053	131	16	a	a	DET
ajst-25053	131	17	covalent	covalent	ADJ
ajst-25053	131	18	closed	close	VERB
ajst-25053	131	19	-	-	PUNCT
ajst-25053	131	20	loop	loop	NOUN
ajst-25053	131	21	structure	structure	NOUN
ajst-25053	131	22	and	and	CCONJ
ajst-25053	131	23	lacks	lack	VERB
ajst-25053	131	24	the	the	DET
ajst-25053	131	25	end	end	NOUN
ajst-25053	131	26	sequence	sequence	NOUN
ajst-25053	131	27	required	require	VERB
ajst-25053	131	28	for	for	ADP
ajst-25053	131	29	exonuclease	exonuclease	NOUN
ajst-25053	131	30	recognition	recognition	NOUN
ajst-25053	131	31	,	,	PUNCT
ajst-25053	131	32	so	so	CCONJ
ajst-25053	131	33	it	it	PRON
ajst-25053	131	34	is	be	AUX
ajst-25053	131	35	not	not	PART
ajst-25053	131	36	easily	easily	ADV
ajst-25053	131	37	degraded	degrade	VERB
ajst-25053	131	38	by	by	ADP
ajst-25053	131	39	exonuclease	exonuclease	NOUN
ajst-25053	131	40	,	,	PUNCT
ajst-25053	131	41	is	be	AUX
ajst-25053	131	42	more	more	ADV
ajst-25053	131	43	stable	stable	ADJ
ajst-25053	131	44	than	than	ADP
ajst-25053	131	45	linear	linear	PROPN
ajst-25053	131	46	mrna	mrna	PROPN
ajst-25053	131	47	,	,	PUNCT
ajst-25053	131	48	and	and	CCONJ
ajst-25053	131	49	has	have	VERB
ajst-25053	131	50	advantages	advantage	NOUN
ajst-25053	131	51	in	in	ADP
ajst-25053	131	52	delivery	delivery	NOUN
ajst-25053	131	53	and	and	CCONJ
ajst-25053	131	54	treatment	treatment	NOUN
ajst-25053	131	55	.	.	PUNCT
ajst-25053	132	1	since	since	SCONJ
ajst-25053	132	2	it	it	PRON
ajst-25053	132	3	does	do	AUX
ajst-25053	132	4	not	not	PART
ajst-25053	132	5	contain	contain	VERB
ajst-25053	132	6	a	a	DET
ajst-25053	132	7	cap	cap	NOUN
ajst-25053	132	8	and	and	CCONJ
ajst-25053	132	9	tail	tail	NOUN
ajst-25053	132	10	structure	structure	NOUN
ajst-25053	132	11	,	,	PUNCT
ajst-25053	132	12	it	it	PRON
ajst-25053	132	13	has	have	VERB
ajst-25053	132	14	advantages	advantage	NOUN
ajst-25053	132	15	in	in	ADP
ajst-25053	132	16	terms	term	NOUN
ajst-25053	132	17	of	of	ADP
ajst-25053	132	18	production	production	NOUN
ajst-25053	132	19	.	.	PUNCT
ajst-25053	133	1	it	it	PRON
ajst-25053	133	2	has	have	AUX
ajst-25053	133	3	also	also	ADV
ajst-25053	133	4	been	be	AUX
ajst-25053	133	5	suggested	suggest	VERB
ajst-25053	133	6	that	that	SCONJ
ajst-25053	133	7	circrna	circrna	NOUN
ajst-25053	133	8	has	have	VERB
ajst-25053	133	9	a	a	DET
ajst-25053	133	10	lower	low	ADJ
ajst-25053	133	11	immune	immune	ADJ
ajst-25053	133	12	prototype	prototype	NOUN
ajst-25053	133	13	,	,	PUNCT
ajst-25053	133	14	cytotoxicity	cytotoxicity	NOUN
ajst-25053	133	15	,	,	PUNCT
ajst-25053	133	16	and	and	CCONJ
ajst-25053	133	17	can	can	AUX
ajst-25053	133	18	exhibit	exhibit	VERB
ajst-25053	133	19	a	a	DET
ajst-25053	133	20	more	more	ADV
ajst-25053	133	21	durable	durable	ADJ
ajst-25053	133	22	immune	immune	ADJ
ajst-25053	133	23	response	response	NOUN
ajst-25053	133	24	.	.	PUNCT
ajst-25053	134	1	circrna	circrna	NOUN
ajst-25053	134	2	have	have	VERB
ajst-25053	134	3	great	great	ADJ
ajst-25053	134	4	potential	potential	NOUN
ajst-25053	134	5	to	to	PART
ajst-25053	134	6	become	become	VERB
ajst-25053	134	7	the	the	DET
ajst-25053	134	8	next	next	ADJ
ajst-25053	134	9	generation	generation	NOUN
ajst-25053	134	10	of	of	ADP
ajst-25053	134	11	mrna	mrna	PROPN
ajst-25053	134	12	drug	drug	NOUN
ajst-25053	134	13	platforms	platform	NOUN
ajst-25053	134	14	,	,	PUNCT
ajst-25053	134	15	however	however	ADV
ajst-25053	134	16	,	,	PUNCT
ajst-25053	134	17	circrna	circrna	NOUN
ajst-25053	134	18	are	be	AUX
ajst-25053	134	19	still	still	ADV
ajst-25053	134	20	in	in	ADP
ajst-25053	134	21	the	the	DET
ajst-25053	134	22	early	early	ADJ
ajst-25053	134	23	stages	stage	NOUN
ajst-25053	134	24	in	in	ADP
ajst-25053	134	25	terms	term	NOUN
ajst-25053	134	26	of	of	ADP
ajst-25053	134	27	design	design	NOUN
ajst-25053	134	28	,	,	PUNCT
ajst-25053	134	29	synthesis	synthesis	NOUN
ajst-25053	134	30	,	,	PUNCT
ajst-25053	134	31	purification	purification	NOUN
ajst-25053	134	32	,	,	PUNCT
ajst-25053	134	33	delivery	delivery	NOUN
ajst-25053	134	34	and	and	CCONJ
ajst-25053	134	35	application	application	NOUN
ajst-25053	134	36	.	.	PUNCT
ajst-25053	135	1	more	more	ADJ
ajst-25053	135	2	research	research	NOUN
ajst-25053	135	3	and	and	CCONJ
ajst-25053	135	4	experiments	experiment	NOUN
ajst-25053	135	5	are	be	AUX
ajst-25053	135	6	needed	need	VERB
ajst-25053	135	7	to	to	PART
ajst-25053	135	8	prove	prove	VERB
ajst-25053	135	9	its	its	PRON
ajst-25053	135	10	feasibility	feasibility	NOUN
ajst-25053	135	11	.	.	PUNCT
ajst-25053	136	1	7	7	X
ajst-25053	136	2	.	.	X
ajst-25053	136	3	conclusion	conclusion	NOUN
ajst-25053	136	4	and	and	CCONJ
ajst-25053	136	5	prospect	prospect	NOUN
ajst-25053	136	6	with	with	ADP
ajst-25053	136	7	the	the	DET
ajst-25053	136	8	deepening	deepening	NOUN
ajst-25053	136	9	of	of	ADP
ajst-25053	136	10	the	the	DET
ajst-25053	136	11	research	research	NOUN
ajst-25053	136	12	on	on	ADP
ajst-25053	136	13	mrna	mrna	PROPN
ajst-25053	136	14	drugs	drug	NOUN
ajst-25053	136	15	,	,	PUNCT
ajst-25053	136	16	more	more	ADV
ajst-25053	136	17	possible	possible	ADJ
ajst-25053	136	18	research	research	NOUN
ajst-25053	136	19	directions	direction	NOUN
ajst-25053	136	20	have	have	AUX
ajst-25053	136	21	been	be	AUX
ajst-25053	136	22	explored	explore	VERB
ajst-25053	136	23	.	.	PUNCT
ajst-25053	137	1	a	a	DET
ajst-25053	137	2	study	study	NOUN
ajst-25053	137	3	has	have	AUX
ajst-25053	137	4	shown	show	VERB
ajst-25053	137	5	that	that	SCONJ
ajst-25053	137	6	a	a	DET
ajst-25053	137	7	multivalent	multivalent	PROPN
ajst-25053	137	8	mrna	mrna	PROPN
ajst-25053	137	9	vaccine	vaccine	NOUN
ajst-25053	137	10	can	can	AUX
ajst-25053	137	11	express	express	VERB
ajst-25053	137	12	antigens	antigen	NOUN
ajst-25053	137	13	of	of	ADP
ajst-25053	137	14	multiple	multiple	ADJ
ajst-25053	137	15	known	know	VERB
ajst-25053	137	16	influenza	influenza	NOUN
ajst-25053	137	17	virus	virus	NOUN
ajst-25053	137	18	subtypes	subtype	NOUN
ajst-25053	137	19	,	,	PUNCT
ajst-25053	137	20	inducing	induce	VERB
ajst-25053	137	21	the	the	DET
ajst-25053	137	22	production	production	NOUN
ajst-25053	137	23	of	of	ADP
ajst-25053	137	24	multiple	multiple	ADJ
ajst-25053	137	25	antibodies	antibody	NOUN
ajst-25053	137	26	.	.	PUNCT
ajst-25053	138	1	this	this	PRON
ajst-25053	138	2	makes	make	VERB
ajst-25053	138	3	it	it	PRON
ajst-25053	138	4	possible	possible	ADJ
ajst-25053	138	5	to	to	PART
ajst-25053	138	6	develop	develop	VERB
ajst-25053	138	7	a	a	DET
ajst-25053	138	8	universal	universal	ADJ
ajst-25053	138	9	flu	flu	NOUN
ajst-25053	138	10	vaccine	vaccine	NOUN
ajst-25053	138	11	.	.	PUNCT
ajst-25053	139	1	meanwhile	meanwhile	ADV
ajst-25053	139	2	,	,	PUNCT
ajst-25053	139	3	a	a	DET
ajst-25053	139	4	multivalent	multivalent	PROPN
ajst-25053	139	5	mrna	mrna	PROPN
ajst-25053	139	6	vaccine	vaccine	NOUN
ajst-25053	139	7	against	against	ADP
ajst-25053	139	8	monkeypox	monkeypox	PROPN
ajst-25053	139	9	virus	virus	NOUN
ajst-25053	139	10	showed	show	VERB
ajst-25053	139	11	a	a	DET
ajst-25053	139	12	strong	strong	ADJ
ajst-25053	139	13	immune	immune	ADJ
ajst-25053	139	14	response	response	NOUN
ajst-25053	139	15	.	.	PUNCT
ajst-25053	140	1	in	in	ADP
ajst-25053	140	2	addition	addition	NOUN
ajst-25053	140	3	,	,	PUNCT
ajst-25053	140	4	mrna	mrna	PROPN
ajst-25053	140	5	vaccines	vaccine	NOUN
ajst-25053	140	6	have	have	AUX
ajst-25053	140	7	emerged	emerge	VERB
ajst-25053	140	8	as	as	ADP
ajst-25053	140	9	promising	promise	VERB
ajst-25053	140	10	cancer	cancer	NOUN
ajst-25053	140	11	therapies	therapy	NOUN
ajst-25053	140	12	.	.	PUNCT
ajst-25053	141	1	in	in	ADP
ajst-25053	141	2	addition	addition	NOUN
ajst-25053	141	3	to	to	ADP
ajst-25053	141	4	dealing	deal	VERB
ajst-25053	141	5	with	with	ADP
ajst-25053	141	6	the	the	DET
ajst-25053	141	7	possible	possible	ADJ
ajst-25053	141	8	emergence	emergence	NOUN
ajst-25053	141	9	of	of	ADP
ajst-25053	141	10	infectious	infectious	ADJ
ajst-25053	141	11	diseases	disease	NOUN
ajst-25053	141	12	,	,	PUNCT
ajst-25053	141	13	mrna	mrna	PROPN
ajst-25053	141	14	vaccines	vaccine	NOUN
ajst-25053	141	15	can	can	AUX
ajst-25053	141	16	also	also	ADV
ajst-25053	141	17	encode	encode	VERB
ajst-25053	141	18	tumor	tumor	NOUN
ajst-25053	141	19	antigens	antigen	NOUN
ajst-25053	141	20	,	,	PUNCT
ajst-25053	141	21	enabling	enable	VERB
ajst-25053	141	22	personalized	personalized	ADJ
ajst-25053	141	23	therapies	therapy	NOUN
ajst-25053	141	24	.	.	PUNCT
ajst-25053	142	1	an	an	DET
ajst-25053	142	2	mrna	mrna	NOUN
ajst-25053	142	3	vaccine	vaccine	NOUN
ajst-25053	142	4	for	for	ADP
ajst-25053	142	5	pancreatic	pancreatic	ADJ
ajst-25053	142	6	ductal	ductal	ADJ
ajst-25053	142	7	cancer	cancer	NOUN
ajst-25053	142	8	(	(	PUNCT
ajst-25053	142	9	pdac	pdac	NOUN
ajst-25053	142	10	)	)	PUNCT
ajst-25053	142	11	has	have	AUX
ajst-25053	142	12	been	be	AUX
ajst-25053	142	13	shown	show	VERB
ajst-25053	142	14	to	to	PART
ajst-25053	142	15	be	be	AUX
ajst-25053	142	16	safe	safe	ADJ
ajst-25053	142	17	and	and	CCONJ
ajst-25053	142	18	feasible	feasible	ADJ
ajst-25053	142	19	in	in	ADP
ajst-25053	142	20	a	a	DET
ajst-25053	142	21	clinical	clinical	ADJ
ajst-25053	142	22	trial	trial	NOUN
ajst-25053	142	23	,	,	PUNCT
ajst-25053	142	24	and	and	CCONJ
ajst-25053	142	25	further	further	ADJ
ajst-25053	142	26	trials	trial	NOUN
ajst-25053	142	27	are	be	AUX
ajst-25053	142	28	being	be	AUX
ajst-25053	142	29	conducted	conduct	VERB
ajst-25053	142	30	[	[	X
ajst-25053	142	31	16	16	NUM
ajst-25053	142	32	]	]	PUNCT
ajst-25053	142	33	.	.	PUNCT
ajst-25053	143	1	there	there	PRON
ajst-25053	143	2	are	be	VERB
ajst-25053	143	3	also	also	ADV
ajst-25053	143	4	protein	protein	NOUN
ajst-25053	143	5	replacement	replacement	NOUN
ajst-25053	143	6	therapies	therapy	NOUN
ajst-25053	143	7	being	be	AUX
ajst-25053	143	8	explored	explore	VERB
ajst-25053	143	9	,	,	PUNCT
ajst-25053	143	10	which	which	DET
ajst-25053	143	11	translate	translate	VERB
ajst-25053	143	12	proteins	protein	NOUN
ajst-25053	143	13	by	by	ADP
ajst-25053	143	14	transfecting	transfecte	VERB
ajst-25053	143	15	mrna	mrna	PROPN
ajst-25053	143	16	into	into	ADP
ajst-25053	143	17	somatic	somatic	ADJ
ajst-25053	143	18	cells	cell	NOUN
ajst-25053	143	19	to	to	PART
ajst-25053	143	20	replace	replace	VERB
ajst-25053	143	21	abnormal	abnormal	ADJ
ajst-25053	143	22	proteins	protein	NOUN
ajst-25053	143	23	or	or	CCONJ
ajst-25053	143	24	to	to	PART
ajst-25053	143	25	supplement	supplement	VERB
ajst-25053	143	26	deficient	deficient	ADJ
ajst-25053	143	27	proteins	protein	NOUN
ajst-25053	143	28	.	.	PUNCT
ajst-25053	144	1	mrna	mrna	PROPN
ajst-25053	144	2	can	can	AUX
ajst-25053	144	3	also	also	ADV
ajst-25053	144	4	be	be	AUX
ajst-25053	144	5	used	use	VERB
ajst-25053	144	6	in	in	ADP
ajst-25053	144	7	car	car	NOUN
ajst-25053	144	8	-	-	PUNCT
ajst-25053	144	9	t	t	NOUN
ajst-25053	144	10	cell	cell	NOUN
ajst-25053	144	11	therapy	therapy	NOUN
ajst-25053	144	12	for	for	ADP
ajst-25053	144	13	autoimmune	autoimmune	ADJ
ajst-25053	144	14	diseases	disease	NOUN
ajst-25053	144	15	,	,	PUNCT
ajst-25053	144	16	and	and	CCONJ
ajst-25053	144	17	a	a	DET
ajst-25053	144	18	clinical	clinical	ADJ
ajst-25053	144	19	trial	trial	NOUN
ajst-25053	144	20	in	in	ADP
ajst-25053	144	21	patients	patient	NOUN
ajst-25053	144	22	with	with	ADP
ajst-25053	144	23	myasthenia	myasthenia	NOUN
ajst-25053	144	24	gravis	gravis	NOUN
ajst-25053	144	25	demonstrated	demonstrate	VERB
ajst-25053	144	26	that	that	SCONJ
ajst-25053	144	27	this	this	DET
ajst-25053	144	28	treatment	treatment	NOUN
ajst-25053	144	29	is	be	AUX
ajst-25053	144	30	more	more	ADV
ajst-25053	144	31	effective	effective	ADJ
ajst-25053	144	32	and	and	CCONJ
ajst-25053	144	33	safer	safe	ADJ
ajst-25053	144	34	than	than	ADP
ajst-25053	144	35	dna	dna	NOUN
ajst-25053	144	36	-	-	PUNCT
ajst-25053	144	37	based	base	VERB
ajst-25053	144	38	car	car	NOUN
ajst-25053	144	39	-	-	PUNCT
ajst-25053	144	40	t	t	NOUN
ajst-25053	144	41	therapy	therapy	NOUN
ajst-25053	144	42	.	.	PUNCT
ajst-25053	145	1	the	the	DET
ajst-25053	145	2	key	key	ADJ
ajst-25053	145	3	technologies	technology	NOUN
ajst-25053	145	4	in	in	ADP
ajst-25053	145	5	mrna	mrna	PROPN
ajst-25053	145	6	design	design	PROPN
ajst-25053	145	7	include	include	VERB
ajst-25053	145	8	mrna	mrna	PROPN
ajst-25053	145	9	modification	modification	NOUN
ajst-25053	145	10	,	,	PUNCT
ajst-25053	145	11	in	in	ADP
ajst-25053	145	12	vitro	vitro	X
ajst-25053	145	13	transcription	transcription	NOUN
ajst-25053	145	14	,	,	PUNCT
ajst-25053	145	15	purification	purification	NOUN
ajst-25053	145	16	,	,	PUNCT
ajst-25053	145	17	and	and	CCONJ
ajst-25053	145	18	delivery	delivery	NOUN
ajst-25053	145	19	systems	system	NOUN
ajst-25053	145	20	.	.	PUNCT
ajst-25053	146	1	at	at	ADP
ajst-25053	146	2	present	present	ADJ
ajst-25053	146	3	,	,	PUNCT
ajst-25053	146	4	the	the	DET
ajst-25053	146	5	application	application	NOUN
ajst-25053	146	6	of	of	ADP
ajst-25053	146	7	these	these	DET
ajst-25053	146	8	technologies	technology	NOUN
ajst-25053	146	9	has	have	AUX
ajst-25053	146	10	been	be	AUX
ajst-25053	146	11	basically	basically	ADV
ajst-25053	146	12	mature	mature	ADJ
ajst-25053	146	13	,	,	PUNCT
ajst-25053	146	14	but	but	CCONJ
ajst-25053	146	15	there	there	PRON
ajst-25053	146	16	are	be	VERB
ajst-25053	146	17	still	still	ADV
ajst-25053	146	18	some	some	DET
ajst-25053	146	19	challenges	challenge	NOUN
ajst-25053	146	20	and	and	CCONJ
ajst-25053	146	21	obstacles	obstacle	NOUN
ajst-25053	146	22	to	to	PART
ajst-25053	146	23	be	be	AUX
ajst-25053	146	24	faced	face	VERB
ajst-25053	146	25	.	.	PUNCT
ajst-25053	147	1	the	the	DET
ajst-25053	147	2	first	first	ADJ
ajst-25053	147	3	is	be	AUX
ajst-25053	147	4	the	the	DET
ajst-25053	147	5	transportation	transportation	NOUN
ajst-25053	147	6	and	and	CCONJ
ajst-25053	147	7	storage	storage	NOUN
ajst-25053	147	8	of	of	ADP
ajst-25053	147	9	mrna	mrna	PROPN
ajst-25053	147	10	vaccines	vaccine	NOUN
ajst-25053	147	11	.	.	PUNCT
ajst-25053	148	1	the	the	DET
ajst-25053	148	2	storage	storage	NOUN
ajst-25053	148	3	conditions	condition	NOUN
ajst-25053	148	4	of	of	ADP
ajst-25053	148	5	most	most	ADJ
ajst-25053	148	6	mrna	mrna	PROPN
ajst-25053	148	7	drugs	drug	NOUN
ajst-25053	148	8	are	be	AUX
ajst-25053	148	9	harsh	harsh	ADJ
ajst-25053	148	10	,	,	PUNCT
ajst-25053	148	11	and	and	CCONJ
ajst-25053	148	12	the	the	DET
ajst-25053	148	13	stability	stability	NOUN
ajst-25053	148	14	decreases	decrease	VERB
ajst-25053	148	15	rapidly	rapidly	ADV
ajst-25053	148	16	with	with	ADP
ajst-25053	148	17	the	the	DET
ajst-25053	148	18	rise	rise	NOUN
ajst-25053	148	19	of	of	ADP
ajst-25053	148	20	temperature	temperature	NOUN
ajst-25053	148	21	.	.	PUNCT
ajst-25053	149	1	many	many	ADJ
ajst-25053	149	2	expired	expired	ADJ
ajst-25053	149	3	vaccines	vaccine	NOUN
ajst-25053	149	4	are	be	AUX
ajst-25053	149	5	wasted	waste	VERB
ajst-25053	149	6	,	,	PUNCT
ajst-25053	149	7	especially	especially	ADV
ajst-25053	149	8	in	in	ADP
ajst-25053	149	9	some	some	DET
ajst-25053	149	10	resource	resource	NOUN
ajst-25053	149	11	-	-	PUNCT
ajst-25053	149	12	poor	poor	ADJ
ajst-25053	149	13	areas	area	NOUN
ajst-25053	149	14	,	,	PUNCT
ajst-25053	149	15	and	and	CCONJ
ajst-25053	149	16	ultra	ultra	ADJ
ajst-25053	149	17	-	-	ADJ
ajst-25053	149	18	low	low	ADJ
ajst-25053	149	19	temperature	temperature	NOUN
ajst-25053	149	20	storage	storage	NOUN
ajst-25053	149	21	becomes	become	VERB
ajst-25053	149	22	a	a	DET
ajst-25053	149	23	problem	problem	NOUN
ajst-25053	149	24	.	.	PUNCT
ajst-25053	150	1	developing	develop	VERB
ajst-25053	150	2	mrna	mrna	PROPN
ajst-25053	150	3	vaccines	vaccine	NOUN
ajst-25053	150	4	with	with	ADP
ajst-25053	150	5	high	high	ADJ
ajst-25053	150	6	stability	stability	NOUN
ajst-25053	150	7	at	at	ADP
ajst-25053	150	8	relatively	relatively	ADV
ajst-25053	150	9	high	high	ADJ
ajst-25053	150	10	temperatures	temperature	NOUN
ajst-25053	150	11	or	or	CCONJ
ajst-25053	150	12	designing	design	VERB
ajst-25053	150	13	lower	low	ADJ
ajst-25053	150	14	-	-	PUNCT
ajst-25053	150	15	cost	cost	NOUN
ajst-25053	150	16	mrna	mrna	PROPN
ajst-25053	150	17	kits	kit	NOUN
ajst-25053	150	18	is	be	AUX
ajst-25053	150	19	a	a	DET
ajst-25053	150	20	possible	possible	ADJ
ajst-25053	150	21	but	but	CCONJ
ajst-25053	150	22	difficult	difficult	ADJ
ajst-25053	150	23	strategy	strategy	NOUN
ajst-25053	150	24	.	.	PUNCT
ajst-25053	151	1	in	in	ADP
ajst-25053	151	2	addition	addition	NOUN
ajst-25053	151	3	,	,	PUNCT
ajst-25053	151	4	because	because	SCONJ
ajst-25053	151	5	the	the	DET
ajst-25053	151	6	clinical	clinical	ADJ
ajst-25053	151	7	application	application	NOUN
ajst-25053	151	8	of	of	ADP
ajst-25053	151	9	mrna	mrna	PROPN
ajst-25053	151	10	vaccines	vaccine	NOUN
ajst-25053	151	11	and	and	CCONJ
ajst-25053	151	12	drugs	drug	NOUN
ajst-25053	151	13	is	be	AUX
ajst-25053	151	14	relatively	relatively	ADV
ajst-25053	151	15	new	new	ADJ
ajst-25053	151	16	,	,	PUNCT
ajst-25053	151	17	many	many	ADJ
ajst-25053	151	18	safety	safety	NOUN
ajst-25053	151	19	issues	issue	NOUN
ajst-25053	151	20	or	or	CCONJ
ajst-25053	151	21	adverse	adverse	ADJ
ajst-25053	151	22	events	event	NOUN
ajst-25053	151	23	may	may	AUX
ajst-25053	151	24	occur	occur	VERB
ajst-25053	151	25	,	,	PUNCT
ajst-25053	151	26	and	and	CCONJ
ajst-25053	151	27	how	how	SCONJ
ajst-25053	151	28	to	to	PART
ajst-25053	151	29	effectively	effectively	ADV
ajst-25053	151	30	reduce	reduce	VERB
ajst-25053	151	31	the	the	DET
ajst-25053	151	32	potential	potential	ADJ
ajst-25053	151	33	risks	risk	NOUN
ajst-25053	151	34	of	of	ADP
ajst-25053	151	35	mrna	mrna	PROPN
ajst-25053	151	36	drugs	drug	NOUN
ajst-25053	151	37	has	have	AUX
ajst-25053	151	38	become	become	VERB
ajst-25053	151	39	a	a	DET
ajst-25053	151	40	key	key	ADJ
ajst-25053	151	41	challenge	challenge	NOUN
ajst-25053	151	42	.	.	PUNCT
ajst-25053	152	1	in	in	ADP
ajst-25053	152	2	summary	summary	NOUN
ajst-25053	152	3	,	,	PUNCT
ajst-25053	152	4	mrna	mrna	PROPN
ajst-25053	152	5	drugs	drug	NOUN
ajst-25053	152	6	are	be	AUX
ajst-25053	152	7	a	a	DET
ajst-25053	152	8	powerful	powerful	ADJ
ajst-25053	152	9	and	and	CCONJ
ajst-25053	152	10	versatile	versatile	ADJ
ajst-25053	152	11	platform	platform	NOUN
ajst-25053	152	12	.	.	PUNCT
ajst-25053	153	1	due	due	ADP
ajst-25053	153	2	to	to	ADP
ajst-25053	153	3	its	its	PRON
ajst-25053	153	4	safety	safety	NOUN
ajst-25053	153	5	,	,	PUNCT
ajst-25053	153	6	rapid	rapid	ADJ
ajst-25053	153	7	production	production	NOUN
ajst-25053	153	8	capacity	capacity	NOUN
ajst-25053	153	9	,	,	PUNCT
ajst-25053	153	10	flexibility	flexibility	NOUN
ajst-25053	153	11	,	,	PUNCT
ajst-25053	153	12	is	be	AUX
ajst-25053	153	13	considered	consider	VERB
ajst-25053	153	14	to	to	PART
ajst-25053	153	15	have	have	VERB
ajst-25053	153	16	great	great	ADJ
ajst-25053	153	17	potential	potential	NOUN
ajst-25053	153	18	.	.	PUNCT
ajst-25053	154	1	but	but	CCONJ
ajst-25053	154	2	many	many	ADJ
ajst-25053	154	3	challenges	challenge	NOUN
ajst-25053	154	4	remain	remain	VERB
ajst-25053	154	5	,	,	PUNCT
ajst-25053	154	6	and	and	CCONJ
ajst-25053	154	7	decades	decade	NOUN
ajst-25053	154	8	of	of	ADP
ajst-25053	154	9	research	research	NOUN
ajst-25053	154	10	have	have	AUX
ajst-25053	154	11	laid	lay	VERB
ajst-25053	154	12	a	a	DET
ajst-25053	154	13	solid	solid	ADJ
ajst-25053	154	14	foundation	foundation	NOUN
ajst-25053	154	15	for	for	ADP
ajst-25053	154	16	mrna	mrna	PROPN
ajst-25053	154	17	drug	drug	PROPN
ajst-25053	154	18	research	research	NOUN
ajst-25053	154	19	,	,	PUNCT
ajst-25053	154	20	and	and	CCONJ
ajst-25053	154	21	further	further	ADJ
ajst-25053	154	22	exploration	exploration	NOUN
ajst-25053	154	23	is	be	AUX
ajst-25053	154	24	needed	need	VERB
ajst-25053	154	25	to	to	PART
ajst-25053	154	26	understand	understand	VERB
ajst-25053	154	27	their	their	PRON
ajst-25053	154	28	full	full	ADJ
ajst-25053	154	29	potential	potential	NOUN
ajst-25053	154	30	.	.	PUNCT
ajst-25053	155	1	going	go	VERB
ajst-25053	155	2	forward	forward	ADV
ajst-25053	155	3	,	,	PUNCT
ajst-25053	155	4	it	it	PRON
ajst-25053	155	5	is	be	AUX
ajst-25053	155	6	recommended	recommend	VERB
ajst-25053	155	7	to	to	PART
ajst-25053	155	8	focus	focus	VERB
ajst-25053	155	9	research	research	NOUN
ajst-25053	155	10	on	on	ADP
ajst-25053	155	11	delivery	delivery	NOUN
ajst-25053	155	12	systems	system	NOUN
ajst-25053	155	13	,	,	PUNCT
ajst-25053	155	14	especially	especially	ADV
ajst-25053	155	15	lnp	lnp	NOUN
ajst-25053	155	16	-	-	PUNCT
ajst-25053	155	17	based	base	VERB
ajst-25053	155	18	research	research	NOUN
ajst-25053	155	19	.	.	PUNCT
ajst-25053	156	1	also	also	ADV
ajst-25053	156	2	,	,	PUNCT
ajst-25053	156	3	keep	keep	VERB
ajst-25053	156	4	an	an	DET
ajst-25053	156	5	eye	eye	NOUN
ajst-25053	156	6	on	on	ADP
ajst-25053	156	7	possible	possible	ADJ
ajst-25053	156	8	security	security	NOUN
ajst-25053	156	9	issues	issue	NOUN
ajst-25053	156	10	.	.	PUNCT
ajst-25053	157	1	in	in	ADP
ajst-25053	157	2	addition	addition	NOUN
ajst-25053	157	3	,	,	PUNCT
ajst-25053	157	4	combining	combine	VERB
ajst-25053	157	5	mrna	mrna	NOUN
ajst-25053	157	6	drugs	drug	NOUN
ajst-25053	157	7	with	with	ADP
ajst-25053	157	8	other	other	ADJ
ajst-25053	157	9	immunotherapies	immunotherapy	NOUN
ajst-25053	157	10	may	may	AUX
ajst-25053	157	11	be	be	AUX
ajst-25053	157	12	a	a	DET
ajst-25053	157	13	good	good	ADJ
ajst-25053	157	14	option	option	NOUN
ajst-25053	157	15	.	.	PUNCT
ajst-25053	158	1	more	more	ADJ
ajst-25053	158	2	clinical	clinical	ADJ
ajst-25053	158	3	trials	trial	NOUN
ajst-25053	158	4	and	and	CCONJ
ajst-25053	158	5	data	datum	NOUN
ajst-25053	158	6	will	will	AUX
ajst-25053	158	7	enrich	enrich	VERB
ajst-25053	158	8	the	the	DET
ajst-25053	158	9	understanding	understanding	NOUN
ajst-25053	158	10	of	of	ADP
ajst-25053	158	11	mrna	mrna	PROPN
ajst-25053	158	12	drugs	drug	NOUN
ajst-25053	158	13	,	,	PUNCT
ajst-25053	158	14	which	which	PRON
ajst-25053	158	15	are	be	AUX
ajst-25053	158	16	becoming	become	VERB
ajst-25053	158	17	a	a	DET
ajst-25053	158	18	sword	sword	NOUN
ajst-25053	158	19	in	in	ADP
ajst-25053	158	20	the	the	DET
ajst-25053	158	21	treatment	treatment	NOUN
ajst-25053	158	22	of	of	ADP
ajst-25053	158	23	infectious	infectious	ADJ
ajst-25053	158	24	diseases	disease	NOUN
ajst-25053	158	25	and	and	CCONJ
ajst-25053	158	26	cancer	cancer	NOUN
ajst-25053	158	27	.	.	PUNCT
ajst-25053	159	1	references	reference	NOUN
ajst-25053	159	2	[	[	X
ajst-25053	159	3	1	1	NUM
ajst-25053	159	4	]	]	X
ajst-25053	159	5	brenner	brenner	NOUN
ajst-25053	159	6	,	,	PUNCT
ajst-25053	159	7	s.	s.	PROPN
ajst-25053	159	8	,	,	PUNCT
ajst-25053	159	9	jacob	jacob	PROPN
ajst-25053	159	10	,	,	PUNCT
ajst-25053	159	11	f.	f.	PROPN
ajst-25053	159	12	,	,	PUNCT
ajst-25053	159	13	&	&	CCONJ
ajst-25053	159	14	meselson	meselson	PROPN
ajst-25053	159	15	,	,	PUNCT
ajst-25053	159	16	m.	m.	NOUN
ajst-25053	159	17	(	(	PUNCT
ajst-25053	159	18	1961	1961	NUM
ajst-25053	159	19	)	)	PUNCT
ajst-25053	159	20	.	.	PUNCT
ajst-25053	160	1	an	an	DET
ajst-25053	160	2	unstable	unstable	ADJ
ajst-25053	160	3	intermediate	intermediate	ADJ
ajst-25053	160	4	carrying	carry	VERB
ajst-25053	160	5	information	information	NOUN
ajst-25053	160	6	from	from	ADP
ajst-25053	160	7	genes	gene	NOUN
ajst-25053	160	8	to	to	ADP
ajst-25053	160	9	ribosomes	ribosome	NOUN
ajst-25053	160	10	for	for	ADP
ajst-25053	160	11	protein	protein	NOUN
ajst-25053	160	12	synthesis	synthesis	NOUN
ajst-25053	160	13	.	.	PUNCT
ajst-25053	161	1	nature	nature	NOUN
ajst-25053	161	2	,	,	PUNCT
ajst-25053	161	3	190(4776	190(4776	NOUN
ajst-25053	161	4	)	)	PUNCT
ajst-25053	161	5	,	,	PUNCT
ajst-25053	161	6	576–581	576–581	NUM
ajst-25053	161	7	.	.	PUNCT
ajst-25053	162	1	[	[	X
ajst-25053	162	2	2	2	NUM
ajst-25053	162	3	]	]	SYM
ajst-25053	162	4	wolff	wolff	NOUN
ajst-25053	162	5	,	,	PUNCT
ajst-25053	162	6	j.	j.	PROPN
ajst-25053	162	7	a.	a.	PROPN
ajst-25053	162	8	,	,	PUNCT
ajst-25053	162	9	malone	malone	PROPN
ajst-25053	162	10	,	,	PUNCT
ajst-25053	162	11	r.	r.	PROPN
ajst-25053	162	12	w.	w.	PROPN
ajst-25053	162	13	,	,	PUNCT
ajst-25053	162	14	williams	williams	PROPN
ajst-25053	162	15	,	,	PUNCT
ajst-25053	162	16	p.	p.	PROPN
ajst-25053	162	17	,	,	PUNCT
ajst-25053	162	18	chong	chong	PROPN
ajst-25053	162	19	,	,	PUNCT
ajst-25053	162	20	w.	w.	PROPN
ajst-25053	162	21	,	,	PUNCT
ajst-25053	162	22	acsadi	acsadi	NOUN
ajst-25053	162	23	,	,	PUNCT
ajst-25053	162	24	g.	g.	PROPN
ajst-25053	162	25	,	,	PUNCT
ajst-25053	162	26	jani	jani	PROPN
ajst-25053	162	27	,	,	PUNCT
ajst-25053	162	28	a.	a.	PROPN
ajst-25053	162	29	,	,	PUNCT
ajst-25053	162	30	&	&	CCONJ
ajst-25053	162	31	felgner	felgner	NOUN
ajst-25053	162	32	,	,	PUNCT
ajst-25053	162	33	p.	p.	NOUN
ajst-25053	162	34	l.	l.	PROPN
ajst-25053	162	35	(	(	PUNCT
ajst-25053	162	36	1990	1990	NUM
ajst-25053	162	37	)	)	PUNCT
ajst-25053	162	38	.	.	PUNCT
ajst-25053	163	1	direct	direct	ADJ
ajst-25053	163	2	gene	gene	NOUN
ajst-25053	163	3	transfer	transfer	NOUN
ajst-25053	163	4	into	into	ADP
ajst-25053	163	5	mouse	mouse	NOUN
ajst-25053	163	6	muscle	muscle	NOUN
ajst-25053	163	7	in	in	ADP
ajst-25053	163	8	vivo	vivo	NOUN
ajst-25053	163	9	.	.	PUNCT
ajst-25053	164	1	science	science	NOUN
ajst-25053	164	2	,	,	PUNCT
ajst-25053	164	3	247(4949	247(4949	NUM
ajst-25053	164	4	)	)	PUNCT
ajst-25053	164	5	,	,	PUNCT
ajst-25053	164	6	1465–1468	1465–1468	NUM
ajst-25053	164	7	.	.	PUNCT
ajst-25053	165	1	[	[	X
ajst-25053	165	2	3	3	X
ajst-25053	165	3	]	]	X
ajst-25053	165	4	kumar	kumar	PROPN
ajst-25053	165	5	,	,	PUNCT
ajst-25053	165	6	p.	p.	PROPN
ajst-25053	165	7	,	,	PUNCT
ajst-25053	165	8	sweeney	sweeney	PROPN
ajst-25053	165	9	,	,	PUNCT
ajst-25053	165	10	t.	t.	PROPN
ajst-25053	165	11	r.	r.	PROPN
ajst-25053	165	12	,	,	PUNCT
ajst-25053	165	13	skabkin	skabkin	NOUN
ajst-25053	165	14	,	,	PUNCT
ajst-25053	165	15	m.	m.	NOUN
ajst-25053	165	16	a.	a.	PROPN
ajst-25053	165	17	,	,	PUNCT
ajst-25053	165	18	skabkina	skabkina	PROPN
ajst-25053	165	19	,	,	PUNCT
ajst-25053	165	20	o.	o.	PROPN
ajst-25053	165	21	v.	v.	PROPN
ajst-25053	165	22	,	,	PUNCT
ajst-25053	165	23	hellen	hellen	VERB
ajst-25053	165	24	,	,	PUNCT
ajst-25053	165	25	c.	c.	PROPN
ajst-25053	165	26	u.	u.	PROPN
ajst-25053	165	27	t.	t.	PROPN
ajst-25053	165	28	,	,	PUNCT
ajst-25053	165	29	&	&	CCONJ
ajst-25053	165	30	pestova	pestova	NOUN
ajst-25053	165	31	,	,	PUNCT
ajst-25053	165	32	t.	t.	PROPN
ajst-25053	165	33	v.	v.	PROPN
ajst-25053	165	34	(	(	PUNCT
ajst-25053	165	35	2014	2014	NUM
ajst-25053	165	36	)	)	PUNCT
ajst-25053	165	37	.	.	PUNCT
ajst-25053	166	1	inhibition	inhibition	NOUN
ajst-25053	166	2	of	of	ADP
ajst-25053	166	3	translation	translation	NOUN
ajst-25053	166	4	by	by	ADP
ajst-25053	166	5	ifit	ifit	PROPN
ajst-25053	166	6	family	family	NOUN
ajst-25053	166	7	members	member	NOUN
ajst-25053	166	8	is	be	AUX
ajst-25053	166	9	determined	determine	VERB
ajst-25053	166	10	by	by	ADP
ajst-25053	166	11	their	their	PRON
ajst-25053	166	12	ability	ability	NOUN
ajst-25053	166	13	to	to	PART
ajst-25053	166	14	interact	interact	VERB
ajst-25053	166	15	selectively	selectively	ADV
ajst-25053	166	16	with	with	ADP
ajst-25053	166	17	the	the	DET
ajst-25053	166	18	5′-terminal	5′-terminal	ADJ
ajst-25053	166	19	regions	region	NOUN
ajst-25053	166	20	of	of	ADP
ajst-25053	166	21	cap0-	cap0-	ADJ
ajst-25053	166	22	,	,	PUNCT
ajst-25053	166	23	cap1and	cap1and	NOUN
ajst-25053	166	24	5′pppmrnas	5′pppmrna	NOUN
ajst-25053	166	25	.	.	PUNCT
ajst-25053	167	1	nucleic	nucleic	ADJ
ajst-25053	167	2	acids	acid	NOUN
ajst-25053	167	3	research	research	NOUN
ajst-25053	167	4	,	,	PUNCT
ajst-25053	167	5	42(5	42(5	NUM
ajst-25053	167	6	)	)	PUNCT
ajst-25053	167	7	,	,	PUNCT
ajst-25053	167	8	3228–3245	3228–3245	NUM
ajst-25053	167	9	.	.	PUNCT
ajst-25053	168	1	[	[	X
ajst-25053	168	2	4	4	NUM
ajst-25053	168	3	]	]	X
ajst-25053	168	4	martin	martin	PROPN
ajst-25053	168	5	,	,	PUNCT
ajst-25053	168	6	s.	s.	PROPN
ajst-25053	168	7	,	,	PUNCT
ajst-25053	168	8	paoletti	paoletti	PROPN
ajst-25053	168	9	,	,	PUNCT
ajst-25053	168	10	e.	e.	PROPN
ajst-25053	168	11	,	,	PUNCT
ajst-25053	168	12	&	&	CCONJ
ajst-25053	168	13	moss	moss	PROPN
ajst-25053	168	14	,	,	PUNCT
ajst-25053	168	15	b.	b.	PROPN
ajst-25053	168	16	(	(	PUNCT
ajst-25053	168	17	1975	1975	NUM
ajst-25053	168	18	)	)	PUNCT
ajst-25053	168	19	.	.	PUNCT
ajst-25053	169	1	purification	purification	NOUN
ajst-25053	169	2	of	of	ADP
ajst-25053	169	3	mrna	mrna	PROPN
ajst-25053	169	4	guanylyltransferase	guanylyltransferase	NOUN
ajst-25053	169	5	and	and	CCONJ
ajst-25053	169	6	mrna	mrna	PROPN
ajst-25053	169	7	(	(	PUNCT
ajst-25053	169	8	guanine-7-	guanine-7-	PROPN
ajst-25053	169	9	)	)	PUNCT
ajst-25053	169	10	methyltransferase	methyltransferase	NOUN
ajst-25053	169	11	from	from	ADP
ajst-25053	169	12	vaccinia	vaccinia	NOUN
ajst-25053	169	13	virions	virion	NOUN
ajst-25053	169	14	.	.	PUNCT
ajst-25053	170	1	journal	journal	NOUN
ajst-25053	170	2	of	of	ADP
ajst-25053	170	3	biological	biological	ADJ
ajst-25053	170	4	chemistry	chemistry	NOUN
ajst-25053	170	5	,	,	PUNCT
ajst-25053	170	6	250(24	250(24	NUM
ajst-25053	170	7	)	)	PUNCT
ajst-25053	170	8	,	,	PUNCT
ajst-25053	170	9	9322–9329	9322–9329	NUM
ajst-25053	170	10	.	.	PUNCT
ajst-25053	171	1	[	[	X
ajst-25053	171	2	5	5	NUM
ajst-25053	171	3	]	]	X
ajst-25053	171	4	lima	lima	PROPN
ajst-25053	171	5	,	,	PUNCT
ajst-25053	171	6	s.	s.	PROPN
ajst-25053	171	7	a.	a.	PROPN
ajst-25053	171	8	,	,	PUNCT
ajst-25053	171	9	chipman	chipman	PROPN
ajst-25053	171	10	,	,	PUNCT
ajst-25053	171	11	l.	l.	PROPN
ajst-25053	171	12	b.	b.	PROPN
ajst-25053	171	13	,	,	PUNCT
ajst-25053	171	14	nicholson	nicholson	PROPN
ajst-25053	171	15	,	,	PUNCT
ajst-25053	171	16	a.	a.	PROPN
ajst-25053	171	17	l.	l.	PROPN
ajst-25053	171	18	,	,	PUNCT
ajst-25053	171	19	chen	chen	PROPN
ajst-25053	171	20	,	,	PUNCT
ajst-25053	171	21	y.-h	y.-h	PROPN
ajst-25053	171	22	.	.	PROPN
ajst-25053	171	23	,	,	PUNCT
ajst-25053	171	24	yee	yee	PROPN
ajst-25053	171	25	,	,	PUNCT
ajst-25053	171	26	b.	b.	PROPN
ajst-25053	171	27	a.	a.	PROPN
ajst-25053	171	28	,	,	PUNCT
ajst-25053	171	29	yeo	yeo	PROPN
ajst-25053	171	30	,	,	PUNCT
ajst-25053	171	31	g.	g.	PROPN
ajst-25053	171	32	w.	w.	PROPN
ajst-25053	171	33	,	,	PUNCT
ajst-25053	171	34	coller	coller	PROPN
ajst-25053	171	35	,	,	PUNCT
ajst-25053	171	36	j.	j.	PROPN
ajst-25053	171	37	,	,	PUNCT
ajst-25053	171	38	&	&	CCONJ
ajst-25053	171	39	pasquinelli	pasquinelli	PROPN
ajst-25053	171	40	,	,	PUNCT
ajst-25053	171	41	a.	a.	PROPN
ajst-25053	171	42	e.	e.	PROPN
ajst-25053	171	43	(	(	PUNCT
ajst-25053	171	44	2017	2017	NUM
ajst-25053	171	45	)	)	PUNCT
ajst-25053	171	46	.	.	PUNCT
ajst-25053	172	1	360	360	NUM
ajst-25053	172	2	short	short	ADJ
ajst-25053	172	3	poly(a	poly(a	NOUN
ajst-25053	172	4	)	)	PUNCT
ajst-25053	172	5	tails	tail	NOUN
ajst-25053	172	6	are	be	AUX
ajst-25053	172	7	a	a	DET
ajst-25053	172	8	conserved	conserved	ADJ
ajst-25053	172	9	feature	feature	NOUN
ajst-25053	172	10	of	of	ADP
ajst-25053	172	11	highly	highly	ADV
ajst-25053	172	12	expressed	express	VERB
ajst-25053	172	13	genes	gene	NOUN
ajst-25053	172	14	.	.	PUNCT
ajst-25053	173	1	nature	nature	PROPN
ajst-25053	173	2	structural	structural	ADJ
ajst-25053	173	3	&	&	CCONJ
ajst-25053	173	4	molecular	molecular	ADJ
ajst-25053	173	5	biology	biology	NOUN
ajst-25053	173	6	,	,	PUNCT
ajst-25053	173	7	24(12	24(12	NUM
ajst-25053	173	8	)	)	PUNCT
ajst-25053	173	9	,	,	PUNCT
ajst-25053	173	10	1057	1057	NUM
ajst-25053	173	11	–	–	PUNCT
ajst-25053	173	12	1063	1063	NUM
ajst-25053	173	13	.	.	PUNCT
ajst-25053	174	1	[	[	X
ajst-25053	174	2	6	6	NUM
ajst-25053	174	3	]	]	X
ajst-25053	174	4	holtkamp	holtkamp	PROPN
ajst-25053	174	5	,	,	PUNCT
ajst-25053	174	6	s.	s.	PROPN
ajst-25053	174	7	,	,	PUNCT
ajst-25053	174	8	kreiter	kreiter	PROPN
ajst-25053	174	9	,	,	PUNCT
ajst-25053	174	10	s.	s.	PROPN
ajst-25053	174	11	,	,	PUNCT
ajst-25053	174	12	selmi	selmi	PROPN
ajst-25053	174	13	,	,	PUNCT
ajst-25053	174	14	a.	a.	NOUN
ajst-25053	174	15	,	,	PUNCT
ajst-25053	174	16	simon	simon	PROPN
ajst-25053	174	17	,	,	PUNCT
ajst-25053	174	18	p.	p.	PROPN
ajst-25053	174	19	,	,	PUNCT
ajst-25053	174	20	koslowski	koslowski	NOUN
ajst-25053	174	21	,	,	PUNCT
ajst-25053	174	22	m.	m.	NOUN
ajst-25053	174	23	,	,	PUNCT
ajst-25053	174	24	huber	huber	PROPN
ajst-25053	174	25	,	,	PUNCT
ajst-25053	174	26	c.	c.	PROPN
ajst-25053	174	27	,	,	PUNCT
ajst-25053	174	28	türeci	türeci	ADJ
ajst-25053	174	29	,	,	PUNCT
ajst-25053	174	30	ö.	ö.	PROPN
ajst-25053	174	31	,	,	PUNCT
ajst-25053	174	32	&	&	CCONJ
ajst-25053	174	33	sahin	sahin	PROPN
ajst-25053	174	34	,	,	PUNCT
ajst-25053	174	35	u.	u.	PROPN
ajst-25053	174	36	(	(	PUNCT
ajst-25053	174	37	2006	2006	NUM
ajst-25053	174	38	)	)	PUNCT
ajst-25053	174	39	.	.	PUNCT
ajst-25053	175	1	modification	modification	NOUN
ajst-25053	175	2	of	of	ADP
ajst-25053	175	3	antigen	antigen	NOUN
ajst-25053	175	4	-	-	PUNCT
ajst-25053	175	5	encoding	encode	VERB
ajst-25053	175	6	rna	rna	NOUN
ajst-25053	175	7	increases	increase	VERB
ajst-25053	175	8	stability	stability	NOUN
ajst-25053	175	9	,	,	PUNCT
ajst-25053	175	10	translational	translational	ADJ
ajst-25053	175	11	efficacy	efficacy	NOUN
ajst-25053	175	12	,	,	PUNCT
ajst-25053	175	13	and	and	CCONJ
ajst-25053	175	14	t	t	NOUN
ajst-25053	175	15	-	-	PUNCT
ajst-25053	175	16	cell	cell	NOUN
ajst-25053	175	17	stimulatory	stimulatory	ADJ
ajst-25053	175	18	capacity	capacity	NOUN
ajst-25053	175	19	of	of	ADP
ajst-25053	175	20	dendritic	dendritic	ADJ
ajst-25053	175	21	cells	cell	NOUN
ajst-25053	175	22	.	.	PUNCT
ajst-25053	176	1	blood	blood	NOUN
ajst-25053	176	2	,	,	PUNCT
ajst-25053	176	3	108(13	108(13	NUM
ajst-25053	176	4	)	)	PUNCT
ajst-25053	176	5	,	,	PUNCT
ajst-25053	176	6	4009–4017	4009–4017	NUM
ajst-25053	176	7	.	.	PUNCT
ajst-25053	177	1	[	[	X
ajst-25053	177	2	7	7	NUM
ajst-25053	177	3	]	]	PUNCT
ajst-25053	177	4	hoerr	hoerr	PROPN
ajst-25053	177	5	,	,	PUNCT
ajst-25053	177	6	i.	i.	PROPN
ajst-25053	177	7	,	,	PUNCT
ajst-25053	177	8	obst	obst	PROPN
ajst-25053	177	9	,	,	PUNCT
ajst-25053	177	10	r.	r.	PROPN
ajst-25053	177	11	,	,	PUNCT
ajst-25053	177	12	rammensee	rammensee	ADJ
ajst-25053	177	13	,	,	PUNCT
ajst-25053	177	14	h.-g	h.-g	PROPN
ajst-25053	177	15	.	.	PROPN
ajst-25053	177	16	,	,	PUNCT
ajst-25053	177	17	&	&	CCONJ
ajst-25053	177	18	jung	jung	PROPN
ajst-25053	177	19	,	,	PUNCT
ajst-25053	177	20	g.	g.	PROPN
ajst-25053	177	21	(	(	PUNCT
ajst-25053	177	22	2000	2000	NUM
ajst-25053	177	23	)	)	PUNCT
ajst-25053	177	24	.	.	PUNCT
ajst-25053	178	1	in	in	ADP
ajst-25053	178	2	vivo	vivo	ADJ
ajst-25053	178	3	application	application	NOUN
ajst-25053	178	4	of	of	ADP
ajst-25053	178	5	rna	rna	NOUN
ajst-25053	178	6	leads	lead	VERB
ajst-25053	178	7	to	to	ADP
ajst-25053	178	8	induction	induction	NOUN
ajst-25053	178	9	of	of	ADP
ajst-25053	178	10	specific	specific	ADJ
ajst-25053	178	11	cytotoxic	cytotoxic	ADJ
ajst-25053	178	12	t	t	NOUN
ajst-25053	178	13	lymphocytes	lymphocyte	NOUN
ajst-25053	178	14	and	and	CCONJ
ajst-25053	178	15	antibodies	antibodie	VERB
ajst-25053	178	16	.	.	PUNCT
ajst-25053	179	1	european	european	ADJ
ajst-25053	179	2	journal	journal	PROPN
ajst-25053	179	3	of	of	ADP
ajst-25053	179	4	immunology	immunology	NOUN
ajst-25053	179	5	,	,	PUNCT
ajst-25053	179	6	30(1	30(1	NUM
ajst-25053	179	7	)	)	PUNCT
ajst-25053	179	8	,	,	PUNCT
ajst-25053	179	9	1–7	1–7	X
ajst-25053	179	10	.	.	PUNCT
ajst-25053	180	1	[	[	X
ajst-25053	180	2	8	8	NUM
ajst-25053	180	3	]	]	SYM
ajst-25053	180	4	carralot	carralot	NOUN
ajst-25053	180	5	,	,	PUNCT
ajst-25053	180	6	j.-p	j.-p	PROPN
ajst-25053	180	7	.	.	PROPN
ajst-25053	180	8	,	,	PUNCT
ajst-25053	180	9	probst	probst	PROPN
ajst-25053	180	10	,	,	PUNCT
ajst-25053	180	11	j.	j.	PROPN
ajst-25053	180	12	,	,	PUNCT
ajst-25053	180	13	hoerr	hoerr	PROPN
ajst-25053	180	14	,	,	PUNCT
ajst-25053	180	15	i.	i.	NOUN
ajst-25053	180	16	,	,	PUNCT
ajst-25053	180	17	scheel	scheel	PROPN
ajst-25053	180	18	,	,	PUNCT
ajst-25053	180	19	b.	b.	PROPN
ajst-25053	180	20	,	,	PUNCT
ajst-25053	180	21	teufel	teufel	PROPN
ajst-25053	180	22	,	,	PUNCT
ajst-25053	180	23	r.	r.	PROPN
ajst-25053	180	24	,	,	PUNCT
ajst-25053	180	25	jung	jung	PROPN
ajst-25053	180	26	,	,	PUNCT
ajst-25053	180	27	g.	g.	PROPN
ajst-25053	180	28	,	,	PUNCT
ajst-25053	180	29	rammensee	rammensee	NOUN
ajst-25053	180	30	,	,	PUNCT
ajst-25053	180	31	h.-g	h.-g	PROPN
ajst-25053	180	32	.	.	PROPN
ajst-25053	180	33	,	,	PUNCT
ajst-25053	180	34	&	&	CCONJ
ajst-25053	180	35	pascolo	pascolo	PROPN
ajst-25053	180	36	,	,	PUNCT
ajst-25053	180	37	s.	s.	PROPN
ajst-25053	180	38	(	(	PUNCT
ajst-25053	180	39	2004	2004	NUM
ajst-25053	180	40	)	)	PUNCT
ajst-25053	180	41	.	.	PUNCT
ajst-25053	181	1	polarization	polarization	NOUN
ajst-25053	181	2	of	of	ADP
ajst-25053	181	3	immunity	immunity	NOUN
ajst-25053	181	4	induced	induce	VERB
ajst-25053	181	5	by	by	ADP
ajst-25053	181	6	direct	direct	ADJ
ajst-25053	181	7	injection	injection	NOUN
ajst-25053	181	8	of	of	ADP
ajst-25053	181	9	naked	naked	ADJ
ajst-25053	181	10	sequencestabilized	sequencestabilize	VERB
ajst-25053	181	11	mrna	mrna	PROPN
ajst-25053	181	12	vaccines	vaccine	NOUN
ajst-25053	181	13	.	.	PUNCT
ajst-25053	182	1	cellular	cellular	ADJ
ajst-25053	182	2	and	and	CCONJ
ajst-25053	182	3	molecular	molecular	ADJ
ajst-25053	182	4	life	life	NOUN
ajst-25053	182	5	sciences	science	NOUN
ajst-25053	182	6	cmls	cmls	NOUN
ajst-25053	182	7	,	,	PUNCT
ajst-25053	182	8	61(18	61(18	NUM
ajst-25053	182	9	)	)	PUNCT
ajst-25053	182	10	,	,	PUNCT
ajst-25053	182	11	2418–2424	2418–2424	NUM
ajst-25053	182	12	.	.	PUNCT
ajst-25053	183	1	[	[	X
ajst-25053	183	2	9	9	NUM
ajst-25053	183	3	]	]	X
ajst-25053	183	4	jansen	jansen	PROPN
ajst-25053	183	5	,	,	PUNCT
ajst-25053	183	6	y.	y.	PROPN
ajst-25053	183	7	,	,	PUNCT
ajst-25053	183	8	kruse	kruse	PROPN
ajst-25053	183	9	,	,	PUNCT
ajst-25053	183	10	v.	v.	PROPN
ajst-25053	183	11	,	,	PUNCT
ajst-25053	183	12	corthals	corthal	NOUN
ajst-25053	183	13	,	,	PUNCT
ajst-25053	183	14	j.	j.	PROPN
ajst-25053	183	15	,	,	PUNCT
ajst-25053	183	16	schats	schat	NOUN
ajst-25053	183	17	,	,	PUNCT
ajst-25053	183	18	k.	k.	PROPN
ajst-25053	183	19	,	,	PUNCT
ajst-25053	183	20	van	van	PROPN
ajst-25053	183	21	dam	dam	PROPN
ajst-25053	183	22	,	,	PUNCT
ajst-25053	183	23	p.-j	p.-j	NOUN
ajst-25053	183	24	.	.	PUNCT
ajst-25053	183	25	,	,	PUNCT
ajst-25053	183	26	seremet	seremet	NOUN
ajst-25053	183	27	,	,	PUNCT
ajst-25053	183	28	t.	t.	PROPN
ajst-25053	183	29	,	,	PUNCT
ajst-25053	183	30	heirman	heirman	PROPN
ajst-25053	183	31	,	,	PUNCT
ajst-25053	183	32	c.	c.	PROPN
ajst-25053	183	33	,	,	PUNCT
ajst-25053	183	34	brochez	brochez	PROPN
ajst-25053	183	35	,	,	PUNCT
ajst-25053	183	36	l.	l.	PROPN
ajst-25053	183	37	,	,	PUNCT
ajst-25053	183	38	kockx	kockx	PROPN
ajst-25053	183	39	,	,	PUNCT
ajst-25053	183	40	m.	m.	NOUN
ajst-25053	183	41	,	,	PUNCT
ajst-25053	183	42	thielemans	thielemans	PROPN
ajst-25053	183	43	,	,	PUNCT
ajst-25053	183	44	k.	k.	PROPN
ajst-25053	183	45	,	,	PUNCT
ajst-25053	183	46	&	&	CCONJ
ajst-25053	183	47	neyns	neyns	PROPN
ajst-25053	183	48	,	,	PUNCT
ajst-25053	183	49	b.	b.	PROPN
ajst-25053	183	50	(	(	PUNCT
ajst-25053	183	51	2020	2020	NUM
ajst-25053	183	52	)	)	PUNCT
ajst-25053	183	53	.	.	PUNCT
ajst-25053	184	1	a	a	DET
ajst-25053	184	2	randomized	randomized	ADJ
ajst-25053	184	3	controlled	control	VERB
ajst-25053	184	4	phase	phase	NOUN
ajst-25053	184	5	ii	ii	NOUN
ajst-25053	184	6	clinical	clinical	ADJ
ajst-25053	184	7	trial	trial	NOUN
ajst-25053	184	8	on	on	ADP
ajst-25053	184	9	mrna	mrna	PROPN
ajst-25053	184	10	electroporated	electroporate	VERB
ajst-25053	184	11	autologous	autologous	ADJ
ajst-25053	184	12	monocytederived	monocytederived	ADJ
ajst-25053	184	13	dendritic	dendritic	ADJ
ajst-25053	184	14	cells	cell	NOUN
ajst-25053	184	15	(	(	PUNCT
ajst-25053	184	16	trimixdc	trimixdc	NOUN
ajst-25053	184	17	-	-	PUNCT
ajst-25053	184	18	mel	mel	PROPN
ajst-25053	184	19	)	)	PUNCT
ajst-25053	184	20	as	as	ADP
ajst-25053	184	21	adjuvant	adjuvant	ADJ
ajst-25053	184	22	treatment	treatment	NOUN
ajst-25053	184	23	for	for	ADP
ajst-25053	184	24	stage	stage	NOUN
ajst-25053	184	25	iii	iii	SYM
ajst-25053	184	26	/	/	SYM
ajst-25053	184	27	iv	iv	NUM
ajst-25053	184	28	melanoma	melanoma	NOUN
ajst-25053	184	29	patients	patient	NOUN
ajst-25053	184	30	who	who	PRON
ajst-25053	184	31	are	be	AUX
ajst-25053	184	32	disease	disease	NOUN
ajst-25053	184	33	-	-	PUNCT
ajst-25053	184	34	free	free	ADJ
ajst-25053	184	35	following	follow	VERB
ajst-25053	184	36	the	the	DET
ajst-25053	184	37	resection	resection	NOUN
ajst-25053	184	38	of	of	ADP
ajst-25053	184	39	macrometastases	macrometastase	NOUN
ajst-25053	184	40	.	.	PUNCT
ajst-25053	185	1	cancer	cancer	NOUN
ajst-25053	185	2	immunology	immunology	NOUN
ajst-25053	185	3	,	,	PUNCT
ajst-25053	185	4	immunotherapy	immunotherapy	NOUN
ajst-25053	185	5	,	,	PUNCT
ajst-25053	185	6	69(12	69(12	NOUN
ajst-25053	185	7	)	)	PUNCT
ajst-25053	185	8	,	,	PUNCT
ajst-25053	185	9	2589–2598	2589–2598	NUM
ajst-25053	185	10	.	.	PUNCT
ajst-25053	186	1	[	[	X
ajst-25053	186	2	10	10	NUM
ajst-25053	186	3	]	]	X
ajst-25053	186	4	alberer	alberer	NOUN
ajst-25053	186	5	,	,	PUNCT
ajst-25053	186	6	m.	m.	NOUN
ajst-25053	186	7	,	,	PUNCT
ajst-25053	186	8	gnad	gnad	NOUN
ajst-25053	186	9	-	-	PUNCT
ajst-25053	186	10	vogt	vogt	PROPN
ajst-25053	186	11	,	,	PUNCT
ajst-25053	186	12	u.	u.	PROPN
ajst-25053	186	13	,	,	PUNCT
ajst-25053	186	14	hong	hong	PROPN
ajst-25053	186	15	,	,	PUNCT
ajst-25053	186	16	h.	h.	PROPN
ajst-25053	186	17	s.	s.	PROPN
ajst-25053	186	18	,	,	PUNCT
ajst-25053	186	19	mehr	mehr	NOUN
ajst-25053	186	20	,	,	PUNCT
ajst-25053	186	21	k.	k.	PROPN
ajst-25053	186	22	t.	t.	PROPN
ajst-25053	186	23	,	,	PUNCT
ajst-25053	186	24	backert	backert	PROPN
ajst-25053	186	25	,	,	PUNCT
ajst-25053	186	26	l.	l.	PROPN
ajst-25053	186	27	,	,	PUNCT
ajst-25053	186	28	finak	finak	PROPN
ajst-25053	186	29	,	,	PUNCT
ajst-25053	186	30	g.	g.	PROPN
ajst-25053	186	31	,	,	PUNCT
ajst-25053	186	32	gottardo	gottardo	PROPN
ajst-25053	186	33	,	,	PUNCT
ajst-25053	186	34	r.	r.	PROPN
ajst-25053	186	35	,	,	PUNCT
ajst-25053	186	36	bica	bica	PROPN
ajst-25053	186	37	,	,	PUNCT
ajst-25053	186	38	m.	m.	NOUN
ajst-25053	186	39	a.	a.	PROPN
ajst-25053	186	40	,	,	PUNCT
ajst-25053	186	41	garofano	garofano	PROPN
ajst-25053	186	42	,	,	PUNCT
ajst-25053	186	43	a.	a.	PROPN
ajst-25053	186	44	,	,	PUNCT
ajst-25053	186	45	koch	koch	PROPN
ajst-25053	186	46	,	,	PUNCT
ajst-25053	186	47	s.	s.	PROPN
ajst-25053	186	48	d.	d.	PROPN
ajst-25053	186	49	,	,	PUNCT
ajst-25053	186	50	fotin	fotin	NOUN
ajst-25053	186	51	-	-	PUNCT
ajst-25053	186	52	mleczek	mleczek	NOUN
ajst-25053	186	53	,	,	PUNCT
ajst-25053	186	54	m.	m.	NOUN
ajst-25053	186	55	,	,	PUNCT
ajst-25053	186	56	hoerr	hoerr	PROPN
ajst-25053	186	57	,	,	PUNCT
ajst-25053	186	58	i.	i.	PROPN
ajst-25053	186	59	,	,	PUNCT
ajst-25053	186	60	clemens	clemens	PROPN
ajst-25053	186	61	,	,	PUNCT
ajst-25053	186	62	r.	r.	PROPN
ajst-25053	186	63	,	,	PUNCT
ajst-25053	186	64	&	&	CCONJ
ajst-25053	186	65	sonnenburg	sonnenburg	PROPN
ajst-25053	186	66	,	,	PUNCT
ajst-25053	186	67	f.	f.	PROPN
ajst-25053	186	68	von	von	PROPN
ajst-25053	186	69	.	.	PUNCT
ajst-25053	187	1	(	(	PUNCT
ajst-25053	187	2	2017	2017	NUM
ajst-25053	187	3	)	)	PUNCT
ajst-25053	187	4	.	.	PUNCT
ajst-25053	188	1	safety	safety	NOUN
ajst-25053	188	2	and	and	CCONJ
ajst-25053	188	3	immunogenicity	immunogenicity	NOUN
ajst-25053	188	4	of	of	ADP
ajst-25053	188	5	a	a	DET
ajst-25053	188	6	mrna	mrna	NOUN
ajst-25053	188	7	rabies	rabie	NOUN
ajst-25053	188	8	vaccine	vaccine	NOUN
ajst-25053	188	9	in	in	ADP
ajst-25053	188	10	healthy	healthy	ADJ
ajst-25053	188	11	adults	adult	NOUN
ajst-25053	188	12	:	:	PUNCT
ajst-25053	188	13	an	an	DET
ajst-25053	188	14	open	open	ADJ
ajst-25053	188	15	-	-	PUNCT
ajst-25053	188	16	label	label	NOUN
ajst-25053	188	17	,	,	PUNCT
ajst-25053	188	18	nonrandomised	nonrandomise	VERB
ajst-25053	188	19	,	,	PUNCT
ajst-25053	188	20	prospective	prospective	ADJ
ajst-25053	188	21	,	,	PUNCT
ajst-25053	188	22	first	first	ADJ
ajst-25053	188	23	-	-	PUNCT
ajst-25053	188	24	in	in	ADP
ajst-25053	188	25	-	-	PUNCT
ajst-25053	188	26	human	human	ADJ
ajst-25053	188	27	phase	phase	NOUN
ajst-25053	188	28	1	1	NUM
ajst-25053	188	29	clinical	clinical	ADJ
ajst-25053	188	30	trial	trial	NOUN
ajst-25053	188	31	.	.	PUNCT
ajst-25053	189	1	the	the	DET
ajst-25053	189	2	lancet	lancet	NOUN
ajst-25053	189	3	,	,	PUNCT
ajst-25053	189	4	390(10101	390(10101	NUM
ajst-25053	189	5	)	)	PUNCT
ajst-25053	189	6	,	,	PUNCT
ajst-25053	189	7	1511–1520	1511–1520	NUM
ajst-25053	189	8	.	.	PUNCT
ajst-25053	190	1	[	[	X
ajst-25053	190	2	11	11	NUM
ajst-25053	190	3	]	]	X
ajst-25053	190	4	del	del	PROPN
ajst-25053	190	5	giudice	giudice	PROPN
ajst-25053	190	6	,	,	PUNCT
ajst-25053	190	7	g.	g.	PROPN
ajst-25053	190	8	,	,	PUNCT
ajst-25053	190	9	rappuoli	rappuoli	ADV
ajst-25053	190	10	,	,	PUNCT
ajst-25053	190	11	r.	r.	PROPN
ajst-25053	190	12	,	,	PUNCT
ajst-25053	190	13	&	&	CCONJ
ajst-25053	190	14	didierlaurent	didierlaurent	PROPN
ajst-25053	190	15	,	,	PUNCT
ajst-25053	190	16	a.	a.	NOUN
ajst-25053	190	17	m.	m.	NOUN
ajst-25053	190	18	(	(	PUNCT
ajst-25053	190	19	2018	2018	NUM
ajst-25053	190	20	)	)	PUNCT
ajst-25053	190	21	.	.	PUNCT
ajst-25053	191	1	correlates	correlate	VERB
ajst-25053	191	2	of	of	ADP
ajst-25053	191	3	adjuvanticity	adjuvanticity	NOUN
ajst-25053	191	4	:	:	PUNCT
ajst-25053	191	5	a	a	DET
ajst-25053	191	6	review	review	NOUN
ajst-25053	191	7	on	on	ADP
ajst-25053	191	8	adjuvants	adjuvant	NOUN
ajst-25053	191	9	in	in	ADP
ajst-25053	191	10	licensed	licensed	ADJ
ajst-25053	191	11	vaccines	vaccine	NOUN
ajst-25053	191	12	.	.	PUNCT
ajst-25053	192	1	seminars	seminar	NOUN
ajst-25053	192	2	in	in	ADP
ajst-25053	192	3	immunology	immunology	NOUN
ajst-25053	192	4	,	,	PUNCT
ajst-25053	192	5	39	39	NUM
ajst-25053	192	6	,	,	PUNCT
ajst-25053	192	7	14–21	14–21	NUM
ajst-25053	192	8	.	.	PUNCT
ajst-25053	193	1	[	[	X
ajst-25053	193	2	12	12	NUM
ajst-25053	193	3	]	]	X
ajst-25053	193	4	garçon	garçon	NOUN
ajst-25053	193	5	,	,	PUNCT
ajst-25053	193	6	n.	n.	PROPN
ajst-25053	193	7	,	,	PUNCT
ajst-25053	193	8	vaughn	vaughn	PROPN
ajst-25053	193	9	,	,	PUNCT
ajst-25053	193	10	d.	d.	PROPN
ajst-25053	193	11	w.	w.	PROPN
ajst-25053	193	12	,	,	PUNCT
ajst-25053	193	13	&	&	CCONJ
ajst-25053	193	14	didierlaurent	didierlaurent	PROPN
ajst-25053	193	15	,	,	PUNCT
ajst-25053	193	16	a.	a.	NOUN
ajst-25053	193	17	m.	m.	NOUN
ajst-25053	193	18	(	(	PUNCT
ajst-25053	193	19	2012	2012	NUM
ajst-25053	193	20	)	)	PUNCT
ajst-25053	193	21	.	.	PUNCT
ajst-25053	194	1	development	development	NOUN
ajst-25053	194	2	and	and	CCONJ
ajst-25053	194	3	evaluation	evaluation	NOUN
ajst-25053	194	4	of	of	ADP
ajst-25053	194	5	as03	as03	PROPN
ajst-25053	194	6	,	,	PUNCT
ajst-25053	194	7	an	an	DET
ajst-25053	194	8	adjuvant	adjuvant	ADJ
ajst-25053	194	9	system	system	NOUN
ajst-25053	194	10	containing	contain	VERB
ajst-25053	194	11	α	α	NOUN
ajst-25053	194	12	-	-	NOUN
ajst-25053	194	13	tocopherol	tocopherol	NOUN
ajst-25053	194	14	and	and	CCONJ
ajst-25053	194	15	squalene	squalene	NOUN
ajst-25053	194	16	in	in	ADP
ajst-25053	194	17	an	an	DET
ajst-25053	194	18	oil	oil	NOUN
ajst-25053	194	19	-	-	PUNCT
ajst-25053	194	20	in	in	ADP
ajst-25053	194	21	-	-	PUNCT
ajst-25053	194	22	water	water	NOUN
ajst-25053	194	23	emulsion	emulsion	NOUN
ajst-25053	194	24	.	.	PUNCT
ajst-25053	195	1	expert	expert	NOUN
ajst-25053	195	2	review	review	NOUN
ajst-25053	195	3	of	of	ADP
ajst-25053	195	4	vaccines	vaccine	NOUN
ajst-25053	195	5	,	,	PUNCT
ajst-25053	195	6	11(3	11(3	NUM
ajst-25053	195	7	)	)	PUNCT
ajst-25053	195	8	,	,	PUNCT
ajst-25053	195	9	349–366	349–366	NUM
ajst-25053	195	10	.	.	PUNCT
ajst-25053	196	1	[	[	X
ajst-25053	196	2	13	13	NUM
ajst-25053	196	3	]	]	X
ajst-25053	196	4	ramachandran	ramachandran	PROPN
ajst-25053	196	5	,	,	PUNCT
ajst-25053	196	6	s.	s.	PROPN
ajst-25053	196	7	,	,	PUNCT
ajst-25053	196	8	satapathy	satapathy	ADJ
ajst-25053	196	9	,	,	PUNCT
ajst-25053	196	10	s.	s.	PROPN
ajst-25053	196	11	r.	r.	PROPN
ajst-25053	196	12	,	,	PUNCT
ajst-25053	196	13	&	&	CCONJ
ajst-25053	196	14	dutta	dutta	PROPN
ajst-25053	196	15	,	,	PUNCT
ajst-25053	196	16	t.	t.	PROPN
ajst-25053	196	17	(	(	PUNCT
ajst-25053	196	18	2022	2022	NUM
ajst-25053	196	19	)	)	PUNCT
ajst-25053	196	20	.	.	PUNCT
ajst-25053	197	1	delivery	delivery	NOUN
ajst-25053	197	2	strategies	strategy	NOUN
ajst-25053	197	3	for	for	ADP
ajst-25053	197	4	mrna	mrna	PROPN
ajst-25053	197	5	vaccines	vaccine	NOUN
ajst-25053	197	6	.	.	PUNCT
ajst-25053	198	1	pharmaceutical	pharmaceutical	ADJ
ajst-25053	198	2	medicine	medicine	NOUN
ajst-25053	198	3	,	,	PUNCT
ajst-25053	198	4	36(1	36(1	NUM
ajst-25053	198	5	)	)	PUNCT
ajst-25053	198	6	,	,	PUNCT
ajst-25053	198	7	11–20	11–20	NUM
ajst-25053	198	8	.	.	PUNCT
ajst-25053	199	1	[	[	X
ajst-25053	199	2	14	14	NUM
ajst-25053	199	3	]	]	X
ajst-25053	199	4	cheng	cheng	PROPN
ajst-25053	199	5	,	,	PUNCT
ajst-25053	199	6	x.	x.	PROPN
ajst-25053	199	7	,	,	PUNCT
ajst-25053	199	8	&	&	CCONJ
ajst-25053	199	9	lee	lee	PROPN
ajst-25053	199	10	,	,	PUNCT
ajst-25053	199	11	r.	r.	PROPN
ajst-25053	199	12	j.	j.	PROPN
ajst-25053	199	13	(	(	PUNCT
ajst-25053	199	14	2016	2016	NUM
ajst-25053	199	15	)	)	PUNCT
ajst-25053	199	16	.	.	PUNCT
ajst-25053	200	1	the	the	DET
ajst-25053	200	2	role	role	NOUN
ajst-25053	200	3	of	of	ADP
ajst-25053	200	4	helper	helper	NOUN
ajst-25053	200	5	lipids	lipid	NOUN
ajst-25053	200	6	in	in	ADP
ajst-25053	200	7	lipid	lipid	ADJ
ajst-25053	200	8	nanoparticles	nanoparticle	NOUN
ajst-25053	200	9	(	(	PUNCT
ajst-25053	200	10	lnps	lnps	PROPN
ajst-25053	200	11	)	)	PUNCT
ajst-25053	200	12	designed	design	VERB
ajst-25053	200	13	for	for	ADP
ajst-25053	200	14	oligonucleotide	oligonucleotide	ADJ
ajst-25053	200	15	delivery	delivery	NOUN
ajst-25053	200	16	.	.	PUNCT
ajst-25053	201	1	advanced	advanced	ADJ
ajst-25053	201	2	drug	drug	NOUN
ajst-25053	201	3	delivery	delivery	NOUN
ajst-25053	201	4	reviews	review	NOUN
ajst-25053	201	5	,	,	PUNCT
ajst-25053	201	6	99	99	NUM
ajst-25053	201	7	,	,	PUNCT
ajst-25053	201	8	129–137	129–137	NUM
ajst-25053	201	9	.	.	PUNCT
ajst-25053	202	1	[	[	X
ajst-25053	202	2	15	15	NUM
ajst-25053	202	3	]	]	X
ajst-25053	202	4	igyártó	igyártó	ADJ
ajst-25053	202	5	,	,	PUNCT
ajst-25053	202	6	b.	b.	PROPN
ajst-25053	202	7	z.	z.	PROPN
ajst-25053	202	8	,	,	PUNCT
ajst-25053	202	9	&	&	CCONJ
ajst-25053	202	10	qin	qin	PROPN
ajst-25053	202	11	,	,	PUNCT
ajst-25053	202	12	z.	z.	PROPN
ajst-25053	202	13	(	(	PUNCT
ajst-25053	202	14	2024	2024	NUM
ajst-25053	202	15	)	)	PUNCT
ajst-25053	202	16	.	.	PUNCT
ajst-25053	203	1	the	the	DET
ajst-25053	203	2	mrna	mrna	PROPN
ajst-25053	203	3	-	-	PUNCT
ajst-25053	203	4	lnp	lnp	PROPN
ajst-25053	203	5	vaccines	vaccine	NOUN
ajst-25053	203	6	–	–	PUNCT
ajst-25053	203	7	the	the	DET
ajst-25053	203	8	good	good	NOUN
ajst-25053	203	9	,	,	PUNCT
ajst-25053	203	10	the	the	DET
ajst-25053	203	11	bad	bad	ADJ
ajst-25053	203	12	and	and	CCONJ
ajst-25053	203	13	the	the	DET
ajst-25053	203	14	ugly	ugly	ADJ
ajst-25053	203	15	?	?	PUNCT
ajst-25053	204	1	frontiers	frontier	NOUN
ajst-25053	204	2	in	in	ADP
ajst-25053	204	3	immunology	immunology	NOUN
ajst-25053	204	4	,	,	PUNCT
ajst-25053	204	5	15	15	NUM
ajst-25053	204	6	.	.	PUNCT
ajst-25053	205	1	[	[	X
ajst-25053	205	2	16	16	NUM
ajst-25053	205	3	]	]	X
ajst-25053	205	4	rojas	rojas	PROPN
ajst-25053	205	5	,	,	PUNCT
ajst-25053	205	6	l.	l.	PROPN
ajst-25053	205	7	a.	a.	PROPN
ajst-25053	205	8	,	,	PUNCT
ajst-25053	205	9	sethna	sethna	NOUN
ajst-25053	205	10	,	,	PUNCT
ajst-25053	205	11	z.	z.	PROPN
ajst-25053	205	12	,	,	PUNCT
ajst-25053	205	13	soares	soares	PROPN
ajst-25053	205	14	,	,	PUNCT
ajst-25053	205	15	k.	k.	PROPN
ajst-25053	205	16	c.	c.	PROPN
ajst-25053	205	17	,	,	PUNCT
ajst-25053	205	18	olcese	olcese	PROPN
ajst-25053	205	19	,	,	PUNCT
ajst-25053	205	20	c.	c.	NOUN
ajst-25053	205	21	,	,	PUNCT
ajst-25053	205	22	pang	pang	NOUN
ajst-25053	205	23	,	,	PUNCT
ajst-25053	205	24	n.	n.	NOUN
ajst-25053	205	25	,	,	PUNCT
ajst-25053	205	26	patterson	patterson	PROPN
ajst-25053	205	27	,	,	PUNCT
ajst-25053	205	28	e.	e.	PROPN
ajst-25053	205	29	,	,	PUNCT
ajst-25053	205	30	lihm	lihm	PROPN
ajst-25053	205	31	,	,	PUNCT
ajst-25053	205	32	j.	j.	PROPN
ajst-25053	205	33	,	,	PUNCT
ajst-25053	205	34	ceglia	ceglia	PROPN
ajst-25053	205	35	,	,	PUNCT
ajst-25053	205	36	n.	n.	NOUN
ajst-25053	205	37	,	,	PUNCT
ajst-25053	205	38	guasp	guasp	NOUN
ajst-25053	205	39	,	,	PUNCT
ajst-25053	205	40	p.	p.	PROPN
ajst-25053	205	41	,	,	PUNCT
ajst-25053	205	42	chu	chu	PROPN
ajst-25053	205	43	,	,	PUNCT
ajst-25053	205	44	a.	a.	PROPN
ajst-25053	205	45	,	,	PUNCT
ajst-25053	205	46	yu	yu	PROPN
ajst-25053	205	47	,	,	PUNCT
ajst-25053	205	48	r.	r.	PROPN
ajst-25053	205	49	,	,	PUNCT
ajst-25053	205	50	chandra	chandra	PROPN
ajst-25053	205	51	,	,	PUNCT
ajst-25053	205	52	a.	a.	PROPN
ajst-25053	205	53	k.	k.	PROPN
ajst-25053	205	54	,	,	PUNCT
ajst-25053	205	55	waters	water	NOUN
ajst-25053	205	56	,	,	PUNCT
ajst-25053	205	57	t.	t.	PROPN
ajst-25053	205	58	,	,	PUNCT
ajst-25053	205	59	ruan	ruan	PROPN
ajst-25053	205	60	,	,	PUNCT
ajst-25053	205	61	j.	j.	PROPN
ajst-25053	205	62	,	,	PUNCT
ajst-25053	205	63	amisaki	amisaki	ADV
ajst-25053	205	64	,	,	PUNCT
ajst-25053	205	65	m.	m.	NOUN
ajst-25053	205	66	,	,	PUNCT
ajst-25053	205	67	zebboudj	zebboudj	PROPN
ajst-25053	205	68	,	,	PUNCT
ajst-25053	205	69	a.	a.	NOUN
ajst-25053	205	70	,	,	PUNCT
ajst-25053	205	71	odgerel	odgerel	PROPN
ajst-25053	205	72	,	,	PUNCT
ajst-25053	205	73	z.	z.	PROPN
ajst-25053	205	74	,	,	PUNCT
ajst-25053	205	75	payne	payne	PROPN
ajst-25053	205	76	,	,	PUNCT
ajst-25053	205	77	g.	g.	PROPN
ajst-25053	205	78	,	,	PUNCT
ajst-25053	205	79	derhovanessian	derhovanessian	PROPN
ajst-25053	205	80	,	,	PUNCT
ajst-25053	205	81	e.	e.	PROPN
ajst-25053	205	82	,	,	PUNCT
ajst-25053	205	83	…	…	PUNCT
ajst-25053	205	84	balachandran	balachandran	NOUN
ajst-25053	205	85	,	,	PUNCT
ajst-25053	205	86	v.	v.	PROPN
ajst-25053	205	87	p.	p.	NOUN
ajst-25053	205	88	(	(	PUNCT
ajst-25053	205	89	2023	2023	NUM
ajst-25053	205	90	)	)	PUNCT
ajst-25053	205	91	.	.	PUNCT
ajst-25053	206	1	personalized	personalize	VERB
ajst-25053	206	2	rna	rna	PROPN
ajst-25053	206	3	neoantigen	neoantigen	PROPN
ajst-25053	206	4	vaccines	vaccine	NOUN
ajst-25053	206	5	stimulate	stimulate	VERB
ajst-25053	206	6	t	t	NOUN
ajst-25053	206	7	cells	cell	NOUN
ajst-25053	206	8	in	in	ADP
ajst-25053	206	9	pancreatic	pancreatic	ADJ
ajst-25053	206	10	cancer	cancer	NOUN
ajst-25053	206	11	.	.	PUNCT
ajst-25053	207	1	nature	nature	NOUN
ajst-25053	207	2	,	,	PUNCT
ajst-25053	207	3	618(7963	618(7963	NUM
ajst-25053	207	4	)	)	PUNCT
ajst-25053	207	5	,	,	PUNCT
ajst-25053	207	6	144–150	144–150	NUM
ajst-25053	207	7	.	.	PUNCT